Équipe
Frédéric Chibon
ONCOSARC :
Oncogenèse des sarcomes
Les spécificités
de notre axe de recherches
Sarcome
Différenciation
Diagnostic
Génome
Oncogenèse
Pronostic
Chromosome
Metastase
Cellule tumorale hybride
Mitose
Traitement
Hétérogénéité
DES PROJETS
DE RECHERCHE
Oncogenèse des sarcomes
Frédéric Chibon
LES FOCUS
DE L’ÉQUIPE
Découvrir
Comprendre
Participer
En live
;
Nous recrutons!
Le groupe "Oncogenèse des sarcomes" de l'ONCOPOLE de Toulouse cherche à se renforcer, pour développer de nouveaux axes. Recherchons CR/DR INSERM.
Faites passer l'info, contactez moi!
Détail sur le site Rh de l'INSERM:https://rh.inserm.fr/Pages/default.aspx
PRODUCTIONS SCIENTIFIQUES
PUBLICATIONS 2026
7813506
CF9MRXB4
2026
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22CPATB9XZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bontoux%20et%20al.%22%2C%22parsedDate%22%3A%222026-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBontoux%2C%20Christophe%2C%20Marie%20Csanyi-Bastien%2C%20Corinne%20Bouvier%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%20Larousserie%2C%20Herv%26%23xE9%3B%20Sartelet%2C%20Marie-Paule%20Algros%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Bibeau%2C%20et%20al.%20%26%23x201C%3BFOS%20Gene%20Fusions%20in%20Osteosarcoma%20Raise%20the%20Hypothesis%20of%20Malignant%20Transformation%20of%20Osteoblastoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%26lt%3B%5C%2Fi%26gt%3B%20488%2C%20no.%203%20%28March%202026%29%3A%20607%26%23x2013%3B16.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-025-04202-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-025-04202-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22FOS%20gene%20fusions%20in%20osteosarcoma%20raise%20the%20hypothesis%20of%20malignant%20transformation%20of%20osteoblastoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Bontoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Csanyi-Bastien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Bouvier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Larousserie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Sartelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Paule%22%2C%22lastName%22%3A%22Algros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Bibeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Aubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gonzague%22%2C%22lastName%22%3A%22de%20Pinieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Faruch-Bilfeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Roussel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sofia%22%2C%22lastName%22%3A%22Galanou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Van%20Acker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Grand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Larquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Peries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%5D%2C%22abstractNote%22%3A%22Osteosarcoma%20is%20the%20most%20common%20malignant%20bone%20tumor%20among%20children%20and%20young%20adults.%20Distinguishing%20between%20osteoblastoma%20and%20osteosarcoma%20can%20be%20particularly%20challenging%2C%20especially%20in%20small%20tissue%20samples%20and%20for%20the%20osteoblastoma-like%20osteosarcoma%20subtype.%20Recent%20studies%20with%20conflicting%20results%20have%20suggested%20a%20potential%20malignant%20transformation%20process%20from%20osteoblastoma%20to%20osteosarcoma.%20This%20study%20aims%20to%20investigate%20the%20hypothesis%20of%20osteoblastoma%20evolving%20into%20osteosarcoma%20and%20to%20discuss%20its%20clinical%20implications.%20We%20conducted%20a%20retrospective%20multicentric%20case-series%20study%2C%20collecting%20clinical%2C%20radiological%2C%20histological%2C%20and%20follow-up%20data%20from%20osteosarcoma%20cases%20suspected%20to%20have%20originated%20from%20malignant%20transformation%20of%20osteoblastoma%20within%20the%20French%20ResOs%20network.%20Molecular%20analyses%20%28fluorescence%20in%20situ%20hybridization%20%28FISH%29%20and%20next-generation%20sequencing%20%28NGS%29%29%20were%20performed.%20We%20included%20two%20cases%20%28one%20female%20and%20one%20male%29%2C%20with%20a%20median%20age%20at%20osteosarcoma%20diagnosis%20of%2042%20and%2073%5Cu00a0years%20old%2C%20respectively.%20One%20patient%20had%20tumor%20located%20in%20the%20axial%20skeleton%2C%20and%20both%20cases%20exhibited%20features%20of%20osteoblastoma-like%20osteosarcoma.%20Notably%2C%20one%20of%20the%20patients%20had%20a%20documented%20history%20of%20osteoblastoma%20diagnosed%20sixteen%20years%20earlier.%20FISH%20analysis%20revealed%20FOS%20rearrangements%20in%20both%20osteosarcoma%20cases%2C%20with%20tumors%20presenting%20uncommon%20fusion%20transcripts%20%28FOS%3A%3AVGLL4%20and%20FOS%3A%3ACOL5A2%29%20identified%20through%20NGS.%20Both%20patients%20were%20alive%20at%20last%20follow-up.%20Our%20findings%20suggest%20that%20osteosarcoma%20can%20rarely%20present%20with%20FOS%20gene%20fusions%20and%20be%20associated%20with%20an%20indolent%20progression%2C%20challenging%20the%20specificity%20of%20such%20signatures%20for%20osteoblastoma%20diagnosis.%20This%20discovery%20also%20raises%20the%20hypothesis%20of%20malignant%20transformation%20from%20osteoblastoma%20to%20osteosarcoma%20and%20underscores%20the%20necessity%20for%20diligent%20monitoring%20of%20FOS-rearranged%20bone-forming%20tumors%20for%20optimal%20therapeutic%20management.%22%2C%22date%22%3A%222026-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-025-04202-6%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221432-2307%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A07%3A44Z%22%7D%7D%2C%7B%22key%22%3A%225ZTAQ969%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Reich%20et%20al.%22%2C%22parsedDate%22%3A%222026-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BReich%2C%20Mathilde%2C%20Derek%20Dinart%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Bellio%2C%20Juliane%20Berchoud%2C%20Myriam%20Jean-Denis%2C%20Maeva%20Bonneau%2C%20Sarah%20Winter%2C%20et%20al.%20%26%23x201C%3BMetastatic%20Osteosarcoma%2C%20Patterns%20of%20Care%20and%20Outcomes%20of%20Patients%20in%20a%20Real-Life%20National%20Setting%20over%20a%20Decade.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20158%2C%20no.%203%20%28February%201%2C%202026%29%3A%20728%26%23x2013%3B37.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.70157%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.70157%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metastatic%20osteosarcoma%2C%20patterns%20of%20care%20and%20outcomes%20of%20patients%20in%20a%20real-life%20national%20setting%20over%20a%20decade%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Reich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derek%22%2C%22lastName%22%3A%22Dinart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Bellio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliane%22%2C%22lastName%22%3A%22Berchoud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Myriam%22%2C%22lastName%22%3A%22Jean-Denis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maeva%22%2C%22lastName%22%3A%22Bonneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Brunet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Duong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Nannini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Gantzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bereng%5Cu00e8re%22%2C%22lastName%22%3A%22Narciso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Marec-Berard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Anract%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Goldwasser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raul%22%2C%22lastName%22%3A%22Perret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascaline%22%2C%22lastName%22%3A%22Boudou-Rouquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Bellera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%5D%2C%22abstractNote%22%3A%22Metastatic%20osteosarcoma%20%28MOS%29%20has%20a%20poor%20prognosis%2C%20and%20few%20treatment%20options.%20This%20multicentre%20observational%20study%20provides%20real-world%20data%20on%20treatment%20patterns%20of%20patients%20with%20MOS%20in%20France.%20The%20primary%20objective%20was%20to%20describe%20treatment%20modalities%20of%20patients%20with%20MOS%20aged%20%5Cu226512%5Cu2009years%20treated%20in%2011%20reference%20network%20centers.%20Secondary%20objectives%20were%20to%20assess%20time%20to%20next%20treatment%20%28TTNT%29%2C%20overall%20survival%20%28OS%29%20and%20prognostic%20factors%20for%20TTNT%20and%20OS.%20From%202008%20to%202018%2C%20262%20patients%20with%20MOS%20were%20included%3B%2088%20patients%20were%20metastatic%20at%20diagnosis%2C%20and%20174%20patients%20had%20a%20metastatic%20relapse.%20Median%20age%20at%20diagnosis%20was%2026%20%2812-86%29.%20A%20total%20of%20227%20%2886.6%25%29%20patients%20received%20systemic%20treatment%20in%20the%20metastatic%20setting%2C%20and%2075%20%2828.6%25%29%20patients%20received%20more%20than%20two%20lines.%20Overall%2C%20153%20%2858.4%25%29%20patients%20underwent%20at%20least%20a%20loco-regional%20procedure%2C%20and%2050%20patients%20%2819.1%25%29%20participated%20in%20a%20clinical%20trial%20in%20the%20metastatic%20setting.%20Median%20OS%20from%20metastasis%20diagnosis%20was%2021.5%5Cu2009months%20%5B95%25%20CI%2018.9-27.0%5D%2C%2023.0%5Cu2009months%20%5B95%25%20CI%2015.0-31.1%5D%20in%20the%20synchronous%20cohort%2C%20and%2021.4%5Cu2009months%20%5B95%25%20CI%2018.7-29.7%5D%20in%20the%20metachronous%20cohort.%20Median%20TTNT%20was%208.2%5Cu2009months%20%5B95%25%20CI%206.7-9.9%5D%2C%205.7%5Cu2009months%20%5B95%25%20CI%204.2-7.2%5D%2C%203.7%5Cu2009months%20%5B95%25%20CI%203.0-4.3%5D%2C%20and%202.9%5Cu2009months%20%5B95%25%20CI%201.8-3.9%5D%20in%20first%2C%20second%2C%20third%2C%20and%20fourth%20line.%20It%20was%207.6%5Cu2009months%20%5B95%25%20CI%205.1-12.5%5D%2C%206%5Cu2009months%20%5B95%25%20CI%203.6-8.7%5D%2C%20and%204.8%5Cu2009months%20%5B95%25%20CI%202.9-7.5%5D%20for%20tyrosine%20kinase%20inhibitors%20such%20as%20regorafenib%20or%20cabozantinib%20in%20first%2C%20second%2C%20and%20third%20line.%20In%20MOS%2C%20the%20benefit%20of%20chemotherapy%20after%20first%20line%20is%20limited.%20TKIs%20show%20encouraging%20activity%20from%20first%20line.%20Inclusion%20in%20clinical%20trials%20should%20be%20prioritized.%22%2C%22date%22%3A%222026-02-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.70157%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221097-0215%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A12%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22XVIGWLHV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brunac%20et%20al.%22%2C%22parsedDate%22%3A%222026-01-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrunac%2C%20Anne-C%26%23xE9%3Bcile%2C%20Camile%20Boulagnon-Rombi%2C%20Janick%20Selves%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Bibeau.%20%26%23x201C%3B%5BHistoseminar%20updates%20for%20diagnostic%20practice%20and%20therapeutic%20targeting%20of%20colorectal%20cancer%20in%202025%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnales%20De%20Pathologie%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2014%2C%202026%2C%20S0242-6498%2825%2900219-6.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2025.11.006%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2025.11.006%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BHistoseminar%20updates%20for%20diagnostic%20practice%20and%20therapeutic%20targeting%20of%20colorectal%20cancer%20in%202025%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-C%5Cu00e9cile%22%2C%22lastName%22%3A%22Brunac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camile%22%2C%22lastName%22%3A%22Boulagnon-Rombi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Bibeau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222026-01-14%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2025.11.006%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220242-6498%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A10%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22FVI59JR8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurence%20et%20al.%22%2C%22parsedDate%22%3A%222026-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLaurence%2C%20Val%26%23xE9%3Brie%2C%20Nina%20Jehanno%2C%20Sylvain%20Dureau%2C%20Lieke%20Mous%2C%20Line%20Claude%2C%20Stelly%20Ballet%2C%20Ga%26%23xEB%3Blle%20Pierron%2C%20et%20al.%20%26%23x201C%3BInterest%20of%20a%20Sequential%20Multimodal%20Approach%20for%20the%20Treatment%20of%20Newly%20Diagnosed%20Patients%20with%20Multimetastatic%20Ewing%20Sarcoma%3A%20Results%20of%20the%20French%20Prospective%20CombinaiR3%20Phase%20II%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBritish%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20134%2C%20no.%202%20%28January%202026%29%3A%20279%26%23x2013%3B88.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41416-025-03263-3%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41416-025-03263-3%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Interest%20of%20a%20sequential%20multimodal%20approach%20for%20the%20treatment%20of%20newly%20diagnosed%20patients%20with%20multimetastatic%20Ewing%20sarcoma%3A%20results%20of%20the%20French%20prospective%20CombinaiR3%20phase%20II%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Laurence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%22%2C%22lastName%22%3A%22Jehanno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Dureau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lieke%22%2C%22lastName%22%3A%22Mous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Line%22%2C%22lastName%22%3A%22Claude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stelly%22%2C%22lastName%22%3A%22Ballet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Pierron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Revon-Rivi%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Lervat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamie%22%2C%22lastName%22%3A%22Probert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Entz-Werle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Mansuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Plantaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Rios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Saumet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22V%5Cu00e9rit%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Castex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Thebaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Cassou-Mounat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Plissonnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Dieppedale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Delattre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Emmanuelle%22%2C%22lastName%22%3A%22Legrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Marec-B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Gouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Berlanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Surdez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nad%5Cu00e8ge%22%2C%22lastName%22%3A%22Corradini%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Ewing%20sarcoma%20%28ES%29%20is%20a%20rare%20tumour%20with%20metastatic%20spread%20in%20~25%25%20of%20cases%20at%20diagnosis.%20Extrapulmonary%20disseminated%20disease%20defines%20very%20high-risk%20%28VHR%29%20patients%2C%20with%20frequent%20relapse%20and%20poor%20overall%20survival%20%28OS%2C%20~30%25%29.%5CnMETHODS%3A%20The%20phase%20II%20CombinaiR3%20trial%20%28NCT03011528%29%20enroled%2045%20VHR%20ES%20patients%20across%2015%20French%20centres%20%282017-2021%29%20to%20evaluate%20a%20strategy%20combining%20dose-dense%20induction%20chemotherapy%2C%20high-dose%20consolidation%2C%20and%20prolonged%20maintenance%20therapy.%20The%20primary%20endpoint%20was%20median%20event-free%20survival%20%28EFS%29.%20Exploratory%20endpoints%20included%20full-body-fluorine-18-fluorodeoxyglucose-positron%20emission%20tomography%5C%2Fcomputed%20tomography%20%28PET%5C%2FCT%29%20and%20circulating%20tumour%20DNA%20%28ctDNA%29%20detection%20during%20treatment.%5CnRESULTS%3A%20Among%2042%20analysed%20patients%20%28median%20age%2014%20years%2C%20range%206-47%29%2C%2029%20had%20a%5Cu00a0primary%20tumour%5Cu00a0volume%20%5Cu2265200%5Cu2009ml%2C%20and%2035%20presented%20with%20bone%5Cu2009%5Cu00b1%5Cu2009bone%20marrow%20metastatic%20lesions%2C%2018%20exhibiting%20more%20than%205%20bone%20lesions.%20At%2048-month%20follow-up%2C%2018-%20and%2036-month%20EFS%20rates%20were%2063.4%25%20and%2053.7%25%2C%20respectively%2C%20with%203-year%20OS%20at%2065.5%25.%20Toxicity%20was%20as%20expected%2C%20with%20no%20treatment-related%20deaths%20or%20maintenance%20therapy%20discontinuations%20due%20to%20toxicity.%20PET%5C%2FCT%20and%20ctDNA%20monitoring%20showed%20strong%20correlation%20at%20diagnosis%20and%20relapse.%5CnDISCUSSION%3A%20This%20study%20supports%20the%20proposed%20experimental%20strategy%20as%20a%20first-line%20option%20for%20selected%20VHR%20ES%20patients%2C%20warranting%20integration%20into%20international%20therapeutic%20discussions.%22%2C%22date%22%3A%222026-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41416-025-03263-3%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221532-1827%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A12%3A09Z%22%7D%7D%2C%7B%22key%22%3A%22K6ABNE8S%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barr%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222026-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBarr%26%23xE9%3B%2C%20Tangui%2C%20Cl%26%23xE9%3Bmence%20Ramier%2C%20Camelia%20Protopopescu%2C%20Philippe%20Sogni%2C%20Karine%20Ory%2C%20Tounes%20Saidi%2C%20Sophie%20Abgrall%2C%20et%20al.%20%26%23x201C%3BPerceived%20Disabling%20Physical%20Pain%20and%20Suicidal%20Ideation%20in%20Aging%20People%20Living%20with%20HIV%20Cured%20of%20Hepatitis%20C%3A%20A%20Multi-Center%20Survey%20in%20France%20%28ANRS%20CO13%20HEPAVIH%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BHIV%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2027%2C%20no.%201%20%28January%202026%29%3A%20106%26%23x2013%3B19.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhiv.70121%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhiv.70121%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Perceived%20disabling%20physical%20pain%20and%20suicidal%20ideation%20in%20aging%20people%20living%20with%20HIV%20cured%20of%20hepatitis%20C%3A%20A%20multi-center%20survey%20in%20France%20%28ANRS%20CO13%20HEPAVIH%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tangui%22%2C%22lastName%22%3A%22Barr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Ramier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camelia%22%2C%22lastName%22%3A%22Protopopescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Sogni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Ory%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tounes%22%2C%22lastName%22%3A%22Saidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Abgrall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Br%5Cu00e9gigeon-Ronot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrizia%22%2C%22lastName%22%3A%22Carrieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Marcellin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ANRS%20CO13%20HEPAVIH%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Suicidal%20ideation%20%28SI%29%20is%20highly%20prevalent%20among%20people%20living%20with%20HIV%20%28PWH%29%20and%20those%20with%20chronic%20hepatitis%20C%20virus%20%28HCV%29%20infection.%20Individuals%20with%20long-term%20HIV-HCV%20co-infection%20face%20specific%20health%20challenges%2C%20including%20heightened%20physical%20pain.%20We%20aimed%20to%20assess%20whether%20disabling%20physical%20pain%20is%20associated%20with%20SI%20in%20aging%20PWH%20who%20have%20been%20cured%20of%20HCV%2C%20after%20controlling%20for%20potential%20correlates%20or%20confounders%20such%20as%20depression%20and%20psychoactive%20substance%20use.%5CnMETHODS%3A%20We%20analysed%20data%20from%20HCV-cured%20PWH%20who%20participated%20in%20a%20multi-center%20cross-sectional%20survey%20embedded%20within%20the%20French%20ANRS%20CO13%20HEPAVIH%20cohort.%20We%20performed%20a%20multivariable%20logistic%20regression%20model%20with%20SI%20%28score%20%26gt%3B0%20for%20the%20ninth%20item%20of%20the%20Patient%20Health%20Questionnaire-9%29%20as%20the%20outcome.%20Disabling%20physical%20pain%20was%20assessed%20using%20an%20answer%20%5Cu2265%26%23039%3Bvery%20much%26%23039%3B%20to%20the%20third%20item%20from%20the%20WHOQOL-HIV%20BREF%20questionnaire.%5CnRESULTS%3A%20Study%20population%20comprised%20396%20HCV-cured%20PWH%20%2873.2%25%20male%29%2C%20among%20whom%2017.7%25%20reported%20SI%20and%2011.9%25%20reported%20disabling%20physical%20pain.%20Participants%20reporting%20disabling%20physical%20pain%20had%20a%20three-fold%20higher%20risk%20of%20SI%20%28adjusted%20odds%20ratio%20%5B95%25%20confidence%20interval%5D%3A%203.07%20%5B1.29-7.34%5D%29%2C%20after%20adjustment%20for%20depression%20%285.52%20%5B2.66-11.43%5D%29%2C%20substance%20use%2C%20and%20lower%20social%20relationships-related%20quality%20of%20life%20%280.72%20%5B0.64-0.80%5D%29.%5CnCONCLUSIONS%3A%20These%20findings%20highlight%20that%20disabling%20physical%20pain%20should%20be%20systematically%20addressed%20among%20PWH%20cured%20of%20HCV%2C%20given%20its%20independent%20association%20with%20SI.%20Routine%20HIV%20follow-up%20care%20should%20integrate%20systematic%20screening%20for%20pain%2C%20mental%20health%20problems%2C%20and%20lack%20of%20social%20support.%20Timely%20referral%20to%20specialized%20services%20may%20help%20prevent%20future%20suicidal%20behaviours%20in%20this%20population.%22%2C%22date%22%3A%222026-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fhiv.70121%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221468-1293%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A10%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22BZSTIY3X%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dupain%20et%20al.%22%2C%22parsedDate%22%3A%222026-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDupain%2C%20C%26%23xE9%3Blia%2C%20Nicolas%20Jacquin%2C%20Aur%26%23xE9%3Blien%20Latouche%2C%20Zo%26%23xE9%3B%20Nevi%26%23xE8%3Bre%2C%20Pierre%20Gestraud%2C%20Abderaouf%20Hamza%2C%20Kenza%20Nedara%2C%20et%20al.%20%26%23x201C%3BManagement%20and%20Survival%20of%20Patients%20with%20Cancer%20of%20Unknown%20Primary%20Discussed%20by%20a%20French%20National%20Multidisciplinary%20Tumour%20Board%3A%20A%20Retrospective%20Analysis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Lancet%20Regional%20Health.%20Europe%26lt%3B%5C%2Fi%26gt%3B%2060%20%28January%202026%29%3A%20101524.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lanepe.2025.101524%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lanepe.2025.101524%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Management%20and%20survival%20of%20patients%20with%20cancer%20of%20unknown%20primary%20discussed%20by%20a%20French%20national%20multidisciplinary%20tumour%20board%3A%20a%20retrospective%20analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9lia%22%2C%22lastName%22%3A%22Dupain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Jacquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Latouche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zo%5Cu00e9%22%2C%22lastName%22%3A%22Nevi%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Gestraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abderaouf%22%2C%22lastName%22%3A%22Hamza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenza%22%2C%22lastName%22%3A%22Nedara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Cockenpot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Allory%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22La%5Cu00ebtitia%22%2C%22lastName%22%3A%22Chanas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Milder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Soubeyran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Blons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Patrikidou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22de%20Bernardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Masliah-Planchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odette%22%2C%22lastName%22%3A%22Mariani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Rouleau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Escande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Boyault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Saintigny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22de%20Fraipont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Blanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Tlemsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Guillou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Flavius%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Noemie%22%2C%22lastName%22%3A%22Fuentealba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Kamal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Bi%5Cu00e8che%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Servant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Le%20Tourneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Watson%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Recent%20clinical%20trials%20have%20shown%20that%20molecularly-guided%20treatments%20can%20improve%20survival%20in%20patients%20with%20cancers%20of%20unknown%20primary%20%28CUP%29.%20However%2C%20the%20feasibility%20and%20clinical%20benefit%20of%20these%20treatments%20for%20CUP%20in%20a%20real-life%20setting%20remain%20uncertain.%20In%20France%2C%20a%20national%20multidisciplinary%20tumour%20board%20dedicated%20to%20patients%20with%20CUP%20%28CUP%20MTB%29%20was%20created%20in%202020%2C%20with%20the%20aims%20of%20coordinating%20pathological%20and%20molecular%20diagnostic%20analyses%20and%20providing%20a%20centralised%20expertise%20for%20therapeutic%20orientation.%20This%20study%20aimed%20at%20evaluating%20the%20diagnostic%20and%20therapeutic%20impact%20of%20the%20CUP%20MTB%20on%20patients%20with%20CUP%20in%20a%20national%20real-life%20setting.%5CnMETHODS%3A%20Patient%20and%20tumour%20characteristics%2C%20treatments%20and%20outcomes%20are%20collected%20prospectively.%20This%20study%20reports%20the%20diagnostic%20and%20therapeutic%20impact%20of%20all%20patients%20discussed%20in%20CUP_MTB%20between%20July%202020%20and%20December%202023.%20The%20diagnostic%20impact%20was%20defined%20as%20the%20identification%20of%20a%20putative%20tissue%20of%20origin%2C%20and%20the%20initiation%20of%20a%20MTB-oriented%20treatment.%20Overall%20survival%20was%20estimated%20using%20the%20Kaplan-Meier%20method%2C%20and%20hazard%20ratios%20were%20calculated%20using%20Cox%20proportional%20hazard%20models.%5CnFINDINGS%3A%20A%20total%20of%20246%20CUP%20patients%20were%20referred%20to%20CUP_MTB%20%28124%20females%20and%20122%20men%29%3B%20187%20%2876%25%29%20underwent%20pathological%20and%20molecular%20characterizations%20as%20recommended%20by%20the%20MTB.%20Tumour%20profiling%20enabled%20the%20identification%20of%20a%20putative%20tissue%20of%20origin%20%28TOO%29%20in%20130%5C%2F187%20%2870%25%29%20patients.%20The%20most%20frequent%20TOO%20were%20gastrointestinal%20%28n%20%3D%2029%3B%2022%25%29%2C%20lung%20%28n%20%3D%2022%3B%2017%25%29%2C%20breast%20%28n%20%3D%2021%3B%2016%25%29%2C%20and%20kidney%20%28n%20%3D%2019%3B%2015%25%29.%20149%20%2861%25%29%20patients%20received%20a%20treatment%20based%20on%20MTB%20recommendation.%20111%5C%2F149%20%2874.5%25%29%20patients%20received%20MTB-oriented%20treatment%2C%20including%20systemic%20treatment%20oriented%20towards%20the%20putative%20TOO%20%28n%20%3D%2095%2C%2063.8%25%29%2C%20or%20treatment%20directed%20towards%20a%20targetable%20molecular%20alteration%20%28n%20%3D%2016%2C%2010.7%25%29.%2038%20%2825.5%25%29%20patients%20for%20whom%20no%20MTB-oriented%20treatment%20could%20be%20recommended%20were%20treated%20with%20empiric%20treatment%20according%20to%20international%20guidelines.%20The%20median%20overall%20survival%20of%20patients%20treated%20with%20MTB-oriented%20treatment%20was%2018.6%20%28IQR%20%3D%2012.0%29%20months%2C%20compared%20to%2011.0%20%28IQR%20%3D%2010.5%29%20months%20in%20patients%20with%20empiric%20treatment%20%28HR%20%3D%200.61%2C%2095%25%20CI%200.38-0.98%2C%20p%20%3D%200.04%29.%5CnINTERPRETATION%3A%20Integration%20of%20clinical%2C%20pathological%20and%20molecular%20data%20within%20an%20expert%20MTB%20is%20feasible%20in%20a%20real-life%20setting%2C%20enables%20access%20to%20molecularly%20guided%20treatments%20and%20improves%20survival%20for%20a%20large%20proportion%20of%20CUP%20patients.%20Our%20findings%20highlight%20the%20benefits%20of%20dedicated%20MTB%20and%20reference%20centres%20to%20improve%20the%20management%20of%20CUP.%5CnFUNDING%3A%20Institut%20Curie%20and%20the%202025%20French%20Genomic%20Medicine%20Initiative.%22%2C%22date%22%3A%222026-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lanepe.2025.101524%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222666-7762%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A10%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22UGMYTKET%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baurain%20et%20al.%22%2C%22parsedDate%22%3A%222026-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBaurain%2C%20Jean-Francois%2C%20Carine%20Kirkove%2C%20Aline%20Francois%2C%20Gwenael%20Ferron%2C%20and%20Mathieu%20Luyckx.%20%26%23x201C%3BAdjuvant%20Treatment%20Algorithm%20Based%20on%20Recent%20ESGO%5C%2FESTRO%5C%2FESP%20Guidelines%20for%20Early%20Endometrial%20Carcinoma%20According%20to%20Prognostic%20Risk%20Groups.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Gynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2037%2C%20no.%201%20%28January%202026%29%3A%20e28.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3802%5C%2Fjgo.2026.37.e28%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3802%5C%2Fjgo.2026.37.e28%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Adjuvant%20treatment%20algorithm%20based%20on%20recent%20ESGO%5C%2FESTRO%5C%2FESP%20guidelines%20for%20early%20endometrial%20carcinoma%20according%20to%20prognostic%20risk%20groups%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Francois%22%2C%22lastName%22%3A%22Baurain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Kirkove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Francois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Luyckx%22%7D%5D%2C%22abstractNote%22%3A%22The%20incidence%20of%20endometrial%20cancer%20%28EC%29%20is%20unfortunately%20increasing.%20Often%20diagnosis%20is%20made%20at%20an%20early%20stage%20and%20surgery%20is%20the%20curative%20treatment.%20Nevertheless%2C%20adjuvant%20treatment%20is%20proposed%20to%20reduce%20the%20risk%20of%20relapse.%20This%20treatment%20is%20tailored%20based%20on%20the%20extent%20of%20the%20disease%2C%20such%20as%20the%20presence%20of%20distant%20metastasis%2C%20the%20extent%20of%20involvement%20of%20adjacent%20organs%20or%20lymph%20nodes.%20However%2C%20histological%20parameters%20such%20as%20myometrial%20invasion%2C%20substantial%20lymphovascular%20space%20invasion%2C%20invasion%20of%20the%20cervical%20stroma%20or%20tumor%20grade%20are%20also%20key%20to%20selecting%20adjuvant%20treatment.%20The%20Cancer%20Genome%20Atlas%20%28TCGA%29%20project%20has%20demonstrated%20the%20superiority%20of%20molecular%20classification%20over%20histological%20evaluation%20in%20EC%20to%20determine%20the%20prognosis.%20The%20International%20Federation%20of%20Gynecology%20and%20Obstetrics%202023%20staging%20for%20EC%20is%20the%20first%20staging%20system%20that%20has%20incorporated%20molecular%20biomarkers%20on%20top%20of%20morpho-histological%20classification.%20Currently%2C%20all%20patients%20should%20have%20a%20molecular%20profile%20of%20their%20tumor%20and%20a%20lymph%20node%20assessment.%20The%20landmark%20treatment%20of%20stage%20I-III%20ECs%20is%20surgery%20followed%20by%20radiotherapy.%20The%20European%20guidelines%20updated%20in%202025%20has%20divided%20EC%20in%204%20risk%20categories%20with%20specific%20adjuvant%20treatment.%20For%20clinicians%2C%20it%20is%20seen%20as%20a%20complex%20landscape%20from%20surveillance%20to%20chemo-radiotherapy.%20Therefore%2C%20we%20propose%20here%20a%20practical%20pocket%20guideline%20for%20adjuvant%20treatment%20of%20early-stage%20EC%20patients%20based%20on%20a%20review%20of%20the%20different%20clinical%20trials%20in%20the%20adjuvant%20setting%20and%20on%20existing%20guidelines.%20This%20pocket%20guideline%20may%20also%20serve%20as%20a%20base%20for%20incorporation%20of%20new%20clinical%20trials%20under%20the%20RAINBO%20umbrella%20research%20program.%22%2C%22date%22%3A%222026-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3802%5C%2Fjgo.2026.37.e28%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222005-0399%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-01-28T11%3A18%3A32Z%22%7D%7D%5D%7D
Bontoux, Christophe, Marie Csanyi-Bastien, Corinne Bouvier, Frédérique Larousserie, Hervé Sartelet, Marie-Paule Algros, Frédéric Bibeau, et al. “FOS Gene Fusions in Osteosarcoma Raise the Hypothesis of Malignant Transformation of Osteoblastoma.” Virchows Archiv: An International Journal of Pathology 488, no. 3 (March 2026): 607–16. https://doi.org/10.1007/s00428-025-04202-6.
Reich, Mathilde, Derek Dinart, Hélène Bellio, Juliane Berchoud, Myriam Jean-Denis, Maeva Bonneau, Sarah Winter, et al. “Metastatic Osteosarcoma, Patterns of Care and Outcomes of Patients in a Real-Life National Setting over a Decade.” International Journal of Cancer 158, no. 3 (February 1, 2026): 728–37. https://doi.org/10.1002/ijc.70157.
Brunac, Anne-Cécile, Camile Boulagnon-Rombi, Janick Selves, and Frédéric Bibeau. “[Histoseminar updates for diagnostic practice and therapeutic targeting of colorectal cancer in 2025].” Annales De Pathologie, January 14, 2026, S0242-6498(25)00219-6. https://doi.org/10.1016/j.annpat.2025.11.006.
Laurence, Valérie, Nina Jehanno, Sylvain Dureau, Lieke Mous, Line Claude, Stelly Ballet, Gaëlle Pierron, et al. “Interest of a Sequential Multimodal Approach for the Treatment of Newly Diagnosed Patients with Multimetastatic Ewing Sarcoma: Results of the French Prospective CombinaiR3 Phase II Trial.” British Journal of Cancer 134, no. 2 (January 2026): 279–88. https://doi.org/10.1038/s41416-025-03263-3.
Barré, Tangui, Clémence Ramier, Camelia Protopopescu, Philippe Sogni, Karine Ory, Tounes Saidi, Sophie Abgrall, et al. “Perceived Disabling Physical Pain and Suicidal Ideation in Aging People Living with HIV Cured of Hepatitis C: A Multi-Center Survey in France (ANRS CO13 HEPAVIH).” HIV Medicine 27, no. 1 (January 2026): 106–19. https://doi.org/10.1111/hiv.70121.
Dupain, Célia, Nicolas Jacquin, Aurélien Latouche, Zoé Nevière, Pierre Gestraud, Abderaouf Hamza, Kenza Nedara, et al. “Management and Survival of Patients with Cancer of Unknown Primary Discussed by a French National Multidisciplinary Tumour Board: A Retrospective Analysis.” The Lancet Regional Health. Europe 60 (January 2026): 101524. https://doi.org/10.1016/j.lanepe.2025.101524.
Baurain, Jean-Francois, Carine Kirkove, Aline Francois, Gwenael Ferron, and Mathieu Luyckx. “Adjuvant Treatment Algorithm Based on Recent ESGO/ESTRO/ESP Guidelines for Early Endometrial Carcinoma According to Prognostic Risk Groups.” Journal of Gynecologic Oncology 37, no. 1 (January 2026): e28. https://doi.org/10.3802/jgo.2026.37.e28.
PUBLICATIONS 2025
7813506
CF9MRXB4
2025
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22KQ5DVZUU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maalouly%20et%20al.%22%2C%22parsedDate%22%3A%222025-12-19%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaalouly%2C%20Georges%2C%20Tarek%20Itani%2C%20and%20Nassim%20Fares.%20%26%23x201C%3BCinnamomum%20Cassia%20Modulates%20Key%20Players%20of%20Gut-Liver%20Axis%20in%20Murine%20Lupus.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBiomedicines%26lt%3B%5C%2Fi%26gt%3B%2014%2C%20no.%201%20%28December%2019%2C%202025%29%3A%206.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fbiomedicines14010006%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fbiomedicines14010006%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cinnamomum%20cassia%20Modulates%20Key%20Players%20of%20Gut-Liver%20Axis%20in%20Murine%20Lupus%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Maalouly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tarek%22%2C%22lastName%22%3A%22Itani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nassim%22%2C%22lastName%22%3A%22Fares%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20Systemic%20lupus%20erythematosus%20is%20a%20multi-faceted%20auto-immune%20disease.%20Growing%20evidence%20points%20to%20gut%20permeability%20and%20microbiota%20as%20key%20players%20in%20the%20development%20of%20the%20disease.%20Cinnamomum%20cassia%20is%20gaining%20attention%20as%20a%20potential%20modifier%20of%20the%20gut%20and%20liver%20health.%20We%20aim%20in%20this%20study%20to%20explore%20the%20effect%20of%20cinnamon%20on%20key%20elements%20of%20the%20gut-liver%20axis%20in%20imiquimod-induced%20lupus.%20Methods%3A%20Female%20C57BL%5C%2F6J%20mice%20were%20stratified%20into%20five%20experimental%20groups%3A%20sham%2C%20sham%20plus%20cinnamon%2C%20lupus%2C%20lupus%20with%20cinnamon%20treatment%2C%20and%20lupus%20with%20pre-%20and%20post-induction%20cinnamon%20treatment.%20Lupus%20was%20induced%20through%20application%20of%201.25%20mg%20of%205%25%20imiquimod%20cream%20to%20the%20right%20ear%2C%20three%20times%20per%20week%20over%20six%20weeks.%20Cinnamomum%20cassia%20was%20given%20orally%20at%20200%20mg%5C%2Fkg%2C%20five%20days%20weekly.%20High-Throughput%20Sequencing%20of%20Bacterial%2016S%20rRNA%20Gene%20was%20used%20on%20fecal%20samples%20with%20subsequent%20bioinformatic%20analysis%20of%20microbiota.%20Western%20blot%20and%20antibody%20array%20were%20used%20to%20measure%20E.%20coli%20translocation%2C%20and%20hepatic%20inflammatory%2C%20oxidative%2C%20and%20apoptotic%20markers.%20Results%3A%20Cinnamon%20treatment%20mitigated%20the%20trend%20toward%20a%20lower%20Firmicutes%5C%2FBacteroidota%20ratio%20in%20the%20lupus%20mice.%20While%20not%20statistically%20significant%2C%20cinnamon%20also%20led%20to%20a%20decrease%20in%20Lachnospiraceae%20abundance.%20Interestingly%2C%20sham%20mice%20given%20cinnamon%20had%20more%20Lactobacillus%20and%20Limosilactobacillus.%20Furthermore%2C%20cinnamon%20effectively%20reversed%20the%20increase%20in%20E.%20coli%20protein%20in%20the%20liver%20and%20normalized%20the%20enhanced%20expression%20of%20TLR-7%2C%20p-NF%5Cu03baB%5C%2FNF%5Cu03baB%2C%20SOD1%20and%20SOD2%20induced%20by%20lupus.%20Conclusions%3A%20Cinnamomum%20cassia%20modulates%20oxidative%2C%20inflammatory%2C%20and%20microbial%20elements%20of%20the%20gut-liver%20axis%20in%20lupus%2C%20offering%20a%20new%20perspective%20on%20lupus%20pathogenesis%20and%20potential%20nutritional%20interventions.%22%2C%22date%22%3A%222025-12-19%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fbiomedicines14010006%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222227-9059%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A15%3A52Z%22%7D%7D%2C%7B%22key%22%3A%2242X4VSTJ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ducrot%20et%20al.%22%2C%22parsedDate%22%3A%222025-12-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDucrot%2C%20Coline%2C%20Derek%20Dinart%2C%20Mathilde%20Reich%2C%20Max%20Piffoux%2C%20Maeva%20Bonneau%2C%20Mathieu%20Larroquette%2C%20Simon%20Nannini%2C%20et%20al.%20%26%23x201C%3BMetastatic%20Chondrosarcoma%2C%20Patterns%20of%20Care%2C%20and%20Outcomes%20of%20Patients%20in%20a%20Real-Life%20National%20Setting%20over%20a%20Decade.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20157%2C%20no.%2011%20%28December%201%2C%202025%29%3A%202325%26%23x2013%3B33.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.70023%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.70023%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Metastatic%20chondrosarcoma%2C%20patterns%20of%20care%2C%20and%20outcomes%20of%20patients%20in%20a%20real-life%20national%20setting%20over%20a%20decade%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coline%22%2C%22lastName%22%3A%22Ducrot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derek%22%2C%22lastName%22%3A%22Dinart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Reich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Piffoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maeva%22%2C%22lastName%22%3A%22Bonneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Larroquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Nannini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliane%22%2C%22lastName%22%3A%22Berchoud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hel%5Cu00e8ne%22%2C%22lastName%22%3A%22Bellio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Cherrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bereng%5Cu00e8re%22%2C%22lastName%22%3A%22Narciso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Gantzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Anract%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sixtine%22%2C%22lastName%22%3A%22de%20Percin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascaline%22%2C%22lastName%22%3A%22Boudou-Rouquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gonzague%22%2C%22lastName%22%3A%22de%20Pinieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Gouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Bellera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%5D%2C%22abstractNote%22%3A%22Metastatic%20chondrosarcoma%20%28MCS%29%20has%20a%20poor%20prognosis%2C%20and%20treatment%20options%20are%20scarce%20in%20this%20rare%20disease.%20This%20multicenter%20observational%20study%20provides%20real-world%20data%20on%20treatment%20patterns%20of%20patients%20with%20MCS%20in%20France.%20Treatment%20characteristics%2C%20outcomes%20in%20terms%20of%20time%20to%20next%20treatment%20%28TTNT%29%20and%20overall%20survival%20%28OS%29%2C%20and%20prognostic%20factors%20of%20patients%20%5Cu226512-year-old%20treated%20for%20a%20MCS%20in%20nine%20French%20reference%20network%20centers%20were%20retrieved%20from%20the%20French%20Sarcoma%20Group%20prospective%20database.%20From%202008%20to%202018%2C%20127%20patients%20with%20MCS%20were%20included%2C%2031%20were%20metastatic%20from%20diagnosis%20%28synchronous%20cohort%29%2C%2089%20had%20a%20metastatic%20relapse%2C%20and%207%20had%20locally%20advanced%20unresectable%20disease%2C%20of%20whom%204%20developed%20secondary%20metastases%20%28metachronous%20cohort%29.%20Median%20age%20at%20diagnosis%20was%2061%5Cu2009years%20%2814-90%29%2C%2058.9%25%20of%20patients%20received%20a%20systemic%20treatment%20with%20a%20median%20of%202%20lines%20%281-6%29%2C%2040.3%25%20had%20a%20locoregional%20procedure%20on%20metastasis%2C%20and%209.7%25%20of%20patients%20participated%20in%20a%20clinical%20trial%20at%20least%20once%20in%20the%20metastatic%20setting.%20Median%20OS%20from%20metastatic%20diagnosis%20was%2012.7%5Cu2009months%20%5B95%25CI%208.2%2C%2014.9%5D%2C%20without%20significant%20difference%20between%20the%20metachronous%20and%20synchronous%20cohorts.%20Median%20TTNT%20was%204.6%5Cu2009months%20%5B95%25CI%203.0%2C%205.9%5D%2C%203.4%5Cu2009months%20%5B95%25CI%202.7%2C%204.8%5D%2C%20and%203.4%5Cu2009months%20%5B95%25CI%202.0%2C%207.9%5D%20in%20first%2C%20second%2C%20and%20third%20lines%2C%20respectively.%20In%20MCS%2C%20benefits%20of%20chemotherapies%20are%20very%20limited.%20Tyrosine%20kinase%20inhibitors%20such%20as%20regorafenib%20or%20pazopanib%20show%20some%20activity%20from%20first%20line.%20Locoregional%20treatment%20of%20metastasis%20is%20associated%20with%20survival%20and%20should%20be%20proposed%20when%20feasible.%20Inclusion%20in%20clinical%20trials%20should%20be%20prioritized.%22%2C%22date%22%3A%222025-12-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.70023%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221097-0215%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A13%3A40Z%22%7D%7D%2C%7B%22key%22%3A%22LSTSK4J6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Valerio%20et%20al.%22%2C%22parsedDate%22%3A%222025-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BValerio%2C%20M.%2C%20T.%20Valentin%2C%20and%20V.%20Sibaud.%20%26%23x201C%3BRipretinib-Related%20Pyoderma%20Gangrenosum%3A%20First%20Description%20and%20Pathophysiological%20Clues.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnales%20De%20Dermatologie%20Et%20De%20Venereologie%26lt%3B%5C%2Fi%26gt%3B%20152%2C%20no.%204%20%28December%202025%29%3A%20103410.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annder.2025.103410%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annder.2025.103410%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ripretinib-related%20pyoderma%20gangrenosum%3A%20first%20description%20and%20pathophysiological%20clues%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Valerio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Sibaud%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-12%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annder.2025.103410%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220151-9638%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A13%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22CC45MKR4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daou%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDaou%2C%20Rouaa%2C%20Maha%20Hoteit%2C%20Jad%20Ch%26%23xE9%3Bmali%2C%20Nikolaos%20Tzenios%2C%20Nassim%20Fares%2C%20and%20Andr%26%23xE9%3B%20El%20Khoury.%20%26%23x201C%3BAssessing%20Kidney%20Injury%20Biomarkers%20and%20OTA%20Exposure%20in%20Urine%20of%20Lebanese%20Adolescents%20Amid%20Economic%20Crisis%20and%20Evolving%20Dietary%20Patterns.%26%23x201D%3B%20%26lt%3Bi%26gt%3BToxins%26lt%3B%5C%2Fi%26gt%3B%2017%2C%20no.%2012%20%28November%2030%2C%202025%29%3A%20577.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Ftoxins17120577%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Ftoxins17120577%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20Kidney%20Injury%20Biomarkers%20and%20OTA%20Exposure%20in%20Urine%20of%20Lebanese%20Adolescents%20Amid%20Economic%20Crisis%20and%20Evolving%20Dietary%20Patterns%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rouaa%22%2C%22lastName%22%3A%22Daou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%22%2C%22lastName%22%3A%22Hoteit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jad%22%2C%22lastName%22%3A%22Ch%5Cu00e9mali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikolaos%22%2C%22lastName%22%3A%22Tzenios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nassim%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%22%2C%22lastName%22%3A%22El%20Khoury%22%7D%5D%2C%22abstractNote%22%3A%22Although%20ochratoxin%20A%20%28OTA%29%20contamination%20has%20been%20previously%20reported%20in%20Lebanon%2C%20this%20study%20is%20the%20first%20worldwide%20to%20assess%20its%20potential%20impact%20on%20renal%20health%20among%20adolescents%20aged%2010%20to%2018%20years.%20In%20this%20cross-sectional%20study%2C%20the%20aim%20was%20to%20evaluate%20the%20levels%20of%20OTA%2C%20OT%5Cu03b1%2C%20and%20kidney%20injury%20biomarkers%2C%20as%20well%20as%20creatinuria%20and%20total%20proteinuria%2C%20while%20correlating%20these%20findings%20with%20dietary%20patterns.%20Urinary%20concentrations%20of%20OTA%2C%20its%20main%20metabolite%20ochratoxin%20%5Cu03b1%20%28OTa%29%2C%20the%20three%20renal%20injury%20biomarkers%20%28N-acetyl-%5Cu03b2-D-glucosaminidase%20%5BNAG%5D%2C%20Kidney%20Injury%20Molecule-1%20%5BKIM-1%5D%2C%20and%20human%20lipocalin-2%20%5BNGAL%5D%29%2C%20and%20two%20renal%20function%20indicators%20%28creatinine%20and%20total%20protein%29%20were%20quantified.%20Associations%20between%20biomarker%20levels%20and%20dietary%20intake%20patterns%20were%20also%20evaluated.%20OTA%20and%20OT%5Cu03b1%20were%20detected%20in%2014.2%25%20and%2059.5%25%20of%20urine%20samples%2C%20respectively.%20NGAL%20and%20NAG%20were%20found%20in%20all%20participants%20at%20low%20concentrations%2C%20with%20the%20NAG-to-creatinine%20ratio%20exceeding%20the%20clinical%20threshold%20in%201.5%25%20of%20samples%2C%20while%20KIM-1%20was%20detected%20in%2086%25%20of%20participants.%20A%20weak%20positive%20correlation%20between%20urinary%20OT%5Cu03b1%20and%20NAG%20suggests%20subtle%20renal%20alterations%20possibly%20linked%20to%20OTA%20exposure.%20Correlations%20between%20biomarker%20levels%20and%20food%20consumption%20were%20generally%20weak%20and%20positive.%20Estimated%20dietary%20intake%20%28EDI%29%20of%20OTA%20generated%20from%20consumption%20patterns%20was%20shown%20to%20be%20less%20than%20the%20probable%20dietary%20intake%20%28PDI%29%20calculated%20from%20urinary%20OTA.%20However%2C%20this%20presented%20a%20limitation%2C%20as%20EDI%20was%20calculated%20from%20previous%20contamination%20data%20in%20Lebanon.%20Overall%2C%20these%20findings%20indicate%20that%20while%20renal%20injury%20biomarkers%20were%20present%20at%20low%20levels%2C%20they%20may%20reflect%20early%20kidney%20stress%20not%20yet%20manifesting%20as%20overt%20pathology%20and%20highlight%20the%20need%20for%20strengthened%20regulatory%20measures%20to%20limit%20OTA%20contamination%20in%20foods%20available%20on%20the%20Lebanese%20market%20and%20for%20longitudinal%20studies%20to%20confirm%20these%20preliminary%20findings.%22%2C%22date%22%3A%222025-11-30%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Ftoxins17120577%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6651%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A16%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22C8F6HPS9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-20%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKhan%2C%20Zeeshan%2C%20Zainab%20Aqeel%20Khan%2C%20Tomas%20Zamora%2C%20Ashish%20Gulia%2C%20Santiago%20A.%20Lozano-Calderon%2C%20Vineet%20J.%20Kurisunkal%2C%20Lee%20M.%20Jeys%2C%20et%20al.%20%26%23x201C%3BWhat%20Is%20Debridement%2C%20Antibiotics%2C%20and%20Implant%20Retention%20in%20Orthopaedic%20Oncology%3F%26%23x202F%3B%3A%20A%20Global%20Cross-Sectional%20Survey%20of%20Surgeons%26%23x2019%3B%20Practices%20and%20Opinions.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBone%20%26amp%3B%20Joint%20Open%26lt%3B%5C%2Fi%26gt%3B%206%2C%20no.%2011%20%28November%2020%2C%202025%29%3A%201495%26%23x2013%3B1503.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1302%5C%2F2633-1462.611.BJO-2025-0114.R2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1302%5C%2F2633-1462.611.BJO-2025-0114.R2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22What%20is%20debridement%2C%20antibiotics%2C%20and%20implant%20retention%20in%20orthopaedic%20oncology%3F%20%3A%20a%20global%20cross-sectional%20survey%20of%20surgeons%27%20practices%20and%20opinions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeeshan%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zainab%20Aqeel%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Zamora%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashish%22%2C%22lastName%22%3A%22Gulia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%20A.%22%2C%22lastName%22%3A%22Lozano-Calderon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vineet%20J.%22%2C%22lastName%22%3A%22Kurisunkal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%20M.%22%2C%22lastName%22%3A%22Jeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22BOOM%20Consensus%20Meeting%20participants%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minna%20K.%22%2C%22lastName%22%3A%22Laitinen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%22%2C%22lastName%22%3A%22Abad%20Repiso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hesham%22%2C%22lastName%22%3A%22Abdelbary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandro%22%2C%22lastName%22%3A%22Abiad%20Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%20A.%22%2C%22lastName%22%3A%22Abood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghaith%22%2C%22lastName%22%3A%22Abou-Nouar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20C.%22%2C%22lastName%22%3A%22Abril%20Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayman%22%2C%22lastName%22%3A%22Abu%20Elhamd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adesegun%22%2C%22lastName%22%3A%22Abudu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marthelena%22%2C%22lastName%22%3A%22Acosta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keisuke%22%2C%22lastName%22%3A%22Ae%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manish%22%2C%22lastName%22%3A%22Agarwal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivek%22%2C%22lastName%22%3A%22Ajit%20Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toru%22%2C%22lastName%22%3A%22Akiyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20I.%22%2C%22lastName%22%3A%22Albergo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Alexander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricio%20A.%22%2C%22lastName%22%3A%22Alfaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bugra%22%2C%22lastName%22%3A%22Alpan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ibrahim%22%2C%22lastName%22%3A%22Alshaygy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Amaya-Valero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimosthenis%22%2C%22lastName%22%3A%22Andreou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Annabell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Anthony%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Aoude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iraia%22%2C%22lastName%22%3A%22Arteagoitia-Colino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Apichat%22%2C%22lastName%22%3A%22Asavamongkolkul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Aston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Libe%22%2C%22lastName%22%3A%22Asua%20Mentxaka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Azzopardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Baad-Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ismail%20T.%22%2C%22lastName%22%3A%22Badr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Baixauli-Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gavin%22%2C%22lastName%22%3A%22Baker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tessa%22%2C%22lastName%22%3A%22Balach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giacomo%20G.%22%2C%22lastName%22%3A%22Baldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janie%22%2C%22lastName%22%3A%22Barry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Basile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefano%22%2C%22lastName%22%3A%22Bastoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammad%20Hardian%22%2C%22lastName%22%3A%22Basuki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henrik%22%2C%22lastName%22%3A%22Bauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%22%2C%22lastName%22%3A%22Bayliss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ricardo%20G.%22%2C%22lastName%22%3A%22Becker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angad%22%2C%22lastName%22%3A%22Bedi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Benevenia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Bengoa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Bergh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marko%22%2C%22lastName%22%3A%22Bergovec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%22%2C%22lastName%22%3A%22Bernthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odion%22%2C%22lastName%22%3A%22Binitie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Boddie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michele%22%2C%22lastName%22%3A%22Boffano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Bonilla%20Huertas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20B.%22%2C%22lastName%22%3A%22Borgognoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%22%2C%22lastName%22%3A%22Botchu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%22%2C%22lastName%22%3A%22Bramer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harriet%22%2C%22lastName%22%3A%22Branford-White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rahat%22%2C%22lastName%22%3A%22Brar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Demien%22%2C%22lastName%22%3A%22Broekhuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20E.%22%2C%22lastName%22%3A%22Broida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tymoteusz%22%2C%22lastName%22%3A%22Budny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%20Dc%22%2C%22lastName%22%3A%22Burke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Cabrolier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%20R.%22%2C%22lastName%22%3A%22Calvo%20Tapies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20A.%22%2C%22lastName%22%3A%22Calvo-Haro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominico%22%2C%22lastName%22%3A%22Campanacci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Carey%20Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20I.%22%2C%22lastName%22%3A%22Carvallo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Casales%20Fresenga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Manuel%22%2C%22lastName%22%3A%22Casanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oscar%22%2C%22lastName%22%3A%22Ceballos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Luis%22%2C%22lastName%22%3A%22Cebrian%20Parra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20K.%22%2C%22lastName%22%3A%22Certain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Chacon%20Cartaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chung%20Ming%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoon%20Joo%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Choong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yang-Guk%22%2C%22lastName%22%3A%22Chung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dawid%22%2C%22lastName%22%3A%22Ciechanowicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%20Angel%22%2C%22lastName%22%3A%22Clara-Altamirano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Clever%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%20Matheo%22%2C%22lastName%22%3A%22Colina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Consuegra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cory%22%2C%22lastName%22%3A%22Couch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gillian%22%2C%22lastName%22%3A%22Cribb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Cuervo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%20A.%22%2C%22lastName%22%3A%22Cusick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solomon%22%2C%22lastName%22%3A%22Dadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tanios%22%2C%22lastName%22%3A%22Dagher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dietmar%22%2C%22lastName%22%3A%22Dammerer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nerys%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%20Pablo%22%2C%22lastName%22%3A%22de%20la%20Rosa%20Martino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%20Javier%22%2C%22lastName%22%3A%22de%20Santos%20de%20la%20Fuente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marieke%22%2C%22lastName%22%3A%22de%20Vaal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Deckers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Delgado%20Obando%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaneel%22%2C%22lastName%22%3A%22Deo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niklas%22%2C%22lastName%22%3A%22Deventer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Di%20Bella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Domson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Davide%20Maria%22%2C%22lastName%22%3A%22Donati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Desiree%20M.%22%2C%22lastName%22%3A%22Dorleijn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Du%20Toit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Debra%22%2C%22lastName%22%3A%22Dunne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodolfo%22%2C%22lastName%22%3A%22Duran%20Ciarrochi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elina%22%2C%22lastName%22%3A%22Ekman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%20M.%22%2C%22lastName%22%3A%22El%20Ghoneimy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Makoto%22%2C%22lastName%22%3A%22Endo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Levent%22%2C%22lastName%22%3A%22Eralp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%22%2C%22lastName%22%3A%22Etaiwi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%22%2C%22lastName%22%3A%22Evans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Will%22%2C%22lastName%22%3A%22Eward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Farese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20C.%22%2C%22lastName%22%3A%22Ferguson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20Filipe%22%2C%22lastName%22%3A%22Ferreira%20Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Fiorenza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Flint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hector%22%2C%22lastName%22%3A%22Flores%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joao%22%2C%22lastName%22%3A%22Freitas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Fuchs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomohiro%22%2C%22lastName%22%3A%22Fujiwara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%20T.%22%2C%22lastName%22%3A%22Funovics%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%22%2C%22lastName%22%3A%22Galli%20Serra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zakareya%22%2C%22lastName%22%3A%22Gamie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Garces-Zarzalejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aaron%22%2C%22lastName%22%3A%22Gazendam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carsten%22%2C%22lastName%22%3A%22Gebert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jasper%20G.%22%2C%22lastName%22%3A%22Gerbers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%22%2C%22lastName%22%3A%22Gerrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Ghert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kanishka%20M.%22%2C%22lastName%22%3A%22Ghosh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Gibbons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%20Carlos%22%2C%22lastName%22%3A%22Gomez-Mier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesus%22%2C%22lastName%22%3A%22Gomez-Vallejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%20R.%22%2C%22lastName%22%3A%22Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fausto%22%2C%22lastName%22%3A%22Gonzalez-Lizan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Gosheger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%22%2C%22lastName%22%3A%22Goudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krista%22%2C%22lastName%22%3A%22Goulding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stavros%20D.%22%2C%22lastName%22%3A%22Goumenos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Griffin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashish%22%2C%22lastName%22%3A%22Gulia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amit%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Guzman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammed%22%2C%22lastName%22%3A%22Haitham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jendrik%22%2C%22lastName%22%3A%22Hardes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Hardoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yusuf%22%2C%22lastName%22%3A%22Hasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Hauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helard%22%2C%22lastName%22%3A%22Havard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rex%22%2C%22lastName%22%3A%22Haydon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Healey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nerea%22%2C%22lastName%22%3A%22Hernandez%20Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%22%2C%22lastName%22%3A%22Hernandez-Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asle%22%2C%22lastName%22%3A%22Hesla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Hess%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Hilton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chindanai%22%2C%22lastName%22%3A%22Hongsaprabhas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Hornicek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Hosking%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleanor%22%2C%22lastName%22%3A%22Houghton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oluwaseyi%20K.%22%2C%22lastName%22%3A%22Idowu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ippolito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Isler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shintaro%22%2C%22lastName%22%3A%22Iwata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jake%22%2C%22lastName%22%3A%22Jagiello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Jeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Jeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luke%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andy%22%2C%22lastName%22%3A%22Johnston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Min%20Wook%22%2C%22lastName%22%3A%22Joo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20C.%22%2C%22lastName%22%3A%22Jutte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kadri%22%2C%22lastName%22%3A%22Kaldas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amar%22%2C%22lastName%22%3A%22Kamat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sudhir%22%2C%22lastName%22%3A%22Kannan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bilal%22%2C%22lastName%22%3A%22Kapanci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeeshan%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroshi%22%2C%22lastName%22%3A%22Kobayashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yehuda%22%2C%22lastName%22%3A%22Kollender%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%22%2C%22lastName%22%3A%22Koob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Kotrych%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Kyte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Maria%22%2C%22lastName%22%3A%22Lamo%20de%20Espinosa%20Vazquez%20de%20Sola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20L.%22%2C%22lastName%22%3A%22Lazarides%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis-Romee%22%2C%22lastName%22%3A%22Le%20Nail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pawel%22%2C%22lastName%22%3A%22Legosz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Burkhard%22%2C%22lastName%22%3A%22Lehner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22Leithner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryse%22%2C%22lastName%22%3A%22Lejoly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerae%20O.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Linares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%22%2C%22lastName%22%3A%22Lozano-Calderon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashish%22%2C%22lastName%22%3A%22Mahendra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferdiansyah%22%2C%22lastName%22%3A%22Mahyudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fermin%20Julian%22%2C%22lastName%22%3A%22Mandia%20Mancebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Martos%20Torrejon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Marx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Camille%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22McCullough%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sam%22%2C%22lastName%22%3A%22McMahon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%20Ricardo%22%2C%22lastName%22%3A%22Medellin%20Rincon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinji%22%2C%22lastName%22%3A%22Miwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Molina%20Uribe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%22%2C%22lastName%22%3A%22Moon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%20Jesus%22%2C%22lastName%22%3A%22Moriel%20Garcesco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carol%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stewart%22%2C%22lastName%22%3A%22Morrison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Mottard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcio%22%2C%22lastName%22%3A%22Moura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linde%22%2C%22lastName%22%3A%22Muster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Nakayama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prashant%22%2C%22lastName%22%3A%22Narhari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Navas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prakash%22%2C%22lastName%22%3A%22Nayak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Neugebauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20T.%22%2C%22lastName%22%3A%22Newman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jyrki%22%2C%22lastName%22%3A%22Nieminen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmy%22%2C%22lastName%22%3A%22Nyqvist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Nystrom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22O%27Reilly-Harbidge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22O%27Toole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vania%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20J.%22%2C%22lastName%22%3A%22Ortiz-Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harzem%22%2C%22lastName%22%3A%22Ozger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Korhan%22%2C%22lastName%22%3A%22Ozkan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Pala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Palmerini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grant%22%2C%22lastName%22%3A%22Pang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Panayiotis%22%2C%22lastName%22%3A%22Papagelopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Paraliticci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20C.%22%2C%22lastName%22%3A%22Parry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sam%22%2C%22lastName%22%3A%22Patton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Peake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Peiro%20Ibanez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Israel%22%2C%22lastName%22%3A%22Perez%20Munoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ganapathy%20Raman%22%2C%22lastName%22%3A%22Perianayagam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20Mork%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joris%22%2C%22lastName%22%3A%22Ploegmakers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Pollock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Powell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Pretell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Puetzler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Qamar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anand%22%2C%22lastName%22%3A%22Raja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raja%20Bhaskara%22%2C%22lastName%22%3A%22Rajasekaran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dipak%20B.%22%2C%22lastName%22%3A%22Ramkumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20Lor%22%2C%22lastName%22%3A%22Randall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20S.%22%2C%22lastName%22%3A%22Rankin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20A.%22%2C%22lastName%22%3A%22Raskin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kumaran%22%2C%22lastName%22%3A%22Rassppan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauris%22%2C%22lastName%22%3A%22Repsa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%22%2C%22lastName%22%3A%22Ropars%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Rose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wael%22%2C%22lastName%22%3A%22Sadek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22German%22%2C%22lastName%22%3A%22Salcedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aasim%22%2C%22lastName%22%3A%22Saleemi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Sambri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hartej%22%2C%22lastName%22%3A%22Sar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Scanferla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Schubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Schwarze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guido%22%2C%22lastName%22%3A%22Scoccianti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashley%22%2C%22lastName%22%3A%22Scrimshire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tetsuya%22%2C%22lastName%22%3A%22Sekita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Shehadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Shoaib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhim%22%2C%22lastName%22%3A%22Shreemal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Shumelinsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Siegel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%22%2C%22lastName%22%3A%22Silveri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Silverwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Friedl%22%2C%22lastName%22%3A%22Sinnaeve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Sison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Slade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Anna%22%2C%22lastName%22%3A%22Smolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franz%22%2C%22lastName%22%3A%22Snyman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%22%2C%22lastName%22%3A%22Sommerville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sahil%22%2C%22lastName%22%3A%22Sood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%22%2C%22lastName%22%3A%22Spiguel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22St-Yves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20L.%22%2C%22lastName%22%3A%22Staals%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Stacchiotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikolaos%22%2C%22lastName%22%3A%22Stavropoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Steadman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20D.%22%2C%22lastName%22%3A%22Stevenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikaela%22%2C%22lastName%22%3A%22Sullivan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwen%22%2C%22lastName%22%3A%22Sys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bartlomiej%22%2C%22lastName%22%3A%22Szostakowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Tamburini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuta%22%2C%22lastName%22%3A%22Taniguchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Temple%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Theil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joachim%22%2C%22lastName%22%3A%22Thorkildsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meagan%22%2C%22lastName%22%3A%22Tibbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Tillman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu%22%2C%22lastName%22%3A%22Toda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaspar%22%2C%22lastName%22%3A%22Tootsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferran%22%2C%22lastName%22%3A%22Torner%20Rubies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Traub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioannis%22%2C%22lastName%22%3A%22Trikoupis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Panagiotis%22%2C%22lastName%22%3A%22Tsagkozis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Tsoi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroyuki%22%2C%22lastName%22%3A%22Tsuchiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veli-Matti%22%2C%22lastName%22%3A%22Vainio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Valcarcel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Valencia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annelies%22%2C%22lastName%22%3A%22Van%20Beeck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Van%20de%20Sande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Van%20Den%20Berghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingrid%22%2C%22lastName%22%3A%22Van%20der%20Geest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lizz%22%2C%22lastName%22%3A%22Van%20der%20Heijden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Van%20der%20Wal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kirsten%22%2C%22lastName%22%3A%22Van%20Langevelde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gualter%22%2C%22lastName%22%3A%22Vaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Velez%20Villa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floortje%22%2C%22lastName%22%3A%22Verspoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koenraad%22%2C%22lastName%22%3A%22Verstraete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Visgauss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oleg%22%2C%22lastName%22%3A%22Vyrva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hazem%22%2C%22lastName%22%3A%22Wafa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%22%2C%22lastName%22%3A%22Walter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wan%20Faisham%22%2C%22lastName%22%3A%22Wan%20Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20Qi%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Warnock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joel%22%2C%22lastName%22%3A%22Werier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wolfram%22%2C%22lastName%22%3A%22Weschenfelder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kwok-Chuen%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjan%22%2C%22lastName%22%3A%22Woulthuyzen-Bakker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%22%2C%22lastName%22%3A%22Wunder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Indica%22%2C%22lastName%22%3A%22Wysinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norio%22%2C%22lastName%22%3A%22Yamamoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhaoming%22%2C%22lastName%22%3A%22Ye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seung-Jae%22%2C%22lastName%22%3A%22Yoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suraya%22%2C%22lastName%22%3A%22Zainul%20Abidin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Zamora%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierluca%22%2C%22lastName%22%3A%22Zecchetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liuzhe%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Pablo%22%2C%22lastName%22%3A%22Zumarraga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Botello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%22%2C%22lastName%22%3A%22Boyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Walid%22%2C%22lastName%22%3A%22Ebeid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T.%22%2C%22lastName%22%3A%22Houdek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajay%22%2C%22lastName%22%3A%22Puri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pietro%22%2C%22lastName%22%3A%22Ruggieri%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20Following%20resection%20of%20a%20primary%20bone%20tumour%2C%20reconstruction%20is%20commonly%20performed%20using%20either%20a%20megaprosthesis%20or%20biological%20reconstruction.%20Periprosthetic%20joint%20infection%20%28PJI%29%20remains%20one%20of%20the%20most%20frequent%20complications.%20Various%20treatment%20strategies%20exist%20for%20PJI%2C%20including%20debridement%2C%20antibiotics%2C%20and%20implant%20retention%20%28DAIR%29%2C%20and%20single-%20and%20two-stage%20revision%2C%20although%20consensus%20on%20optimal%20management%20remains%20elusive.%20This%20study%20aimed%20to%20investigate%20the%20global%20practices%20regarding%20DAIR%20in%20tumour%20cases%20through%20an%20electronic%20survey%20among%20orthopaedic%20oncology%20surgeons.%5CnMETHODS%3A%20A%20global%20cross-sectional%20observational%20survey%20study%20was%20distributed%20to%20272%20orthopaedic%20oncology%20surgeons%20who%20attended%20the%20BOOM%20Consensus%20Meeting%20in%20January%202024.%20The%20survey%20contained%2019%20multiple%20choice%20questions%20focusing%20on%20DAIR%20practices.%20Responses%20were%20collected%20anonymously%20and%20analyzed%20using%20descriptive%20statistics.%5CnRESULTS%3A%20The%20survey%20was%20completed%20by%20173%5C%2F272%20surgeons%20%2864%25%29%20from%2044%20countries.%20While%2062%25%20%28169%5C%2F272%29%20routinely%20performed%20radical%20soft-tissue%20debridement%20in%20DAIR%2C%20only%2039%25%20exchanged%20all%20modular%20components%2C%20indicating%20variability%20in%20surgical%20approaches.%20DAIR%20was%20more%20commonly%20performed%20in%20acute%20rather%20than%20chronic%20infections%2C%20with%2055%25%20finding%20it%20very%20useful%20in%20acute%20cases.%20The%20use%20of%20local%20antibiotic%20delivery%20was%20supported%20by%2056%25%2C%20although%20only%2049%25%20found%20antibiotic%20cement%20coatings%20beneficial.%20Systemic%20antibiotic%20duration%20post-DAIR%20varied%2C%20with%2039%25%20favouring%20six%20weeks%20and%2035%25%20preferring%20three%20months.%5CnCONCLUSION%3A%20The%20study%20highlights%20global%20inconsistencies%20in%20DAIR%20practices%20for%20PJI%20in%20orthopaedic%20oncology%2C%20with%20financial%20disparities%20impacting%20modular%20component%20exchange.%20Standardized%20definitions%20are%20lacking%2C%20and%20we%20propose%20that%20if%20only%20polyethylene%20is%20changed%2C%20then%20the%20procedure%20is%20referred%20to%20as%20%26%23039%3Bpoly%20exchange%26%23039%3B%3B%20we%20recommend%20defining%20the%20procedure%20as%20DAIR%20when%20extensive%20debridement%2C%20lavage%2C%20and%20removal%2C%20wash%2C%20and%20reimplanting%20of%20all%20modular%20components%20is%20done%20while%20retaining%20stable%20stems%2C%20followed%20by%20suppressive%20antibiotic%20therapy%3B%20and%20finally%2C%20we%20recommend%20that%20if%20all%20the%20modular%20components%20are%20changed%20for%20new%20ones%2C%20the%20procedure%20is%20referred%20to%20as%20%26%23039%3BDAIR%20plus%26%23039%3B.%22%2C%22date%22%3A%222025-11-20%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1302%5C%2F2633-1462.611.BJO-2025-0114.R2%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222633-1462%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A07%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22D9E9QWN5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Valentin%20et%20al.%22%2C%22parsedDate%22%3A%222025-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BValentin%2C%20Thibaud%2C%20Nicolas%20Penel%2C%20and%20Maud%20Toulmonde.%20%26%23x201C%3B%5BSarcoma%3A%20a%20plural%20entity%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BLa%20Revue%20Du%20Praticien%26lt%3B%5C%2Fi%26gt%3B%2075%2C%20no.%209%20%28November%202025%29%3A%20954%26%23x2013%3B58.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BSarcoma%3A%20a%20plural%20entity%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%5D%2C%22abstractNote%22%3A%22A%20PLURAL%20ENTITY.%20Sarcoma%20are%20a%20heterogeneous%20group%20of%20150%20different%20histopathological%20entities%2C%20developed%20from%20soft%20tissues%20or%20bone%20of%20any%20anatomical%20location.Their%20estimated%20incidence%20is%20around%2070%20cases%20for%20100%20000%20people.%20They%20can%20occur%20in%20patients%20of%20any%20age%2C%20including%20children%2C%20the%20median%20age%20of%20onset%20being%20around%2060%20years.%20Most%20sarcomas%20are%20sporadic%2C%20since%20predisposing%20factors%20are%20rare.%20In%20France%2C%20the%20treatment%20of%20patiens%20with%20sarcomas%20must%20be%20carried%20out%2C%20within%20a%20center%20belonging%20to%20Netsarc%2B%20networt%20as%20soon%20as%20a%20diagnosis%20is%20suspected%2C%20to%20offer%20them%20a%20better%20prognosis%2C%20mostly%20explained%20by%20the%20quality%20of%20the%20surgery%2C%20a%20major%20prognostic%20factor%20in%20these%20diseases.%22%2C%22date%22%3A%222025-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222101-017X%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A11%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22MNB4BPMS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alouani%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-30%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAlouani%2C%20Emily%2C%20Julien%20Taieb%2C%20David%20Tougeron%2C%20Guillaume%20Roces%2C%20Antoine%20Hollebecque%2C%20Pauline%20Parent%2C%20Simon%20Pernot%2C%20et%20al.%20%26%23x201C%3BEfficacy%20of%20Immunotherapy%20in%20Gastrointestinal%20%28GI%29%20Tumors%20with%20Mismatch%20Repair%20Deficient%20%28MMRd%29%20Unusual%20Phenotype%3A%20An%20AGEO%20Real-World%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20for%20Immunotherapy%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2013%2C%20no.%2010%20%28October%2030%2C%202025%29%3A%20e011436.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2024-011436%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjitc-2024-011436%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20of%20immunotherapy%20in%20gastrointestinal%20%28GI%29%20tumors%20with%20mismatch%20repair%20deficient%20%28MMRd%29%20unusual%20phenotype%3A%20an%20AGEO%20real-world%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emily%22%2C%22lastName%22%3A%22Alouani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Taieb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Tougeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Roces%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Hollebecque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Parent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Pernot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20A.%22%2C%22lastName%22%3A%22Sinicrope%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Hautefeuille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meher%22%2C%22lastName%22%3A%22Ben-Abdelghani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Dutherage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Hafliger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Sclafani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Muller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Perkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Th%5Cu00e9r%5Cu00e8se%22%2C%22lastName%22%3A%22Masson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Aparicio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9lia%22%2C%22lastName%22%3A%22Coutzac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Mazard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Decraecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Jaffrelot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosine%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Tumors%20with%20mismatch%20repair%20deficiency%20%28MMRd%29%20classically%20display%20concomitant%20loss%20of%20MLH1%5C%2FPMS2%20or%20MSH2%5C%2FMSH6%20on%20immunohistochemistry%20%28IHC%29%20with%20microsatellite%20instability-high%20%28MSI-High%29%20status%20on%20molecular%20testing.%20Nevertheless%2C%20a%20different%20phenotype%20can%20occur%20in%20up%20to%2015%25%20of%20MMRd%20tumors%20%28unusual%20phenotype%29.%20Data%20on%20the%20efficacy%20of%20immunotherapy%20in%20this%20population%20remain%20scarce.%5CnMETHODS%3A%20We%20conducted%20a%20retrospective%20study%20within%20the%20IMMUNODIG%20MSI%20cohort%20including%20patients%20with%20advanced%20gastrointestinal%20MMRd%20tumors%20treated%20with%20immune%20checkpoint%20blockade%20in%20the%20real-world%20setting.%20We%20selected%20patients%20with%20both%20IHC%20and%20MSI%20assays%20data%20available.%20Unusual%20MMRd%20tumors%20were%20classified%20into%20four%20distinct%20groups%3A%20%281%29%20isolated%20loss%20of%20PMS2%20or%20MSH6%20with%20MSI-H%20%28isolated%5C%2FMSI-H%29%2C%20%282%29%20complex%20loss%20of%20MMR%20proteins%20with%20MSI-H%20%28complex%5C%2FMSI-H%29%2C%20%283%29%20loss%20of%20one%20or%20more%20MMR%20proteins%20without%20MSI-H%20%28MMRd-IHC%5C%2Fmicrosatellite%20stability%20%28MSS%29%20or%20MSI-low%20%28MSI-L%29%29%2C%20and%20%284%29%20four%20MMR%20proteins%20retained%20with%20MSI-H%20%28retained%20IHC%5C%2FMSI-H%29.%5CnRESULTS%3A%20Out%20of%20759%20patients%20in%20the%20IMMUNODIG-MSI%20cohort%2C%20571%20patients%20met%20inclusion%20criteria.%20Of%20these%2C%2090%20%2815.8%25%29%20had%20an%20unusual%20phenotype%20%2847%20isolated%5C%2FMSI-H%2C%2019%20complex%5C%2FMSI-H%2C%2016%20MMRd-IHC%5C%2FMSS%20or%20MSI-L%20and%208%20retained%20IHC%5C%2FMSI-H%29.%20Compared%20with%20classical%20phenotypes%2C%20patients%20with%20a%20tumor%20harboring%20an%20unusual%20phenotype%20had%20a%20younger%20age%20at%20treatment%20%28p%3D0.005%29%2C%20increased%20RAS%20mutation%20%28p%3D0.005%29%2C%20reduced%20BRAF%20p.V600E%20mutation%20rates%20%28p%26lt%3B0.001%29%2C%20a%20higher%20proportion%20of%20Lynch%20syndrome%20%28p%26lt%3B0.001%29%20and%20a%20higher%20prevalence%20of%20non-colorectal%20cancers%20%28p%3D0.021%29.%20After%20a%20median%20follow-up%20of%2028.1%20months%20%28mo%29%2C%20there%20was%20a%20significant%20difference%20in%20progression-free%20survival%2C%20with%20median%20values%20of%20not%20reached%2C%2066.4%20mo%2C%2037.2%20mo%2C%2018.3%20mo%20and%205.5%20mo%20for%20complex%5C%2FMSI-H%2C%20isolated%5C%2FMSI-H%2C%20classical%2C%20retained%20IHC%5C%2FMSI-H%20and%20MMRd-IHC%5C%2FMSS%20or%20MSI-L%20subgroups%2C%20respectively%20%28p%26lt%3B0.001%29.%20Notably%2C%20objective%20response%20rates%20were%2059.1%25%2C%2058.7%25%2C%20and%2063.2%25%20for%20complex%5C%2FMSI-H%2C%20isolated%5C%2FMSI-H%20and%20classical%20contrasting%20with%2050%25%20and%2025%25%20for%20retained%20IHC%5C%2FMSI-H%20and%20MMRd-IHC%5C%2FMSS%20or%20MSI-L%2C%20with%20no%20complete%20response%20observed%20in%20the%20latter%20two.%5CnCONCLUSION%3A%20Our%20findings%20underscore%20the%20need%20for%20dual%20testing%20and%20advocate%20for%20the%20presence%20of%20both%20MMRd-IHC%20and%20MSI-H%20for%20optimal%20immunotherapy%20response.%20Of%20note%2C%20complex%20MMR%20aberrations%20and%20isolated%20PMS2%5C%2FMSH6%20losses%20with%20MSI-H%20may%20represent%20promising%20candidates%20for%20enhanced%20immunotherapy%20efficacy.%22%2C%22date%22%3A%222025-10-30%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fjitc-2024-011436%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222051-1426%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A10%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22DX448BMX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bompas%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBompas%2C%20Emmanuelle%2C%20Loic%20Campion%2C%20Maud%20Toulmonde%2C%20Axel%20Le%20Cesne%2C%20M%26%23xE9%3Blanie%20Saint-Jean%2C%20C%26%23xE9%3Bleste%20Lebbe%2C%20Thibaud%20Valentin%2C%20et%20al.%20%26%23x201C%3BOutcome%20of%201773%20Superficial%20Non-Dermatofibrosarcoma%20Sarcomas%20A%20French%20Sarcoma%20Group%20Study%20%28FSG%29%20from%20the%20NETSARC%20Database.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20229%20%28October%2016%2C%202025%29%3A%20115788.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2025.115788%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2025.115788%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcome%20of%201773%20superficial%20non-dermatofibrosarcoma%20sarcomas%20A%20French%20Sarcoma%20Group%20study%20%28FSG%29%20from%20the%20NETSARC%20database%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Campion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%5Cu00e9lanie%22%2C%22lastName%22%3A%22Saint-Jean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9leste%22%2C%22lastName%22%3A%22Lebbe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Rios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Duffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Carr%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Perrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%22%2C%22lastName%22%3A%22Ropars%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitri%22%2C%22lastName%22%3A%22Tzanis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascaline%22%2C%22lastName%22%3A%22Boudou-Roquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Tlemsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sixtine%22%2C%22lastName%22%3A%22de%20Percin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Desmoulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Causeret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Ducoulombier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esma%22%2C%22lastName%22%3A%22Saada-Bouzid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Bertucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Emmanuel%22%2C%22lastName%22%3A%22Kurtz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Gantzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Medhi%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armelle%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Gouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Meeus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Michot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariella%22%2C%22lastName%22%3A%22Spatalo-Ceruso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Verret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Honor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Ryckewaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gauthier%22%2C%22lastName%22%3A%22Decanter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Camille%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitri%22%2C%22lastName%22%3A%22Gangloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Salas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9rang%5Cu00e8re%22%2C%22lastName%22%3A%22Narciso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Moreau-Bachelard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%20Rom%5Cu00e9e%22%2C%22lastName%22%3A%22Le%20Nail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Dubray-Longeras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Fiorenza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Chagneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Guillemet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Yves%22%2C%22lastName%22%3A%22Blay%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Clinical%20practice%20guidelines%20for%20managing%20superficial%20non-dermatofibrosarcoma%20soft%20tissue%20sarcomas%20%28NDSTS%29%20vary%20depending%20on%20surgical%20margins.%20This%20study%20assessed%20NDSTS%20outcomes%20by%20margin%20status%20and%20re-excision%20%28RE%29%20in%20the%20nationwide%20NETSARC%2B%20database.%5CnMETHODS%3A%20This%20retrospective%20study%20%28MR004-346%29%20of%201773%20patients%20used%20clinical%20data%20from%20the%20NETSARC%20database%20between%2001%5C%2F01%5C%2F2010%20and%2012%5C%2F30%5C%2F2017.%20Analyses%20focused%20on%20local%20relapse-free%20survival%20%28LRFS%29%20and%20overall%20survival%20%28OS%29.%5CnRESULTS%3A%20Pre-surgery%2C%2031%5Cu202f%25%20of%20patients%20underwent%20local%20staging%20with%20imaging%2C%2046%5Cu202f%25%20biopsy%2C%20and%2017.8%5Cu202f%25%20a%20reference%20center%20multidisciplinary%20tumor%20board%20%28MDTB%29.%20Initial%20margin%20quality%20was%20R0%2C%20R1%2C%20R2%2C%20and%20unknown%20for%2037%5Cu202f%25%2C%2036%5Cu202f%25%2C%2013%5Cu202f%25%2C%20and%2012.8%5Cu202f%25%20of%20patients%20respectively.%20Univariate%20analysis%20positively%20correlated%20R0%20surgery%20with%20preoperative%20biopsy%20%28p%5Cu202f%26lt%3B%5Cu202f0.001%29%2C%20adequate%20local%20imaging%20for%20tumors%20%5Cu2265%5Cu202f5%5Cu202fcm%20%28p%5Cu202f%26lt%3B%5Cu202f0.009%29%2C%20case%20discussion%20within%20a%20NETSARC%2B%5Cu202fMDTB%20%28p%5Cu202f%26lt%3B%5Cu202f0.001%29%2C%20and%20tumor%20size%26lt%3B%5Cu202f5%5Cu202fcm%20%28p%5Cu202f%26lt%3B%5Cu202f0.001%29.%20Reference%20network%20surgery%20resulted%20in%20higher%20proportions%20of%20R0%20margins%20%28p%5Cu202f%26lt%3B%5Cu202f0.001%29.%20Re-excision%20%28RE%29%20was%20performed%20in%209.7%5Cu202f%25%2C%2063%5Cu202f%25%2C79%5Cu202f%25%2C%20and%2034%5Cu202f%25%20of%20patients%20following%20initial%20surgery%20with%20R0%2C%20R1%2C%20R2%2C%20and%20unknown%20margins%2C%20respectively.%20Multivariate%20analysis%20identified%20several%20poor%20LRFS%20prognostic%20factors%3A%20size%20%5Cu2265%5Cu202f5%5Cu202fcm%20%28HR%3D1.47%2C%20p%5Cu202f%3D%5Cu202f0.002%29%2C%20angiosarcoma%20%28HR%3D2.95%2C%20p%5Cu202f%26lt%3B%5Cu202f0.001%29%2C%20surgery%20outside%20a%20NETSARC%20network%20%28HR%3D1.61%2C%20p%5Cu202f%3D%5Cu202f0.003%29%2C%20old%20age%20%28p%5Cu202f%26lt%3B%5Cu202f0.001%29%2C%20and%20no%20final%20R0%20margin%20%28HR%3D2.60%2C%20p%5Cu202f%26lt%3B%5Cu202f0.001%29.%20Multivariate%20analysis%20identified%20several%20poor%20OS%20prognostic%20factors%3A%20angiosarcoma%20%28HR%3D2.03%2C%20p%5Cu202f%3D%5Cu202f0.065%29%2C%20trunk%5C%2Fhead%20and%20neck%20site%20%28HR%3D1.57%2C%20p%5Cu202f%3D%5Cu202f0.004%29%2C%20grades%202%20and%203%20%28respectively%20HR%3D2.21%2C%20p%5Cu202f%3D%5Cu202f0.039%20and%20HR%3D4.35%2C%20p%5Cu202f%26lt%3B%5Cu202f0.001%29%2C%20age%20%28p%5Cu202f%26lt%3B%5Cu202f0.001%29%2C%20and%20no%20final%20R0%20margins%20%28HR%3D2.02%2C%20p%5Cu202f%26lt%3B%5Cu202f0.001%29.%5CnCONCLUSION%3A%20Sarcoma%20clinical%20practice%20guideline%20compliance%20was%20associated%20with%20better%20surgery%20quality%2C%20reduced%20local%20relapse%20rates%2C%20and%20improved%20survival.%22%2C%22date%22%3A%222025-10-16%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejca.2025.115788%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221879-0852%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A12%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22LBP7IDFP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Blay%20et%20al.%22%2C%22parsedDate%22%3A%222025-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBlay%2C%20Jean-Yves%2C%20Maud%20Toulmonde%2C%20Thibaud%20Valentin%2C%20Nelly%20Firmin%2C%20Sarah%20Watson%2C%20Florence%20Duffaud%2C%20Emmanuelle%20Bompas%2C%20et%20al.%20%26%23x201C%3BClinical%20Presentation%2C%20Management%20and%20Outcome%20of%2011%2C132%20Patients%20with%20Liposarcoma%20Patients%3A%20A%20Population-Based%20Study%20from%20the%20NETSARC%2B%20Registry.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Lancet%20Regional%20Health.%20Europe%26lt%3B%5C%2Fi%26gt%3B%2057%20%28October%202025%29%3A%20101403.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lanepe.2025.101403%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lanepe.2025.101403%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20presentation%2C%20management%20and%20outcome%20of%2011%2C132%20patients%20with%20liposarcoma%20patients%3A%20a%20population-based%20study%20from%20the%20NETSARC%2B%20registry%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Duffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Rios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Ropars%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Anract%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armelle%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Gantzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis-Rom%5Cu00e9e%22%2C%22lastName%22%3A%22Le%20Nail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esma%22%2C%22lastName%22%3A%22Saada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Hervieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Bertucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Dubray-Longeras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Crenn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Perrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Soibinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Verret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gauthier%22%2C%22lastName%22%3A%22Decanter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Carrere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Henon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariella%22%2C%22lastName%22%3A%22Spalato-Ceruso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loic%22%2C%22lastName%22%3A%22Lebellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Colard-Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Camille%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Gouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Faron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Ryckewaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Meeus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Honor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Ngo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Meurgey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Chemin-Airiau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Ducimetiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Morelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Liposarcomas%20%28LPS%29%20are%20among%20the%20most%20common%20sarcomas%2C%20but%20gather%20a%20diversity%20of%20rare%20to%20ultrarare%20molecular%20subtypes%20whose%20presentations%20and%20natural%20histories%20are%20partially%20characterized.%20The%20aim%20of%20the%20work%20was%20to%20describe%20the%20presentation%20and%20outcome%20of%20the%20different%20LPS%20histotypes%20from%20the%20NETSARC%2B%20registry.%5CnMETHODS%3A%20NETSARC%2B%20%28netsarc.org%29%20is%20a%20network%20of%2026%20reference%20sarcoma%20centers%20with%20specialized%20multidisciplinary%20tumor%20boards%20%28MDTB%29%2C%20funded%20by%20the%20French%20INCA%20since%202010%20aiming%20to%20improve%20the%20quality%20of%20care%20of%20sarcoma%20patients.%20Patients%26%23039%3B%20characteristics%2C%20treatment%20and%20outcomes%20are%20collected%20in%20a%20nationwide%20database.%20This%20work%20describes%20the%20outcome%20of%20all%20LPS%20confirmed%20by%20central%20review%20pathology%20review%20and%20integrated%20between%202010%20and%202023%20in%20the%20NETSARC%2B%20database.%5CnFINDINGS%3A%2011%2C132%20liposarcomas%20are%20included%20in%20the%20database%20for%20an%20estimated%20incidence%20of%2011.5%5C%2F106%5C%2Fy.%20Median%20age%20was%2065%20%28Q1-Q3%3A%2053-74%2C%20range%200-97%20y%29%2C%20with%206529%20males%20%2858.7%25%29%2C%20with%204220%20%2837.9%25%29%20dedifferentiated%20%28DDLPS%29%2C%201838%20%2816.5%25%29%20well%20differentiated%20LPS%20%28WDLPS%29%20%26amp%3B%202424%20%2821.8%25%29%20atypical%20lipomatous%20tumours%20%28ALT%29%2C%201371%20%2812.3%25%29%20myxoid%20LPS%20%28MyxLPS%29%2C%20450%20%284.0%25%29%20pleomorphic%20LPS%20%28PLPS%29%2C%20177%20%281.6%25%29%20high%20grade%20myxoid%20LPS%20%28HGMLPS%29%2C%2024%20%280.2%25%29%20mixed%20type%20liposarcomas%20%28MTLPS%29%2C%2014%20%280.1%25%29%20myxoid%20pleomorphic%20LPS%20%28MPLPS%29%20and%20614%20%285.5%25%29%20non%20classified%20LPS%20%28NCLPS%29.%20Age%2C%20sex%20and%20sites%20differed%20across%20histotypes%2C%20but%20overall%2C%20all%20histotypes%20were%20represent%20in%20all%20age%20groups%20and%20sites.%20We%20report%20first%20on%20a%20difference%20in%20the%20sex%20ratio%20of%20liposarcoma%20in%20different%20age%20groups.%20Women%20were%20less%20frequently%20affected%20with%20liposarcomas%20after%2050%2C%20in%20DDLPS%2C%20MyxLPS%20and%20HGMLPS.%20The%20median%20overall%20survival%20of%20DDLPS%20was%20144%20months%2C%20significantly%20worse%20than%20that%20of%20MyxLPS%20%28HR%3A%200.26%20%5B95%25%20CI%200.21-0.33%5D%29%2C%20PLPS%20%28HR%3A%200.76%20%5B95%25%20CI%200.59-0.98%5D%29%2C%20HGMLPS%20%28HR%3A%200.30%20%5B95%25%20CI%200.18-0.50%5D%29%2C%20WDLPS%20%28HR%3A%200.30%20%5B95%25%20CI%200.24-0.37%5D%29%2C%20unclassified%20LPS%20%28HR%3A%200.53%20%5B95%25%20CI%200.37-0.75%5D%29.%20In%20addition%20to%20a%20lower%20incidence%2C%20women%20aged%20%26gt%3B50%20had%20a%20better%20relapse%20free%20and%20overall%20survival%20than%20male%2C%20while%20this%20was%20not%20observed%20in%20the%20group%20aged%2050%20or%20under.%20In%20multivariate%20analyses%2C%20size%20and%20age%20were%20independent%20prognostic%20factors%20for%20the%20most%20common%20subgroups%2C%20but%20specific%20prognostic%20parameters%20were%20observed%20in%20each%20molecular%20subgroup.%20Female%20%26gt%3B50%20was%20an%20independent%20favorable%20prognostic%20factor%20for%20the%20largest%20groups%20of%20DDLPS.%5CnINTERPRETATION%3A%20In%20this%20nationwide%20series%20of%20pathology-confirmed%20LPS%2C%20the%20clinical%20presentation%2C%20management%20and%20survival%20of%20histotypes%20are%20very%20different%20with%20age-related%20sex%20differences%20favoring%20women%20%26gt%3B50.%20DDLPS%20is%20the%20subtype%20with%20the%20worse%20prognosis.%5CnFUNDING%3A%20This%20work%20was%20supported%20by%20the%20following%20grants%3A%20NetSARC%2B%20%28INCA%29%2C%20RREPS%20%28INCA%29%2C%20RESOS%20%28INCA%29%2C%20INTERSARC%2B%20%28INCA%29%2C%20LabEx%20DEvweCAN%20%28ANR-10-LABX-0061%29%2C%20LYriCAN%2B%20%28INCa-DGOS-INSERM-ITMO%20cancer_18%2C003%29%2C%20Ligue%20Nationale%20contre%20le%20Cancer%2C%20Ligue%20Contre%20le%20Cancer%20%28Comit%5Cu00e9%20de%20l%26%23039%3BAin%29%2C%20Fondation%20ARC%2C%20and%20EURACAN%20%28EU%20project%20739521%29.%22%2C%22date%22%3A%222025-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lanepe.2025.101403%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222666-7762%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A13%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22EGA2PP3M%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barr%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222025-09-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBarr%26%23xE9%3B%2C%20Tangui%2C%20Cl%26%23xE9%3Bmence%20Ramier%2C%20Linda%20Wittkop%2C%20Philippe%20Sogni%2C%20David%20Zucman%2C%20Rapha%26%23xEB%3Blle%20Tardieu%2C%20Patrizia%20Carrieri%2C%20Fabienne%20Marcellin%2C%20and%20ANRS%20CO13%20HEPAVIH%20Study%20Group.%20%26%23x201C%3BLow%20CD4%20Cell%20Count%20Is%20Associated%20With%20Post-Hepatitis%20C%20Virus%20Cure%20Mortality%20in%20People%20With%20HIV%20%28ANRS%20CO13%20HEPAVIH%20Cohort%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Infectious%20Diseases%3A%20An%20Official%20Publication%20of%20the%20Infectious%20Diseases%20Society%20of%20America%26lt%3B%5C%2Fi%26gt%3B%2081%2C%20no.%202%20%28September%2016%2C%202025%29%3A%20e28%26%23x2013%3B30.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciaf016%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciaf016%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Low%20CD4%20Cell%20Count%20Is%20Associated%20With%20Post-Hepatitis%20C%20Virus%20Cure%20Mortality%20in%20People%20With%20HIV%20%28ANRS%20CO13%20HEPAVIH%20Cohort%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tangui%22%2C%22lastName%22%3A%22Barr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Ramier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linda%22%2C%22lastName%22%3A%22Wittkop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Sogni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Zucman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00eblle%22%2C%22lastName%22%3A%22Tardieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrizia%22%2C%22lastName%22%3A%22Carrieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Marcellin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ANRS%20CO13%20HEPAVIH%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-09-16%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciaf016%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221537-6591%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A11%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22CAVZBITB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fazel%20et%20al.%22%2C%22parsedDate%22%3A%222025-09-15%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFazel%2C%20Mina%2C%20Romain%20Varnier%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Vanacker%2C%20Nicolas%20Penel%2C%20Sarah%20Watson%2C%20Benjamin%20Verret%2C%20Thibaud%20Valentin%2C%20et%20al.%20%26%23x201C%3BClinical%20and%20Biological%20Factors%20Associated%20with%20Response%20to%20Immune%20Checkpoint%20Inhibitors%20in%20Advanced%20Sarcomas%3A%20IMPRESARC%2C%20a%20French%20Retrospective%20Multicenter%20Cohort%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%26lt%3B%5C%2Fi%26gt%3B%20131%2C%20no.%2018%20%28September%2015%2C%202025%29%3A%20e70052.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcncr.70052%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcncr.70052%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20and%20biological%20factors%20associated%20with%20response%20to%20immune%20checkpoint%20inhibitors%20in%20advanced%20sarcomas%3A%20IMPRESARC%2C%20a%20French%20retrospective%20multicenter%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mina%22%2C%22lastName%22%3A%22Fazel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Varnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Vanacker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Verret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Waisse%22%2C%22lastName%22%3A%22Waissi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Meurgey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Ducimeti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armelle%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Brahmi%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Immune%20checkpoint%20inhibitors%20%28ICIs%29%20in%20unselected%20sarcomas%20yield%20limited%20response%20rates%20and%20tumor%20control.%20Long-term%20responders%20have%20however%20been%20reported%2C%20suggesting%20a%20critical%20challenge%20in%20refining%20patient%20selection%2C%20by%20identifying%20reliable%20predictive%20factors%20for%20response.%5CnMETHODS%3A%20The%20authors%20conducted%20a%20multicenter%2C%20retrospective%20study%20of%20patients%20with%20advanced%20sarcomas%20treated%20with%20ICIs%20in%20six%20French%20reference%20sarcoma%20centers.%20The%20study%20assessed%20efficacy%20and%20safety%2C%20as%20well%20as%20clinical%20and%20biological%20variables%20associated%20with%20objective%20response%20rate%20%28ORR%29%2C%20progression-free%20survival%20%28PFS%29%2C%20and%20overall%20survival%20%28OS%29.%5CnRESULTS%3A%20A%20total%20of%20272%20patients%20were%20included%20in%20the%20analysis.%20The%20ORR%20was%2017%25%2C%20with%2016%25%20partial%20responses%20and%201%25%20complete%20responses.%20Stable%20disease%20%28SD%29%20occurred%20in%2033%25%20of%20patients%2C%20resulting%20in%20a%20disease%20control%20rate%20of%2049%25.%20Median%20PFS%20was%202.7%20months%20%2895%25%20confidence%20interval%20%5BCI%5D%2C%202.5-3.4%29%2C%20with%2028%25%20of%20patients%20showing%20PFS%20%26gt%3B6%20months%20and%2013%25%20with%20PFS%20%26gt%3B12%20months.%20Median%20OS%20was%2013.5%20months%20%2895%25%20CI%2C%2011.0-17.3%29.%20The%20safety%20profile%20was%20consistent%20with%20that%20of%20clinical%20trials%2C%20with%205%25%20of%20patients%20experiencing%20grade%20%5Cu22653%20adverse%20events%20and%2010%25%20discontinuing%20treatment%20due%20to%20toxicity.%20Poorer%20outcomes%20were%20associated%20with%20high%20Eastern%20Cooperative%20Oncology%20Group%20performance%20status%20%28%5Cu22651%29%2C%20cyclophosphamide%20coadministration%2C%20and%20high%20derived%20neutrophil-to-lymphocyte%20ratio.%20Anti-programmed%20death-ligand%201%20%28PD-L1%29%20therapies%20were%20associated%20with%20shorter%20OS%20compared%20to%20anti-PD-1.%20Histotypes%20such%20as%20alveolar%20soft%20part%20sarcoma%20%28ASPS%29%20had%20better%20survival%2C%20whereas%20dedifferentiated%20liposarcoma%20had%20poorer%20outcomes.%5CnCONCLUSIONS%3A%20Despite%20a%20short%20median%20PFS%2C%20certain%20histological%20subtypes%2C%20including%20ASPS%2C%20chordomas%2C%20SMARCA4-deficient%20tumors%2C%20gastro-intestinal%20stromal%20tumor%2C%20and%20NF1%20mutations%2C%20showed%20strong%20activity%20signals%2C%20indicating%20long-term%20responses%20in%20some%20patients.%22%2C%22date%22%3A%222025-09-15%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fcncr.70052%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221097-0142%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A12%3A49Z%22%7D%7D%2C%7B%22key%22%3A%2295GS5ZFI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Blay%20et%20al.%22%2C%22parsedDate%22%3A%222025-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBlay%2C%20J.-Y.%2C%20Q.%20Devin%2C%20M.%20Toulmonde%2C%20A.%20Dufresne%2C%20N.%20Penel%2C%20A.%20Adenis%2C%20M.%20Rios%2C%20et%20al.%20%26%23x201C%3BTwenty-Year%20Survival%20of%20Advanced%20Gastrointestinal%20Stromal%20Tumours%20Treated%20with%20Imatinib%3A%20Exploratory%20Long-Term%20Follow-up%20of%20the%20BFR14%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2036%2C%20no.%209%20%28September%202025%29%3A%201035%26%23x2013%3B46.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2025.05.535%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2025.05.535%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Twenty-year%20survival%20of%20advanced%20gastrointestinal%20stromal%20tumours%20treated%20with%20imatinib%3A%20exploratory%20long-term%20follow-up%20of%20the%20BFR14%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-Y.%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Q.%22%2C%22lastName%22%3A%22Devin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Adenis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Rios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bertucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Duffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Collard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Pracht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Hervieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Verret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I.%22%2C%22lastName%22%3A%22Ray-Coquard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Cassier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Henon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Perol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Chabaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Gastrointestinal%20stromal%20tumours%20%28GIST%29%20are%20driven%20by%20mutations%20in%20KIT%20and%20platelet%20derived%20growth%20factor%20receptor%20A%20%28PDGFRA%29%20kinases%20in%20%26gt%3B75%25%20of%20patients.%20Imatinib%2C%20a%20tyrosine%20kinase%20inhibitor%2C%20has%20shown%20efficacy%20in%20metastatic%20GIST%20but%20the%20long-term%20survival%20impact%20remains%20less%20understood%2C%20especially%20after%20extended%20treatment%20durations.%5CnPATIENTS%20AND%20METHODS%3A%20The%20BFR14%20study%2C%20initiated%20in%202002%2C%20is%20a%20multicentric%20randomized%20phase%20III%20clinical%20trial%20involving%20434%20patients%20with%20advanced%20or%20unresectable%20GIST%2C%20treated%20with%20imatinib.%20This%20long-term%20follow-up%20aimed%20to%20assess%20the%20survival%20outcomes%20of%20the%20patients%20prospectively%20included%20in%20this%20study.%20Patient%20demographics%2C%20mutation%20status%2C%20overall%20survival%20%28OS%29%20and%20response%20rates%20were%20collected.%5CnRESULTS%3A%20With%20a%20median%20follow-up%20of%20219%20months%2C%20median%20OS%20was%2075.3%20months.%20Survival%20rates%20at%2010%2C%2015%2C%20and%2020%20years%20were%2033.9%25%2C%2019.8%25%2C%20and%2013.1%25%2C%20respectively.%20Factors%20significantly%20associated%20with%20better%20survival%20included%20female%20sex%2C%20gastric%20tumour%20location%2C%20smaller%20primary%20tumour%20size%2C%20and%20KIT%20exon%2011%20mutations.%20Complete%20response%20to%20imatinib%20and%20complete%20surgical%20resection%20of%20metastases%20with%20R0%20resections%20are%20associated%20with%20a%20doubling%20of%20median%20survival%20and%20a%20significantly%20prolonged%20OS.%5CnCONCLUSIONS%3A%20This%20long-term%20follow-up%20of%20the%20BFR14%20trial%20shows%20long-term%20efficacy%20of%20imatinib%20in%20patients%20with%20advanced%20GIST.%20Complete%20resection%20of%20metastasis%20and%20achievement%20of%20complete%20response%20is%20associated%20with%20a%20doubling%20of%20median%20survival.%22%2C%22date%22%3A%222025-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annonc.2025.05.535%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221569-8041%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A14%3A08Z%22%7D%7D%2C%7B%22key%22%3A%222XPJ5GLC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Michot%20et%20al.%22%2C%22parsedDate%22%3A%222025-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMichot%2C%20A.%2C%20A.%20Giraud%2C%20M.%20Karanian%2C%20M.%20La%26%23xE9%3B%2C%20M.%20Fau%2C%20D.%20Adam%2C%20R.%20Wernert%2C%20et%20al.%20%26%23x201C%3BRadiation-Associated%20Angiosarcoma%20of%20the%20Breast%3A%20Consider%20Chemotherapy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Surgical%20Oncology%3A%20The%20Journal%20of%20the%20European%20Society%20of%20Surgical%20Oncology%20and%20the%20British%20Association%20of%20Surgical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2051%2C%20no.%209%20%28September%202025%29%3A%20110202.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2025.110202%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2025.110202%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Radiation-associated%20angiosarcoma%20of%20the%20breast%3A%20consider%20chemotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Michot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Giraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22La%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Fau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Adam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Wernert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20M.%22%2C%22lastName%22%3A%22Guilloit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Calais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Rios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Thyss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Causeret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Sunyach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Tzanis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Sargos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Stoeckle%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Radiation-associated%20angiosarcoma%20%28RAAS%29%20of%20the%20breast%20arises%20as%20a%20rare%20secondary%20effect%20of%20radiotherapy%20administered%20for%20breast%20cancer.%20The%20prognosis%20for%20RAAS%20is%20poorly%20understood%2C%20and%20surgical%20outcomes%20are%20often%20unsatisfactory.%20Our%20group%20investigated%20the%20impact%20of%20neoadjuvant%20chemotherapy%20%28NAC%29%20on%20RAAS.%20This%20study%20aims%20to%20refine%20prognostic%20factors%20and%20assess%20the%20effect%20of%20NAC%20on%20breast%20RAAS.%5CnMETHODS%3A%20We%20analyzed%20M0%20patients%20who%20underwent%20surgery%20for%20breast%20RAAS.%20Prognostic%20factors%20for%20overall%20survival%20%28OS%29%2C%20time%20to%20distant%20progression%20%28TTDP%29%2C%20and%20time%20to%20loco-regional%20progression%20%28TTLP%29%20were%20identified.%20Outcomes%20in%20patients%20receiving%20surgery%20alone%20%28S%29%20were%20compared%20to%20those%20receiving%20NAC%20followed%20by%20surgery%20%28NAC%5Cu00a0%2B%5Cu00a0S%29%20using%20Cox%20regression.%20Results%20were%20further%20validated%20through%20a%20propensity%20score%20model.%5CnRESULTS%3A%20Out%20of%20180%20patients%20%28179%20women%29%2C%20141%20received%20S%2C%20and%2039%20received%20NAC%5Cu00a0%2B%5Cu00a0S.%20Median%20follow-up%20was%205.5%20years.%20The%205-year%20OS%20rate%20was%2050%5Cu00a0%25.%20Local%20recurrence%20occurred%20twice%20as%20often%20as%20metastases%2C%20with%20TTLP%20and%20TTDP%20rates%20of%2068%5Cu00a0%25%20and%2036%5Cu00a0%25%2C%20respectively.%20TTLP%20for%20patients%20treated%20with%20NAC%5Cu00a0%2B%5Cu00a0S%20and%20Swas%2053%5Cu00a0%25%20vs.%2030%5Cu00a0%25%20%28p%5Cu00a0%3D%5Cu00a00.03%29%2C%20respectively.%20Both%2C%20treatment%20sequence%20%28NAC%5Cu00a0%2B%5Cu00a0S%20vs.%20S%29%20and%20age%2C%20independently%20predicted%20TTLP%2C%20a%20finding%20confirmed%20by%20the%20propensity%20score%20model.%5CnCONCLUSION%3A%20For%20patients%20with%20breast%20RAAS%2C%20Neoadjuvant%20chemotherapy%20followed%20by%20surgery%20appears%20to%20offer%20superior%20local%20control%20compared%20to%20surgery%20alone%2C%20potentially%20enhancing%20quality%20of%20life.%22%2C%22date%22%3A%222025-09%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejso.2025.110202%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221532-2157%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A13%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22SJVTKZ7A%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Callegaro%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCallegaro%2C%20Dario%2C%20Gabriele%20Tin%26%23xE8%3B%2C%20Felix%20Boakye%20Oppong%2C%20Axelle%20Nzokirantevye%2C%20Saskia%20Liti%26%23xE8%3Bre%2C%20Stefano%20Percio%2C%20Andrea%20Carenzo%2C%20et%20al.%20%26%23x201C%3BCINSARC%20and%20Sarculator%20in%20Patients%20with%20Primary%20Retroperitoneal%20Sarcoma%3A%20A%20Combined%20Analysis%20of%20Single-Institution%20Data%20and%20the%20EORTC-STBSG-62092%20Trial%20%28STRASS%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Cancer%20Research%3A%20An%20Official%20Journal%20of%20the%20American%20Association%20for%20Cancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2031%2C%20no.%2015%20%28August%201%2C%202025%29%3A%203239%26%23x2013%3B48.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-25-0099%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-25-0099%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CINSARC%20and%20Sarculator%20in%20Patients%20with%20Primary%20Retroperitoneal%20Sarcoma%3A%20A%20Combined%20Analysis%20of%20Single-Institution%20Data%20and%20the%20EORTC-STBSG-62092%20Trial%20%28STRASS%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dario%22%2C%22lastName%22%3A%22Callegaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriele%22%2C%22lastName%22%3A%22Tin%5Cu00e8%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%20Boakye%22%2C%22lastName%22%3A%22Oppong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axelle%22%2C%22lastName%22%3A%22Nzokirantevye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saskia%22%2C%22lastName%22%3A%22Liti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefano%22%2C%22lastName%22%3A%22Percio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Carenzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loris%22%2C%22lastName%22%3A%22De%20Cecco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Brich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessia%22%2C%22lastName%22%3A%22Bertolotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Collini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Maria%22%2C%22lastName%22%3A%22Frezza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rick%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Winan%20J.%22%2C%22lastName%22%3A%22van%20Houdt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosalba%22%2C%22lastName%22%3A%22Miceli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandro%22%2C%22lastName%22%3A%22Pasquali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Gronchi%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20The%20Complexity%20INdex%20in%20SARComas%20%28CINSARC%29%20predicts%20the%20metastatic%20risk%20in%20patients%20with%20soft-tissue%20sarcoma.%20The%20aims%20of%20this%20study%20were%20to%20provide%20the%20first%20independent%20validation%20of%20CINSARC%20in%20patients%20with%20retroperitoneal%20sarcoma%20%28RPS%29%20and%20evaluate%20whether%20CINSARC%20could%20enhance%20the%20performance%20of%20Sarculator.%5CnEXPERIMENTAL%20DESIGN%3A%20A%20retrospective%20cohort%20included%20patients%20with%20primary%20localized%20RPS%20resected%20with%20curative%20intent%20%282011-2015%29%20at%20a%20single%20institution.%20The%20STRASS%20cohort%20comprised%20patients%20from%20the%20surgery-only%20arm%20of%20the%20EORTC-STBSG-62092%20%28STRASS%29%20trial%20who%20had%20undergone%20CINSARC%20categorization.%20Patients%20were%20classified%20as%20CINSARC%20low-risk%20%28C1%29%20versus%20high-risk%20%28C2%29.%20Primary%20study%20endpoints%20were%20overall%20survival%20%28OS%29%20and%20disease-free%20survival%20%28DFS%29.%20Sarculator%20performance%20was%20assessed%20in%20terms%20of%20discrimination%20%28the%20Harrell%20C-index%29%20and%20calibration%20%28calibration%20plots%20and%20the%20Brier%20score%29%20before%20and%20after%20adding%20CINSARC.%5CnRESULTS%3A%20The%20study%20cohorts%20included%20104%20and%2069%20patients%2C%20respectively%2C%20with%20similar%20OS.%20In%20a%20pooled%20cohort%2C%20in%20multivariable%20analysis%20for%20OS%20considering%20Sarculator%20and%20CINSARC%2C%20only%20Sarculator%20was%20significantly%20associated%20with%20OS%20%5BHR%2C%201.93%3B%2095%25%20confidence%20interval%20%28CI%29%2C%201.35-2.74%3B%20P%20%26lt%3B%200.001%5D.%20In%20multivariable%20analysis%20for%20DFS%2C%20both%20Sarculator%20%28HR%2C%201.51%3B%2095%25%20CI%2C%201.09-2.09%3B%20P%20%3D%200.013%29%20and%20CINSARC%20%28HR%2C%202.01%3B%2095%25%20CI%2C%201.26-3.23%3B%20P%20%3D%200.004%29%20were%20significantly%20associated%20with%20DFS.%20However%2C%20the%20addition%20of%20CINSARC%20did%20not%20improve%20Sarculator%26%23039%3Bs%20discrimination%20or%20calibration%20for%20either%20OS%20or%20DFS.%5CnCONCLUSIONS%3A%20This%20study%20validates%20CINSARC%20as%20a%20prognostic%20predictor%20for%20OS%20and%20DFS%20in%20patients%20with%20primary%20RPS.%20CINSARC%20did%20not%20improve%20the%20performance%20of%20Sarculator%2C%20suggesting%20that%20its%20addition%20to%20the%20Sarculator%20may%20not%20provide%20added%20clinical%20benefit.%22%2C%22date%22%3A%222025-08-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-25-0099%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221557-3265%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A06%3A46Z%22%7D%7D%2C%7B%22key%22%3A%226QYQFFQK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Penel%20et%20al.%22%2C%22parsedDate%22%3A%222025-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPenel%2C%20N.%2C%20A.%20Italiano%2C%20J.%20Wallet%2C%20L.%20Chaigneau%2C%20B.%20Verret%2C%20N.%20Firmin%2C%20S.%20Watson%2C%20et%20al.%20%26%23x201C%3BRegorafenib%20as%20Maintenance%20Therapy%20after%20First-Line%20Doxorubicin-Based%20Chemotherapy%20in%20Advanced%20Non-Adipocytic%20Soft%20Tissue%20Sarcomas%20Patients%3A%20A%20Double-Blind%20Randomised%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2036%2C%20no.%208%20%28August%202025%29%3A%20944%26%23x2013%3B53.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2025.03.024%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2025.03.024%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Regorafenib%20as%20maintenance%20therapy%20after%20first-line%20doxorubicin-based%20chemotherapy%20in%20advanced%20non-adipocytic%20soft%20tissue%20sarcomas%20patients%3A%20a%20double-blind%20randomised%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Wallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Chaigneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Verret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Bertucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Henon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Brunot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Spalato-Ceruso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Vanseymortier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Heyman-Decoupigny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Ryckewaert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20C.%22%2C%22lastName%22%3A%22Le%20Deley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Perrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Blay%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20There%20is%20no%20approved%20maintenance%20therapy%20in%20advanced%20non-adipocytic%20soft%20tissue%20sarcomas%20%28STS%29.%20We%20explore%20here%20the%20role%20of%20regorafenib%20as%20a%20potential%20maintenance%20therapy%20after%20first-line%20treatment.%5CnPATIENTS%20AND%20METHODS%3A%20EREMISS%20%28NCT03793361%29%20was%20a%20double-blind%2C%20placebo-controlled%2C%20comparative%2C%201%20%3A%201%20randomised%20phase%20II%20trial%20assessing%20the%20activity%20and%20safety%20of%20regorafenib%20%28120%20mg%5C%2Fday%2C%203%20weeks%20on%5C%2F1%20week%20off%29%20in%20patients%20with%20non-adipocytic%20STS%2C%20who%20had%20stable%20disease%20or%20partial%20response%20after%20six%20cycles%20of%20doxorubicin-based%20chemotherapy%20as%20first-line%20treatment%20of%20advanced%20disease.%20The%20primary%20endpoint%20was%20progression-free%20survival%20%28PFS%29%20according%20to%20RECIST%201.1%20evaluated%20by%20blinded%20central%20review.%20Based%20on%20the%20following%20assumptions%3A%20PFS%20%28placebo%29%20%3D%204%20months%2C%20expected%20PFS%20%28regorafenib%29%20%3D%207%20months%2C%20hazard%20ratio%20%28HR%29%20%3D%200.57%2C%20one-sided%20%5Cu03b1%20%3D%200.05%20and%20%5Cu03b2%20%3D%200.10%2C%20110%20events%20and%20126%20patients%20were%20required.%20This%20study%20was%20supported%20by%20French%20National%20Cancer%20Institute%2C%20a%20patient%20advocacy%20group%20and%20Bayer%20HealthCare.%5CnRESULTS%3A%20The%20study%20population%20consisted%20of%20126%20patients%20enrolled%20in%2017%20centres%20from%20May%202019%20to%20November%202022.%20Female%20patients%20accounted%20for%2055%25%20of%20total%20enrolment.%20The%20median%20age%20was%2058%20years%20%28range%2018-85%20years%29.%20The%20most%20common%20histological%20subtype%20was%20leiomyosarcoma%20%2859%25%29.%20The%20primary%20objective%20was%20assessable%20in%20122%20patients%20%28109%20events%29.%20Median%20PFS%20by%20blinded%20central%20review%20was%203.5%20%28placebo%29%20versus%205.6%20months%20%28regorafenib%29%20%28HR%20%3D%200.53%2C%2095%25%20CI%200.36-0.78%3B%20P%20%3D%200.001%29.%20Median%20overall%20survival%20was%2020.5%20versus%2027.6%20months%20%28HR%20%3D%200.78%2C%2095%25%20CI%200.50-1.22%2C%20P%20%3D%200.28%29.%20The%20proportion%20of%20patients%20with%20grade%20%5Cu22653%20adverse%20events%20was%204.8%25%20%28placebo%29%20versus%2056.3%25%20%28regorafenib%29.%20The%20most%20common%20grade%20%5Cu22653%20clinical%20adverse%20events%20in%20the%20regorafenib%20arm%20were%20asthenia%20%289%25%29%2C%20arterial%20hypertension%20%288%25%29%2C%20and%20rash%20%288%25%29.%5CnCONCLUSION%3A%20This%20trial%20met%20its%20primary%20objective%2C%20regorafenib%20significantly%20delayed%20disease%20progression%20after%20first-line%20treatment%20in%20advanced%20non-adipocytic%20STS.%20This%20was%20associated%20with%20a%20non-significant%20trend%20of%20overall%20survival%20improvement.%22%2C%22date%22%3A%222025-08%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annonc.2025.03.024%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221569-8041%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A14%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22NP8NYQ7C%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Toulmonde%20et%20al.%22%2C%22parsedDate%22%3A%222025-06-27%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BToulmonde%2C%20Maud%2C%20Jean-Philippe%20Gu%26%23xE9%3Bgan%2C%20Mariella%20Spalato-Ceruso%2C%20Thibaud%20Valentin%2C%20Rastilav%20Bahleda%2C%20Florent%20Peyraud%2C%20Christophe%20Rey%2C%20et%20al.%20%26%23x201C%3BReshaping%20the%20Tumor%20Microenvironment%20of%20Cold%20Soft-Tissue%20Sarcomas%20with%20Anti-Angiogenics%3A%20A%20Phase%202%20Trial%20of%20Regorafenib%20Combined%20with%20Avelumab.%26%23x201D%3B%20%26lt%3Bi%26gt%3BSignal%20Transduction%20and%20Targeted%20Therapy%26lt%3B%5C%2Fi%26gt%3B%2010%2C%20no.%201%20%28June%2027%2C%202025%29%3A%20202.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41392-025-02278-9%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41392-025-02278-9%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Reshaping%20the%20tumor%20microenvironment%20of%20cold%20soft-tissue%20sarcomas%20with%20anti-angiogenics%3A%20a%20phase%202%20trial%20of%20regorafenib%20combined%20with%20avelumab%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Gu%5Cu00e9gan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariella%22%2C%22lastName%22%3A%22Spalato-Ceruso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rastilav%22%2C%22lastName%22%3A%22Bahleda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Peyraud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mich%5Cu00e8le%22%2C%22lastName%22%3A%22Kind%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coralie%22%2C%22lastName%22%3A%22Cantarel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Bellera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Vanhersecke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alban%22%2C%22lastName%22%3A%22Bessede%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Italiano%22%7D%5D%2C%22abstractNote%22%3A%22The%20majority%20of%20sarcomas%20are%20under%20the%20influence%20of%20a%20tumor%20microenvironment%20that%20dampens%20immune%20activity%2C%20resulting%20in%20resistance%20to%20monoclonal%20antibodies%20targeting%20immune%20checkpoints%20and%20reduced%20clinical%20effectiveness.%20Preclinical%20studies%20indicate%20that%20targeting%20abnormal%20neoangiogenesis%20by%20inhibiting%20vascular%20endothelial%20growth%20factor%20receptor%20%28VEGFR%29%20can%20alter%20the%20TME%2C%20thereby%20promoting%20T%20cell%20infiltration%20and%20increasing%20tumor%20immunogenicity.%20The%20REGOMUNE%20study%2C%20a%20phase%20II%20clinical%20trial%2C%20assessed%20the%20therapeutic%20combination%20of%20regorafenib%2C%20a%20multityrosine%20kinase%20inhibitor%20that%20targets%20VEGFR2%20and%20the%20PD-L1%20blocker%20avelumab%2C%20in%20individuals%20with%20advanced%20%26quot%3Bcold%26quot%3B%20STS%20characterized%20by%20a%20lack%20of%20mature%20tertiary%20lymphoid%20structures%20%28mTLS%29.%20Forty-nine%20mTLS-negative%20STS%20patients%20were%20enrolled%2C%20including%20leiomyosarcoma%20%2845%25%29%2C%20synovial%20sarcoma%20%2818%25%29%2C%20and%20other%20subtypes.%20The%20objective%20response%20rate%20was%2011.0%25%20%2895%25%20CI%3A%204.0%25%20-%2022.0%25%29%2C%20with%20median%20progression-free%20survival%20and%20overall%20survival%20of%201.8%20months%20%2895%25%20CI%2C%201.7-3.5%20months%29%20and%2015.1%20months%2C%20respectively.%20Frequent%20adverse%20events%20included%20grade%201%20or%202%20palmar-plantar%20erythrodysesthesia%2C%20fatigue%2C%20and%20diarrhea.%20On-treatment%20multiplex%20immunofluorescence%20analysis%20revealed%20significant%20increases%20in%20CD8%5Cu2009%2B%5Cu2009T%20cell%20and%20B%20cell%20infiltration%20and%20PD1%20expression%20on%20immune%20cells.%20Plasma%20analysis%20indicated%20significant%20upregulation%20of%20soluble%20PD-L1%20%28sPD-L1%29%20levels%20and%20tryptophan%20consumption.%20Overall%2C%20these%20results%20indicate%20that%20anti-angiogenic%20therapy%20modulates%20the%20tumor%20microenvironment%20in%20patients%20with%20cold%20STS%20and%20highlight%20the%20need%20for%20complementary%20strategies%20to%20enhance%20the%20functional%20activity%20of%20immune%20cells%20in%20this%20particular%20setting.%20Clinical%20trial%20registration%20number%3A%20NCT03475953.%22%2C%22date%22%3A%222025-06-27%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41392-025-02278-9%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222059-3635%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A13%3A54Z%22%7D%7D%2C%7B%22key%22%3A%2255Z2X2JI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Winter%20et%20al.%22%2C%22parsedDate%22%3A%222025-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWinter%2C%20Sarah%2C%20Thibaud%20Valentin%2C%20Anne%20Ducassou%2C%20Sylvie%20Helfre%2C%20Pablo%20Berlanga%2C%20Lauriane%20Lemelle%2C%20Aude%20Marie-Cardine%2C%20Pascaline%20Boudou%20Rouquette%2C%20and%20Val%26%23xE9%3Brie%20Laurence.%20%26%23x201C%3B%5BExtra-pulmonary%20metastatic%20Ewing%20sarcoma%3A%20The%20French%20GroupOs%20diagnostic%20and%20therapeutic%20recommendations%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20112%2C%20no.%206%20%28June%202025%29%3A%20619%26%23x2013%3B25.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2024.01.014%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2024.01.014%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BExtra-pulmonary%20metastatic%20Ewing%20sarcoma%3A%20The%20French%20GroupOs%20diagnostic%20and%20therapeutic%20recommendations%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Helfre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Berlanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauriane%22%2C%22lastName%22%3A%22Lemelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Marie-Cardine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascaline%20Boudou%22%2C%22lastName%22%3A%22Rouquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Laurence%22%7D%5D%2C%22abstractNote%22%3A%22Patients%20who%20develop%20Ewing%20sarcoma%20with%20extra-pulmonary%20metastasis%20have%20a%20poor%20prognosis.%20A%20recent%20French%20protocol%2C%20CombinaiR3%2C%20was%20set%20up%20to%20evaluate%20the%20efficacy%20of%20induction%20chemotherapy%20followed%20by%20high-dose%20chemotherapy%20and%20metronomic%20maintenance%20treatment.%20It%20is%20now%20closed%20for%20inclusions%20and%20while%20waiting%20for%20the%20results%2C%20we%20propose%20a%20French%20consensus%20guideline%20for%20the%20management%20of%20patients%20diagnosed%20with%20Ewing%20sarcoma%20with%20extra-pulmonary%20dissemination.%20Main%20recommendations%20include%20induction%20chemotherapy%20with%20nine%20cycles%20of%20vincristine%5C%2Fdoxorubicin%5C%2Fcyclophosphamide%20alternating%20with%20ifosfamide%5C%2Fetoposide.%20In%20case%20of%20insufficient%20response%2C%20other%20chemotherapy%20combination%20or%20inclusion%20in%20a%20clinical%20trial%20should%20be%20considered.%20Induction%20chemotherapy%20should%20be%20followed%20by%20local%20treatment%2C%20consisting%20of%20surgery%20and%5C%2For%20radiotherapy.%20Optimal%20local%20treatment%20is%20a%20milestone%20in%20the%20management%20of%20patients%20with%20Ewing%20sarcoma%20and%20should%20be%20discussed%20with%20experts%20and%20surgeons%5C%2Fradiotherapists%20working%20in%20the%20sarcoma%20network.%20High-dose%20chemotherapy%20%28HDC%29%20containing%20busulfan%20and%20melphalan%20followed%20by%20autologous%20stem-cell%20transplantation%20is%20still%20unclear%2C%20with%20contradictory%20results.%20HDC%20will%20then%20be%20discussed%20in%20national%20tumor%20board%20and%20administered%20to%20patients%20when%20compatible%20with%20local%20treatment.%20Given%20the%20high%20relapse%20rate%20observed%20among%20these%20metastatic%20patients%2C%20maintenance%20chemotherapy%20%28so%20called%20metronomic%20regimen%29%20will%20then%20be%20given%20for%20two%20years.%22%2C%22date%22%3A%222025-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2024.01.014%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221769-6917%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A15%3A16Z%22%7D%7D%2C%7B%22key%22%3A%227K38B5GY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Valentin%20et%20al.%22%2C%22parsedDate%22%3A%222025-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BValentin%2C%20Thibaud%2C%20Sarah%20Winter%2C%20Valentine%20Martin%2C%20Marie%20Csanyi%2C%20Perrine%20Marec%20Berard%2C%20Val%26%23xE9%3Brie%20Laurence%2C%20and%20Nathalie%20Gaspar.%20%26%23x201C%3BPrimary%20Cutaneous%5C%2FSubcutaneous%20Ewings%20Sarcoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20112%2C%20no.%206%20%28June%202025%29%3A%20611%26%23x2013%3B18.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2023.10.011%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2023.10.011%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Primary%20cutaneous%5C%2Fsubcutaneous%20Ewings%20sarcoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valentine%22%2C%22lastName%22%3A%22Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Csanyi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Marec%20Berard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Laurence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%5D%2C%22abstractNote%22%3A%22Amongst%20Ewing%20sarcoma%20family%20of%20tumours%2C%20%28EFST%29%2C%20cutaneous%5C%2Fsubcutaneous%20Ewing%20sarcoma%20are%20defined%20as%20tumours%20arising%20from%20cutaneous%20or%20subcutaneous%20tissue%2C%20not%20invading%20the%20underlying%20aponeurosis.%20They%20are%20rare%20tumours%2C%20with%20less%20than%20200%20patients%20published.%20They%20are%20typically%20small%20tumours%20%28less%20than%205cm%29%2C%20and%20can%20arise%20at%20any%20anatomical%20location%2C%20with%20a%20particular%20tropism%20for%20distal%2C%20truncal%20and%20head%5C%2Fneck%20locations%2C%20compared%20to%20classical%20Ewing%20sarcoma.%20Like%20other%20conjunctive%20tumours%2C%20they%20have%20to%20be%20treated%20in%20specialized%20centers%2C%20with%20a%20diagnostic%20procedure%20following%20ESMO%20guidelines%20about%20soft-tissue%20tumours%2C%20favoring%20a%20core%20needle%20biopsy%20in%20most%20cases.%20They%20share%20classical%20pathological%20and%20molecular%20features%20of%20EFST%20%28including%20EWSR1%20rearrangement%29.%20Metastatic%20presentation%20is%20rare%20%28less%20than%205%25%20at%20diagnosis%29%2C%20but%20must%20be%20carefully%20searched%20using%20appropriated%20imaging%20considered%20the%20bad%20prognosis%20of%20these%20patients.%20Treatment%20strategy%20relies%20on%20neoadjuvant%20and%20adjuvant%20chemotherapy%2C%20surrounding%20the%20local%20treatment.%20Patients%20with%20localized%20disease%20have%20good%20prognosis%20and%20have%20to%20be%20treated%20with%20the%20dual%20objective%20of%20curability%2C%20and%20of%20minimizing%20acute%20and%20late%20toxicity.%20That%20is%20why%20in%20case%20of%20small%20tumours%20%28%26lt%3B200mL%29%2C%20patients%20can%20be%20treated%20with%20less%20intensive%20protocols%2C%20as%20Saint%20Jude%26%23039%3Bs%20%28low-dose%20semi-continuous%20cyclophosphamide%5C%2Fdoxorubicin%20regimen%20as%20induction%20chemotherapy%20and%20vincristine%5C%2Factinomycin%20courses%20as%20maintenance%20therapy%29%2C%20setting%20aside%20the%20option%20of%20classical%20VDC%5C%2FIE%20protocol%20for%20larger%20tumors.%20Local%20treatment%20must%20rely%20on%20carcinologic%20surgery%2C%20with%20the%20aim%20to%20avoid%20radiotherapy%20when%20possible.%20Patients%20with%20metastatic%20disease%20have%20bad%20prognosis%20resemble%20classical%20Ewing%20sarcoma%2C%20and%20have%20to%20be%20treated%20accordingly.%22%2C%22date%22%3A%222025-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2023.10.011%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221769-6917%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A15%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22U9MB9E5I%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brahmi%20et%20al.%22%2C%22parsedDate%22%3A%222025-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrahmi%2C%20Mehdi%2C%20Maud%20Toulmonde%2C%20Sarah%20Winter%2C%20Sixtine%20De%20Percin%2C%20Thibaud%20Valentin%2C%20Nad%26%23xE8%3Bge%20Corradini%2C%20Justine%20Gantzer%2C%20et%20al.%20%26%23x201C%3B%5BRecurrent%20or%20refractory%20Osteosarcoma%20and%20Ewing%20sarcoma-French%20guidelines%20from%20the%20FSG%5C%2FNETSARC%20and%20GroupOs%20groups%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20112%2C%20no.%206%20%28June%202025%29%3A%20601%26%23x2013%3B10.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2024.03.010%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2024.03.010%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BRecurrent%20or%20refractory%20Osteosarcoma%20and%20Ewing%20sarcoma-French%20guidelines%20from%20the%20FSG%5C%2FNETSARC%20and%20GroupOs%20groups%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mehdi%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sixtine%22%2C%22lastName%22%3A%22De%20Percin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nad%5Cu00e8ge%22%2C%22lastName%22%3A%22Corradini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Gantzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Marec-Berard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Gouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Line%22%2C%22lastName%22%3A%22Claude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Tlemsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Berlanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22GroupOs%20%28Groupe%20de%20travail%20multidisciplinaire%20des%20tumeurs%20osseuses%20fran%5Cu00e7ais%29%22%7D%5D%2C%22abstractNote%22%3A%22Osteosarcoma%20%28OS%29%20and%20Ewing%20Sarcoma%20%28ES%29%20are%20the%20two%20most%20frequent%20malignant%20bone%20tumors%20in%20children%2C%20adolescents%20and%20young%20adults.%20In%20case%20of%20disease%20recurrence%2C%20both%20are%20characterized%20by%20an%20aggressive%20behaviour%20and%20a%20relatively%20poor%20overall%20survival%20rate%2C%20with%20approximately%20a%20third%20of%20patients%20having%20a%20long-term%20disease-free%20survival.%20In%20case%20of%20recurrent%20or%20refractory%20%28R%5C%2FR%29%20disease%2C%20the%20therapeutic%20strategy%20should%20be%20discussed%20in%20multidisciplinary%20staff%20meetings%20with%20expertise%20in%20bone%20sarcoma%20management.%20The%20standard%20management%20of%20R%5C%2FR%20OS%20depends%20on%20the%20disease-free%20interval%20and%20the%20number%20and%20sites%20of%20metastases%20and%20is%20primarily%20surgical%20in%20patients%20with%20isolated%20lung%20metastases%20or%20local%20relapse.%20On%20the%20other%20hand%2C%20conventional%20chemotherapy%20remains%20the%20standard%20for%20R%5C%2FR%20ES%20and%20include%20high-dose%20ifosfamide%2C%20cyclophosphamide%20with%20topotecan%20and%20irinotecan%20with%20temozolomide.%22%2C%22date%22%3A%222025-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2024.03.010%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221769-6917%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A14%3A23Z%22%7D%7D%2C%7B%22key%22%3A%226TH7KVP8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Alouani%20et%20al.%22%2C%22parsedDate%22%3A%222025-06%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAlouani%2C%20E.%2C%20C.%20Canivet%2C%20B.%20Bournet%2C%20L.%20Buscail%2C%20J.%20Selves%2C%20B.%20Napoleon%2C%20L.%20Palazzo%2C%20et%20al.%20%26%23x201C%3BIs%20Survival%20Influenced%20by%20Metastatic%20Site%20in%20Synchronous%20Metastatic%20Pancreatic%20Adenocarcinoma%20%28PDAC%29%3F%20A%20Prospective%20Real-World%20BACAP%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BESMO%20Gastrointestinal%20Oncology%26lt%3B%5C%2Fi%26gt%3B%208%20%28June%202025%29%3A%20100144.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmogo.2025.100144%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmogo.2025.100144%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Is%20survival%20influenced%20by%20metastatic%20site%20in%20synchronous%20metastatic%20pancreatic%20adenocarcinoma%20%28PDAC%29%3F%20A%20prospective%20real-world%20BACAP%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Alouani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Canivet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Bournet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Buscail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Napoleon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Palazzo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Flori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Guibert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.-C.%22%2C%22lastName%22%3A%22Brunac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Maulat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Muscari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.-Z.%22%2C%22lastName%22%3A%22Mokrane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Gourgou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Roca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22BACAP%20Consortium%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Advanced%20pancreatic%20ductal%20adenocarcinoma%20%28PDAC%29%20carries%20a%20dismal%20prognosis%20with%20a%205-year%20survival%20rate%20of%203%25.%20While%20treated%20as%20an%20even%20population%2C%20previous%20retrospective%20studies%20suggested%20significantly%20different%20survival%20rates%20for%20patients%20with%20lung-only%20metastases%20when%20compared%20with%20other%20patients.%20This%20study%20aims%20to%20explore%20prospectively%20the%20difference%20in%20survival%20outcome%20based%20on%20initial%20site%20of%20metastases%20in%20synchronous%20metastatic%20PDAC.%5CnPATIENTS%20AND%20METHODS%3A%20This%20is%20a%20prospective%20observational%20study%20including%20all%20adult%20patients%20with%20synchronous%20metastatic%20PDAC%20in%20BACAP%20%28national%20Anatomo-Clinical%20Database%20on%20Pancreatic%20Adenocarcinoma%29.%20Data%20regarding%20patients%26%23039%3B%20demographics%2C%20tumor%20characteristics%20and%20survival%20outcomes%20were%20analyzed.%5CnRESULTS%3A%20Overall%2C%20559%20patients%20were%20included%20%2852.8%25%20male%2C%20mean%20age%2069%20years%29%20of%20which%2026%20%284.7%25%29%2C%2065%20%2811.6%25%29%2C%20299%20%2853.5%25%29%20and%20169%20%2830.2%25%29%20patients%20had%20lung-only%2C%20peritoneal-only%2C%20liver-only%20and%20multi-site%20metastases%20at%20diagnosis%2C%20respectively.%20The%20median%20overall%20survival%20%28OS%29%20was%20significantly%20different%20according%20to%20metastatic%20site%20%28P%20%26lt%3B%200.001%29%20with%20a%20median%20OS%20for%20lung-only%2C%20peritoneum-only%2C%20liver-only%20and%20multi-site%20of%2012.6%20months%20%5B95%25%20confidence%20interval%20%28CI%29%209.7-16.9%20months%5D%2C%208.6%20months%20%2895%25%20CI%205.4-11.5%20months%29%2C%207.9%20months%20%2895%25%20CI%206.5-8.9%20months%29%20and%204.5%20months%20%2895%25%20CI%203.9-5.8%20months%29%2C%20respectively.%20The%20median%20progression-free%20survival%20%28PFS%29%20was%20also%20significantly%20different%20according%20to%20metastatic%20site%20%28P%20%26lt%3B%200.01%29%20with%20a%20median%20PFS%20of%206.3%20months%20%2895%25%20CI%202.7-9.1%20months%29%2C%205.1%20months%20%2895%25%20CI%203.7-6.2%20months%29%2C%204.7%20months%20%2895%25%20CI%203.3-5.7%20months%29%20and%203.2%20months%20%2895%25%20CI%202.6-4.1%20months%29%2C%20respectively.%5CnCONCLUSIONS%3A%20Patients%20with%20lung-only%20metastases%20represented%204.7%25%20of%20synchronous%20metastatic%20PDAC%20patients%20and%20exhibited%20improved%20survival.%20These%20results%20suggest%20that%20a%20subset%20of%20patients%20with%20synchronous%20metastatic%20PDAC%20could%20benefit%20from%20more%20aggressive%20locoregional%20treatments.%22%2C%22date%22%3A%222025-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmogo.2025.100144%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222949-8198%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A09%3A49Z%22%7D%7D%2C%7B%22key%22%3A%227JFGUEQH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Julieron%20et%20al.%22%2C%22parsedDate%22%3A%222025-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJulieron%2C%20Morbize%2C%20Anne%20Gomez-Mascard%2C%20C%26%23xE9%3Bcile%20V%26%23xE9%3Brit%26%23xE9%3B%2C%20Maud%20Toulmonde%2C%20Cyril%20Lervat%2C%20Mich%26%23xE8%3Ble%20Kind%2C%20and%20Juliette%20Thariat.%20%26%23x201C%3B%5BRecommendations%20from%20the%20group%20of%20bone%20tumors%20of%20the%20French%20Childhood%20Cancer%20Society%20and%20the%20French%20Sarcoma%20Group%5C%2FGroup%20for%20the%20Study%20of%20Bone%20Tumors%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20112%2C%20no.%206%20%28June%202025%29%3A%20574%26%23x2013%3B91.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2024.03.009%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2024.03.009%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BRecommendations%20from%20the%20group%20of%20bone%20tumors%20of%20the%20French%20Childhood%20Cancer%20Society%20and%20the%20French%20Sarcoma%20Group%5C%2FGroup%20for%20the%20Study%20of%20Bone%20Tumors%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morbize%22%2C%22lastName%22%3A%22Julieron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22V%5Cu00e9rit%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Lervat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mich%5Cu00e8le%22%2C%22lastName%22%3A%22Kind%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Thariat%22%7D%5D%2C%22abstractNote%22%3A%22Osteosarcomas%20of%20the%20mandible%20represent%203-8%25%20of%20osteosarcomas.%20The%20rarity%20of%20this%20anatomic%20site%20and%20its%20specific%20treatment%20explain%20that%20only%20retrospective%20and%20a%20few%20prospective%20studies%20are%20available%20in%20literature.%20However%2C%20there%20is%20a%20consistent%20evidence%20on%20the%20natural%20history%20and%20treatment%20of%20these%20tumors%2C%20which%20clearly%20differentiates%20them%20from%20osteosarcomas%20of%20the%20long%20bones.%20The%20aim%20of%20this%20study%20was%20to%20draw%20up%20recommendations%20based%20on%20these%20data%20and%20on%20a%20retrospective%20study%20by%20the%20French%20Sarcoma%20Group%20%28GSF-GETO%29.%20Osteosarcomas%20of%20the%20mandible%20should%20be%20centrally%20reviewed%20by%20an%20expert%20pathologist.%20MDM2%2C%20GNAS%20and%20RASAL1%20status%20should%20be%20checked%2C%20and%20a%20fragment%20should%20be%20frozen.%20Complete%20surgical%20resection%20with%20wide%20margins%20is%20the%20cornerstone%20of%20treatment.%20Mandibular%20reconstruction%20techniques%20can%20reduce%20the%20sequelae.%20Contrary%20to%20the%20validated%20treatment%20for%20osteosarcomas%20of%20limbs%2C%20the%20role%20of%20chemotherapy%20to%20prevent%20metastasis%20or%20local%20recurrence%20has%20yet%20to%20be%20clarified%20for%20mandibular%20osteosarcomas.%20The%20role%20of%20postoperative%20radiotherapy%2C%20in%20adults%2C%20should%20be%20discussed%20for%20these%20tumors%2C%20whose%20wide%20soft-tissue%20resection%20may%20be%20difficult%20to%20confirm.%20In%20children%2C%20adjuvant%20chemotherapy%20is%20preferable%20in%20cases%20of%20uncertain%5C%2Fpossibly%20incomplete%20resection.%20Relapse%20of%20mandibular%20osteosarcomas%20is%20primarily%20local.%20Pulmonary%20metastases%20are%20delayed%20and%20less%20frequent%20than%20in%20long-bone%20osteosarcomas.%20The%20overall%20survival%20rate%20at%20five%20years%20is%20about%2070%25.%22%2C%22date%22%3A%222025-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2024.03.009%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221769-6917%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A08%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22FZNYZXBK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Boudou-Rouquette%20et%20al.%22%2C%22parsedDate%22%3A%222025-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBoudou-Rouquette%2C%20Pascaline%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Brique%20Larousserie%2C%20Val%26%23xE9%3Brie%20Dumaine%2C%20Anne%20Gomez-Mascard%2C%20Val%26%23xE9%3Brie%20Bousson%2C%20Axel%20Le%20Cesne%2C%20Gualter%20Vaz%2C%20et%20al.%20%26%23x201C%3B%5BUpdate%20of%20the%20recommendations%20for%20the%20management%20and%20treatment%20of%20giant%20cell%20bone%20tumors%2C%20on%20behalf%20of%20GroupOS%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20112%2C%20no.%206%20%28June%202025%29%3A%20626%26%23x2013%3B37.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2024.01.013%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2024.01.013%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BUpdate%20of%20the%20recommendations%20for%20the%20management%20and%20treatment%20of%20giant%20cell%20bone%20tumors%2C%20on%20behalf%20of%20GroupOS%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascaline%22%2C%22lastName%22%3A%22Boudou-Rouquette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9rique%22%2C%22lastName%22%3A%22Larousserie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Dumaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Bousson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gualter%22%2C%22lastName%22%3A%22Vaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gonzague%22%2C%22lastName%22%3A%22de%20Pinieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Missenard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Gouin%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Giant%20cell%20tumours%20%28GCTs%29%20are%20benign%20primary%20bone%20tumours%20that%20frequently%20present%20with%20local%20recurrence%20and%20occasionally%20malignant%20transformation%20to%20high-grade%20sarcoma.%20Surgery%20is%20the%20mainstay%20of%20treatment%20and%20generally%20consists%20of%20intralesional%20curettage.%20Denosumab%20was%20approved%20by%20the%20European%20Medicines%20Agency%20%28EMA%29%20in%202014%20for%20the%20treatment%20of%20skeletally%20mature%20adults%20and%20adolescents%20with%20unresectable%20GCTs%20or%20where%20resection%20is%20likely%20to%20result%20in%20severe%20morbidity.%5CnMETHODS%3A%20On%20the%20basis%20of%20national%20recommendations%20established%20in%202016%20and%20a%20summary%20of%20the%20current%20state%20of%20knowledge%2C%20a%20GroupOS%20working%20group%20was%20set%20up%20to%20update%20and%20develop%20recommendations%20on%20the%20management%20and%20treatment%20of%20GCTs%20in%20adults%2C%20as%20well%20as%20on%20the%20place%20of%20denosumab.%5CnRESULTS%3A%20Seven%20recommendations%20are%20proposed%20here%3A%20%281%29%20diagnostic%20approach%20and%20imaging%20work-up%3B%20%282%29%20principles%20of%20treatment%20for%20GCTs%20of%20the%20limbs%3B%20%283%29%20indications%20for%20denosumab%20in%20GCTs%20of%20the%20limbs%3B%20%284%29%20specific%20features%20of%20GCTs%20of%20axial%20location%20and%20multifocal%20GCTs%3B%20%285%29%20therapeutic%20strategy%20following%20progression%20after%20treatment%20with%20denosumab%3B%20%286%29%20progression%20under%20treatment%20with%20denosumab%20and%20suspicion%20of%20malignant%20form%20of%20GCT%20under%20denosumab%3B%20%287%29%20monitoring%20procedures.%5CnCONCLUSION%3A%20There%20are%20still%20unresolved%20issues%2C%20such%20as%20the%20optimal%20duration%20of%20treatment%20or%20the%20precise%20interval%20between%20maintenance%20doses%20of%20denosumab.%20Rarely%2C%20GCTs%20undergo%20malignant%20transformation.%20No%20clinical%2C%20histological%20or%20radiographic%20criteria%20can%20accurately%20predict%20subsequent%20aggressive%20behaviour.%22%2C%22date%22%3A%222025-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2024.01.013%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221769-6917%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A07%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22G8LFFHXA%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vande%20Perre%20et%20al.%22%2C%22parsedDate%22%3A%222025-05-14%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVande%20Perre%2C%20Pierre%2C%20Ayman%20Al%20Saati%2C%20Bastien%20Cabarrou%2C%20Julien%20Plenecassagnes%2C%20Julia%20Gilhodes%2C%20Nils%20Monselet%2C%20Norbert%20Lignon%2C%20et%20al.%20%26%23x201C%3BGermline%20Sequencing%20of%20Familial%20and%20Sporadic%20Early-Onset%20Colorectal%20Cancer%3A%20A%20Novel%20Pattern%20of%20Genes.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Molecular%20Sciences%26lt%3B%5C%2Fi%26gt%3B%2026%2C%20no.%2010%20%28May%2014%2C%202025%29%3A%204672.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms26104672%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fijms26104672%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Germline%20Sequencing%20of%20Familial%20and%20Sporadic%20Early-Onset%20Colorectal%20Cancer%3A%20A%20Novel%20Pattern%20of%20Genes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Vande%20Perre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayman%22%2C%22lastName%22%3A%22Al%20Saati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Plenecassagnes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Gilhodes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nils%22%2C%22lastName%22%3A%22Monselet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Lignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Villarzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Gourdain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Chipoulet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Collet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Mallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosine%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Toulas%22%7D%5D%2C%22abstractNote%22%3A%22The%20majority%20of%20early-onset%20colorectal%20cancers%20%28EOCRCs%29%20are%20not%20substantiated%20by%20germline%20variants%20in%20the%20main%20CRC%20predisposition%20genes%20%28the%20%26quot%3BDIGE%26quot%3B%20panel%29.%20To%20identify%20potentially%20novel%20EOCRC-specific%20predisposition%20genes%2C%20we%20analyzed%20585%20cancer%20pathway%20genes%20in%20an%20EOCRC%20patient%20cohort%20%28n%20%3D%2087%2C%20diagnosis%20%5Cu2264%2040%20years%2C%20DIGE-%29%2C%20and%20compared%20their%20variant%20spectrum%20to%20the%20GnomAD%20cancer-free%20database.%20We%20identified%20high-impact%20variants%20%28HVs%29%20in%2015%20genes%20significantly%20over-represented%20in%20EOCRC.%20Among%20the%2032%20unrelated%20patients%20with%20a%20CRC%20family%20history%20%28i.e.%2C%20with%20a%20potentially%20dominant%20transmission%20pattern%29%2C%209%20presented%20HVs%20in%20ten%20genes%2C%20four%20of%20which%20had%20a%20DNA%20repair%20function.%20We%20subsequently%20sequenced%20these%2015%20genes%20in%20a%20cohort%20of%2082%20late-onset%20CRCs%20%28diagnosis%20%5Cu2265%2050%20years%2C%20DIGE-%29%20and%20found%20variants%20in%2011%20of%20these%20genes%20to%20be%20specific%20to%20EOCRC.%20We%20then%20screened%20these%2011%20genes%20in%20our%20patient%20database%20%28n%20%3D%206482%29%2C%20which%20only%20contained%202%25%20of%20EOCRCs%20%28DIGE-%29%2C%20and%20identified%20two%20other%20EOCRC%20cases%20diagnosed%20after%20our%20cohort%20constitution%2C%20with%20HVs%20in%20RECQL4%20and%20NUTM1.%20Altogether%2C%20we%20found%20that%2037.5%25%20and%2018.75%25%20of%20patients%20carrying%20heterozygous%20NUTM1%20and%20RECQL4%20HVs%2C%20respectively%2C%20in%20our%20database%20were%20diagnosed%20with%20EOCRC.%20Our%20work%20has%20identified%20a%20pattern%20of%20germline%20variants%20not%20previously%20associated%20with%20EOCRC.%22%2C%22date%22%3A%222025-05-14%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fijms26104672%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221422-0067%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A10%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22NJNDLN49%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sargos%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSargos%2C%20P.%2C%20M.%20P.%20Sunyach%2C%20A.%20Ducassou%2C%20C.%20Llacer%2C%20D.%20Dinart%2C%20A.%20Michot%2C%20T.%20Valentin%2C%20et%20al.%20%26%23x201C%3BResults%20of%20a%20Phase%20Ib%20Study%20of%20Olaparib%20with%20Concomitant%20Radiotherapy%20in%20Soft-Tissue%20Sarcoma%3A%20A%20French%20Sarcoma%20Group%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2036%2C%20no.%205%20%28May%202025%29%3A%20592%26%23x2013%3B600.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2025.01.016%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annonc.2025.01.016%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Results%20of%20a%20phase%20Ib%20study%20of%20olaparib%20with%20concomitant%20radiotherapy%20in%20soft-tissue%20sarcoma%3A%20a%20French%20sarcoma%20group%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Sargos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Sunyach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Llacer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Dinart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Michot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Y.%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Gillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bellera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Italiano%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Radiotherapy%20is%20essential%20for%20locoregional%20control%20in%20resectable%20soft-tissue%20sarcoma%20and%20remains%20a%20key%20strategy%20for%20unresectable%20soft-tissue%20sarcoma.%20Poly-ADP-ribose%20polymerase%20inhibitors%2C%20such%20as%20olaparib%2C%20may%20enhance%20radiosensitivity%20by%20targeting%20DNA%20damage%20repair%20pathways.%5CnPATIENTS%20AND%20METHODS%3A%20This%20multicenter%20phase%20Ib%20trial%20evaluated%20the%20combination%20of%20olaparib%20and%20radiotherapy%20in%20soft-tissue%20sarcoma%20of%20the%20limbs%20or%20trunk%20wall.%20Olaparib%20was%20administered%20twice%20daily%20at%20doses%20of%2025%2C%2050%2C%20100%2C%20or%20150%20mg%20during%20the%20dose-escalation%20phase.%20Radiotherapy%20consisted%20of%2050%20Gy%20%2825%20fractions%29%20for%20resectable%20tumors%20or%2059.4%20Gy%20%2833%20fractions%29%20for%20unresectable%20tumors.%20Radiotherapy%20was%20exclusively%20preoperative%20for%20operable%20patients.%20Primary%20objectives%20were%20to%20determine%20the%20maximum%20tolerated%20dose%20and%20recommended%20phase%20II%20dose.%20Dose%20escalation%20was%20conducted%20using%20the%20time-to-event%20continual%20reassessment%20method.%20Histological%20response%20was%20assessed%20in%20surgical%20cases%2C%20and%20RECIST%201.1%20criteria%20were%20applied%20for%20non-surgical%20cases.%5CnRESULTS%3A%20Between%20October%202016%20and%20April%202021%2C%2041%20patients%20were%20recruited%20across%20five%20French%20centers.%20The%20recommended%20phase%20II%20dose%20was%20identified%20as%20100%20mg%20olaparib%20twice%20daily.%20For%20operable%20patients%2C%20a%20favorable%20histological%20response%20was%20observed%20in%2033%25%20of%20patients%2C%20with%20a%20local%20relapse-free%20survival%20rate%20of%2090.5%25%20at%201%20year.%20In%20contrast%2C%20among%20patients%20with%20inoperable%20tumors%2C%20the%20median%20progression-free%20survival%20was%207.7%20months%20%2895%25%20confidence%20interval%202.6-28.4%20months%29%2C%20with%20partial%20responses%20achieved%20in%2020%25%20of%20cases%20and%20stable%20disease%20in%2060%25.%20Grade%203%20radiation%20dermatitis%20was%20the%20most%20frequent%20adverse%20event%20%2834.1%25%29%2C%20and%20two%20patients%20experienced%20grade%205%20toxicity%20%284.8%25%29.%5CnCONCLUSION%3A%20The%20combination%20of%20olaparib%20and%20radiotherapy%20is%20feasible%20for%20soft-tissue%20sarcoma%20patients%20but%20requires%20stringent%20selection%2C%20avoiding%20patients%20with%20tumors%20involving%20critical%20vascular%20structures%20or%20those%20at%20high%20surgical%20risk%2C%20to%20minimize%20severe%20complications.%20Further%20randomized%20trials%20are%20warranted%20to%20validate%20efficacy%20and%20safety%20compared%20with%20radiotherapy%20alone.%22%2C%22date%22%3A%222025-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annonc.2025.01.016%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221569-8041%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A15%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22D2D8HX8A%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Allaume%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAllaume%2C%20Pierre%2C%20Rapha%26%23xEB%3Bl%20Bourgade%2C%20Arnaud%20Uguen%2C%20Thierry%20P%26%23xE9%3Bcot%2C%20Sophie%20Prevot%2C%20Catherine%20Guettier%2C%20Janick%20Selves%2C%20et%20al.%20%26%23x201C%3B%5BA%20national%20survey%20from%20the%20French%20Society%20of%20Pathology%20on%20research%20and%20application%20of%20artificial%20intelligence%20in%20pathology%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnales%20De%20Pathologie%26lt%3B%5C%2Fi%26gt%3B%2045%2C%20no.%203%20%28May%202025%29%3A%20224%26%23x2013%3B32.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2024.12.008%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2024.12.008%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BA%20national%20survey%20from%20the%20French%20Society%20of%20Pathology%20on%20research%20and%20application%20of%20artificial%20intelligence%20in%20pathology%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Allaume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22Bourgade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Uguen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22P%5Cu00e9cot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Prevot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Guettier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Bertheau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Franchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magali%22%2C%22lastName%22%3A%22Svrcek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Sabourin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Brevet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Calderaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Rioux-Leclercq%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Loussouarn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne-Florence%22%2C%22lastName%22%3A%22Kammerer-Jacquet%22%7D%5D%2C%22abstractNote%22%3A%22The%202030%20French%20Innovation%20Healthcare%20national%20plan%20defined%20%26quot%3BDigital%20Healthcare%26quot%3B%20as%20one%20of%20its%20priority.%20The%20deployment%20of%20digital%20pathology%20and%20artificial%20intelligence%20fits%20perfectly%20into%20this%20framework.%20Therefore%20we%20evaluated%20the%20pathologist%26%23039%3Bs%20interest%20in%20those%20fields%20by%20conducting%20an%20online%20survey%20among%20members%20of%20the%20French%20Society%20of%20Pathology%2C%20mainly%20composed%20of%20senior%20pathologists%20and%20trainees%20%28n%3D2301%29.%20We%20collected%20123%20answers%20originating%20nationwide%20and%20representative%20of%20all%20status%20of%20practice.%20A%20heavy%20majority%20of%20participants%20%2883%25%29%20declared%20themselves%20%26quot%3Binterested%20or%20very%20interested%26quot%3B%20in%20digital%20transition%20and%20AI.%20Twenty-six%20percent%20of%20participants%20took%20part%20in%20academic%20research%20projects%20and%2020%25%20in%20industrial%20research%20projects.%20With%20digital%20pathology%20becoming%20increasingly%20common%20nationwide%2C%20there%20is%20a%20growing%20interest%20of%20pathologists%20in%20the%20development%20and%20validation%20of%20AI%20algorithms.%20In%20order%20to%20support%20this%20dynamic%2C%20a%20commission%20for%20research%20on%20artificial%20intelligence%20has%20been%20created%20under%20the%20authority%20of%20the%20French%20Society%20of%20Pathology.%22%2C%22date%22%3A%222025-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2024.12.008%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220242-6498%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A11%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22PZEXKP83%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zamora%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZamora%2C%20Tomas%2C%20Eduardo%20Botello%2C%20Thomas%20Jenkins%2C%20Charlotte%20Jeys%2C%20Minna%20Laitinen%2C%20Ajay%20Puri%2C%20Lee%20Jeys%2C%20and%20BOOM%20consensus%20meeting%20participants.%20%26%23x201C%3BGlobal%20and%20Regional%20Disparities%20in%20Access%20to%20Specialist%20Sarcoma%20Services.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBone%20%26amp%3B%20Joint%20Open%26lt%3B%5C%2Fi%26gt%3B%206%2C%20no.%204%20%28April%2011%2C%202025%29%3A%20425%26%23x2013%3B31.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1302%5C%2F2633-1462.64.BJO-2024-0208.R1%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1302%5C%2F2633-1462.64.BJO-2024-0208.R1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Global%20and%20regional%20disparities%20in%20access%20to%20specialist%20sarcoma%20services%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Zamora%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Botello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Jeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minna%22%2C%22lastName%22%3A%22Laitinen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajay%22%2C%22lastName%22%3A%22Puri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%22%2C%22lastName%22%3A%22Jeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22BOOM%20consensus%20meeting%20participants%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20Cancer%20care%20guidelines%20have%20been%20developed%20in%20many%20subspecialities%2C%20usually%20in%20advanced%20health%20systems.%20However%2C%20there%20are%20notable%20global%20disparities%20in%20healthcare%20access%2C%20which%20can%20impact%20sarcoma%20care.%20Unfortunately%2C%20there%20is%20a%20lack%20of%20global%20data%20on%20this%20subject.%20Our%20aim%20was%20to%20describe%20access%20to%20sarcoma%20care%20based%20on%20a%20comprehensive%20global%20survey%20among%20orthopaedic%20oncologists%2C%20and%20assess%20for%20global%20as%20well%20as%20regional%20differences.%5CnMETHODS%3A%20A%2025-question%20survey%20was%20emailed%20to%20the%20attendees%20of%20the%202024%20Birmingham%20Orthopaedic%20Oncology%20Meeting%20and%20included%20questions%20about%20the%20respondents%26%23039%3B%20training%20and%20practice%2C%20access%20to%20sarcoma%20centres%2C%20and%20specific%20items%20for%20sarcoma%20diagnosis%20and%20treatment.%20For%20data%20analysis%20and%20comparison%2C%20countries%20were%20grouped%20geographically%20and%20per%20the%20World%20Bank%26%23039%3Bs%20income%20classification.%5CnRESULTS%3A%20A%20total%20of%20192%20specialists%20from%2047%20countries%20completed%20the%20survey%20%2867%25%29.%20Overall%2C%2040%25%20declared%20that%20most%20patients%20in%20their%20country%20were%20treated%20in%20a%20specialized%20sarcoma%20centre.%20Declared%20access%20to%20specific%20diagnostic%20technology%20ranged%20from%2069%25%20%28translocation%20studies%29%20to%2086%25%20%28various%20immunohistochemistry%29.%20Only%2031%25%20stated%20having%20access%20to%20proton%20therapy%20and%2082%25%20to%20all%20possible%20reconstruction%20methods.%20Compromise%20of%20ideal%20surgical%20management%20because%20of%20prior%20treatments%20and%20financial%20constraints%20was%20declared%20to%20have%20happened%20regularly%20in%2040%25%20and%2017%25%20of%20practices%2C%20respectively.%20Regions%20with%20better-developed%20healthcare%20systems%20had%20improved%20access%20to%20all%20aspects%20surveyed.%20Similar%20results%20were%20observed%20when%20comparing%20high-income%20countries%20against%20low-%20to%20middle-income%20countries.%5CnCONCLUSION%3A%20Our%20study%20highlights%20substantial%20global%20and%20regional%20disparities%20in%20access%20to%20sarcoma%20services%2C%20which%20could%20potentially%20impact%20clinical%20outcomes.%20Further%20studies%20are%20needed%20to%20clarify%20this%20reality.%22%2C%22date%22%3A%222025-04-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1302%5C%2F2633-1462.64.BJO-2024-0208.R1%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222633-1462%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A08%3A24Z%22%7D%7D%2C%7B%22key%22%3A%222ZCHRD6V%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dutour%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDutour%2C%20Aurelie%2C%20Michela%20Pasello%2C%20Luke%20Farrow%2C%20Mahetab%20H.%20Amer%2C%20Natacha%20Entz-Werl%26%23xE9%3B%2C%20Michaela%20Nathrath%2C%20Katia%20Scotlandi%2C%20Sibylle%20Mittnacht%2C%20and%20Anne%20Gomez-Mascard.%20%26%23x201C%3BMicroenvironment%20Matters%3A%20Insights%20from%20the%20FOSTER%20Consortium%20on%20Microenvironment-Driven%20Approaches%20to%20Osteosarcoma%20Therapy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Metastasis%20Reviews%26lt%3B%5C%2Fi%26gt%3B%2044%2C%20no.%202%20%28April%2010%2C%202025%29%3A%2044.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10555-025-10257-3%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10555-025-10257-3%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Microenvironment%20matters%3A%20insights%20from%20the%20FOSTER%20consortium%20on%20microenvironment-driven%20approaches%20to%20osteosarcoma%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Dutour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michela%22%2C%22lastName%22%3A%22Pasello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luke%22%2C%22lastName%22%3A%22Farrow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahetab%20H.%22%2C%22lastName%22%3A%22Amer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Entz-Werl%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michaela%22%2C%22lastName%22%3A%22Nathrath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katia%22%2C%22lastName%22%3A%22Scotlandi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sibylle%22%2C%22lastName%22%3A%22Mittnacht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%5D%2C%22abstractNote%22%3A%22Osteosarcoma%20%28OS%29%2C%20a%20prevalent%20malignant%20bone%20tumor%2C%20has%20seen%20limited%20progress%20in%20treatment%20efficacy%20and%20patient%20outcomes%20over%20decades.%20Recent%20insights%20into%20the%20tumor%20microenvironment%20%28TME%29%20have%20revealed%20its%20crucial%20role%20in%20tumor%20progression%20and%20therapeutic%20resistance%2C%20particularly%20in%20OS.%20This%20review%20offers%20a%20comprehensive%20exploration%20of%20the%20OS%20microenvironment%2C%20meticulously%20dissecting%20its%20crucial%20components%3A%20the%20mesenchymal%20stromal%20TME%2C%20the%20immune%20microenvironment%2C%20hypoxia-induced%20adaptations%2C%20and%20the%20impact%20of%20the%20physical%20microenvironment.%20By%20demonstrating%20how%20these%20elements%20collectively%20drive%20tumor%20proliferation%2C%20immune%20evasion%2C%20and%20invasion%2C%20this%20review%20explores%20the%20intricate%20molecular%20and%20cellular%20dynamics%20at%20play.%20Furthermore%2C%20innovative%20approaches%20targeting%20the%20OS%20microenvironment%2C%20such%20as%20immunotherapies%2C%20are%20presented.%20This%20review%20highlights%20the%20importance%20of%20the%20TME%20in%20OS%20progression%20and%20its%20potential%20as%20a%20source%20of%20novel%20therapeutic%20strategies%2C%20offering%20new%20hope%20for%20improved%20patient%20outcomes.%22%2C%22date%22%3A%222025-04-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10555-025-10257-3%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221573-7233%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A08%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22NMHFF2LG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22PFMG2025%20contributors%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPFMG2025%20contributors.%20%26%23x201C%3BPFMG2025-Integrating%20Genomic%20Medicine%20into%20the%20National%20Healthcare%20System%20in%20France.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Lancet%20Regional%20Health.%20Europe%26lt%3B%5C%2Fi%26gt%3B%2050%20%28March%202025%29%3A%20101183.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lanepe.2024.101183%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lanepe.2024.101183%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PFMG2025-integrating%20genomic%20medicine%20into%20the%20national%20healthcare%20system%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22PFMG2025%20contributors%22%7D%5D%2C%22abstractNote%22%3A%22Integrating%20genomic%20medicine%20into%20healthcare%20systems%20is%20a%20health%20policy%20challenge%20that%20requires%20continuously%20transferring%20scientific%20advances%20into%20clinics%20and%20ensuring%20equal%20access%20for%20patients.%20France%20was%20one%20of%20the%20first%20countries%20to%20integrate%20genome%20sequencing%20into%20clinical%20practice%20at%20a%20nationwide%20level%2C%20with%20the%20ambition%20to%20provide%20more%20accurate%20diagnostics%20and%20personalized%20treatments.%20Since%202016%2C%20the%20French%20government%20has%20invested%20%5Cu20ac239M%20in%20the%202025%20French%20Genomic%20Medicine%20Initiative%20%28PFMG2025%29%20which%20has%20so%20far%20focused%20on%20patients%20with%20rare%20diseases%20%28RD%29%2C%20cancer%20genetic%20predisposition%20%28CGP%29%20and%20cancers.%20PFMG2025%20has%20addressed%20numerous%20challenges%20to%20set%20up%20an%20operational%20organizational%20framework.%20As%20of%20December%20the%2031st%202023%2C%2012%2C737%20results%20were%20returned%20to%20prescribers%20for%20RD%5C%2FCGP%20patients%20%28median%20delivery%20time%3A%20202%20days%2C%20diagnostic%20yield%3A%2030.6%25%29%20and%203109%20for%20cancer%20patients%20%28median%20delivery%20time%3A%2045%20days%29.%20PFMG2025%26%23039%3Bs%20future%20priorities%20encompass%20ensuring%20economic%20sustainability%2C%20strengthening%20links%20with%20research%2C%20empowering%20patients%20and%20practitioners%2C%20and%20fostering%20collaborations%20with%20European%20partners.%5CnFUNDING%3A%20As%20of%20December%20the%2031st%202023%2C%20%5Cu20ac239M%20have%20been%20invested%20by%20the%20French%20government.%22%2C%22date%22%3A%222025-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lanepe.2024.101183%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222666-7762%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A14%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22HBGAIA6E%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barr%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBarr%26%23xE9%3B%2C%20Tangui%2C%20Cl%26%23xE9%3Bmence%20Ramier%2C%20Karine%20Ory%2C%20Philippe%20Sogni%2C%20Hugues%20Aumaitre%2C%20Tounes%20Saidi%2C%20Patrizia%20Carrieri%2C%20Fabienne%20Marcellin%2C%20and%20ANRS%20CO13%20HEPAVIH%20Study%20Group.%20%26%23x201C%3BTransient%20CD4%20Cell%20Recovery%20after%20Hepatitis%20C%20Virus%20Cure%20in%20HIV%5C%2FHepatitis%20C%20Virus%20Coinfected%20Patients%20%28ANRS%20CO13%20HEPAVIH%20Cohort%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BHIV%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2026%2C%20no.%203%20%28March%202025%29%3A%20500%26%23x2013%3B503.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhiv.13752%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fhiv.13752%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Transient%20CD4%20cell%20recovery%20after%20hepatitis%20C%20virus%20cure%20in%20HIV%5C%2Fhepatitis%20C%20virus%20coinfected%20patients%20%28ANRS%20CO13%20HEPAVIH%20cohort%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tangui%22%2C%22lastName%22%3A%22Barr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Ramier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Ory%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Sogni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugues%22%2C%22lastName%22%3A%22Aumaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tounes%22%2C%22lastName%22%3A%22Saidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrizia%22%2C%22lastName%22%3A%22Carrieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Marcellin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ANRS%20CO13%20HEPAVIH%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fhiv.13752%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221468-1293%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A11%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22IASIII6S%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Barr%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBarr%26%23xE9%3B%2C%20Tangui%2C%20Cl%26%23xE9%3Bmence%20Ramier%2C%20Karine%20Ory%2C%20Tounes%20Saidi%2C%20Philippe%20Sogni%2C%20Fabien%20Zoulim%2C%20Morgane%20Bureau-Stoltmann%2C%20et%20al.%20%26%23x201C%3BLiver%20Enzyme%20Elevation%20After%20Hepatitis%20C%20Virus%20Cure%3A%20Is%20There%20a%20Sex%20Effect%3F%20%28ANRS%20CO13%20HEPAVIH%20Cohort%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Viral%20Hepatitis%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%203%20%28March%202025%29%3A%20e70007.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjvh.70007%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjvh.70007%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Liver%20Enzyme%20Elevation%20After%20Hepatitis%20C%20Virus%20Cure%3A%20Is%20There%20a%20Sex%20Effect%3F%20%28ANRS%20CO13%20HEPAVIH%20Cohort%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tangui%22%2C%22lastName%22%3A%22Barr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Ramier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Ory%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tounes%22%2C%22lastName%22%3A%22Saidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Sogni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Zoulim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Bureau-Stoltmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camelia%22%2C%22lastName%22%3A%22Protopopescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabienne%22%2C%22lastName%22%3A%22Marcellin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrizia%22%2C%22lastName%22%3A%22Carrieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22ANRS%20CO13%20HEPAVIH%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-03%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fjvh.70007%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221365-2893%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A11%3A08Z%22%7D%7D%2C%7B%22key%22%3A%229TRL9ZHB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Poumeaud%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPoumeaud%2C%20F.%2C%20T.%20Valentin%2C%20N.%20Fares%2C%20B.%20Segier%2C%20S.%20Watson%2C%20B.%20Verret%2C%20C.%20Tlemsani%2C%20et%20al.%20%26%23x201C%3BSarcomas%20Developed%20in%20Patients%20with%20Lynch%20Syndrome%20Are%20Enriched%20in%20Pleomorphic%20Soft-Tissue%20Sarcomas%20and%20Are%20Sensitive%20to%20Immunotherapy.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Cancer%26lt%3B%5C%2Fi%26gt%3B%20216%20%28February%205%2C%202025%29%3A%20115196.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2024.115196%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejca.2024.115196%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sarcomas%20developed%20in%20patients%20with%20Lynch%20Syndrome%20are%20enriched%20in%20pleomorphic%20soft-tissue%20sarcomas%20and%20are%20sensitive%20to%20immunotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Poumeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Segier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Watson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Verret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Tlemsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Lejeune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Sabouret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-C.%22%2C%22lastName%22%3A%22Thery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cottereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cauchin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Lancon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Nambot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Zattara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Coudert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Fourme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Nogues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Tougeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Prieur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.-A.%22%2C%22lastName%22%3A%22Collonge-Rame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Denis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Laurent-Puig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Chieze-Valero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Dreyfus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Jaffrelot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Vande%20Perre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rochaix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Rochefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Campoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Lasset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Guimbaud%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Sarcomas%20do%20not%20belong%20to%20the%20Lynch%20Syndrome%20%28LS%29-tumour%20spectrum.%20A%20growing%20body%20literature%20has%20reported%20sarcomas%20in%20patients%20with%20LS.%20Clinical%20and%20tumour%20characteristics%20of%20these%20patients%20remain%20unknown.%5CnPATIENTS%20AND%20METHODS%3A%20We%20set%20up%20the%20first%20national%20retrospective%20study%2C%20SarcLynch%2C%20describing%20the%20pathological%20and%20clinical%20characteristics%20of%20sarcomas%20developed%20in%20patients%20with%20LS.%20Patients%20were%20identified%20from%20two%20national%20networks%20and%20included%20from%2023%20centres%20in%20France.%5CnRESULTS%3A%20Eighty-one%20patients%20participated%20in%20the%20SarcLynch%20study.%20Sixty-seven%20%2883%5Cu202f%25%29%20tumours%20were%20soft-tissue%20sarcomas%20%28STS%29%20and%2014%20%2817%5Cu202f%25%29%20bone%20sarcomas.%20Among%20STS%2C%2059%20%2888%5Cu202f%25%29%20showed%20a%20pleomorphic%20component%2C%20with%20undifferentiated%20pleomorphic%20sarcoma%20%28UPS%29%20%2836%5Cu202f%25%29%20and%20pleomorphic%20rhabdomyosarcoma%20%28pRMS%29%20%2821%5Cu202f%25%29%20being%20the%20most%20represented%20subtypes.%20Sarcoma%20was%20the%20first%20neoplastic%20event%20in%2032%20patients%20%2840%5Cu202f%25%29.%20Thirty-two%20patients%20%2840%5Cu202f%25%29%20were%20carriers%20of%20MSH2%20germline%20pathogenic%20variants.%20Among%20patients%20who%20underwent%20an%20assessment%20of%20deficient%20mismatch%20repair%20%28dMMR%29%20by%20immunohistochemistry%20and%5C%2For%20molecular%20biology%20status%2C%2075%5Cu202f%25%20were%20dMMR%20by%20immunohistochemistry%20and%2045%5Cu202f%25%20were%20microsatellite%20instability%20high%20%28MSI-H%29.%20Eight%20patients%20received%20immune%20checkpoint%20inhibitors%20and%204%20%2850%5Cu202f%25%29%20exhibited%20an%20objective%20response%20with%203%20complete%20radiological%20response%20including%201%20patient%20with%20pathological%20complete%20response.%20Duration%20of%20response%20ranged%20from%206%20to%2020%20months.%5CnCONCLUSIONS%3A%20SarcLynch%2C%20the%20largest%20multicentric%20series%20describing%20sarcomas%20developed%20in%20patients%20with%20LS%2C%20revealed%20an%20enrichment%20in%20patients%20with%20pleomorphic%20sarcomas%20-%20especially%20UPS%20and%20pRMS.%20This%20finding%20strongly%20supports%20screening%20for%20MMR%20status%20evaluation%20in%20these%20rare%20histotypes%20both%20for%20oncogenetic%20screening%20and%20therapeutic%20interest.%20Considering%20an%20objective%20response%20rate%20of%2050%5Cu202f%25%2C%20access%20to%20immunotherapy%20should%20be%20considered%20in%20these%20tumours.%22%2C%22date%22%3A%222025-02-05%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejca.2024.115196%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221879-0852%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A07%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22J4A5ZMYU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jeys%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJeys%2C%20Lee%20M.%2C%20Guy%20V.%20Morris%2C%20Vineet%20J.%20Kurisunkal%2C%20Eduardo%20Botello%2C%20Richard%20A.%20Boyle%2C%20Walid%20Ebeid%2C%20Matthew%20T.%20Houdek%2C%20et%20al.%20%26%23x201C%3BIdentifying%20Consensus%20and%20Areas%20for%20Future%20Research%20in%20Chondrosarcoma%26%23x202F%3B%3A%20A%20Report%20from%20the%20Birmingham%20Orthopaedic%20Oncology%20Meeting.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Bone%20%26amp%3B%20Joint%20Journal%26lt%3B%5C%2Fi%26gt%3B%20107-B%2C%20no.%202%20%28February%201%2C%202025%29%3A%20246%26%23x2013%3B52.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1302%5C%2F0301-620X.107B2.BJJ-2024-0643.R1%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1302%5C%2F0301-620X.107B2.BJJ-2024-0643.R1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Identifying%20consensus%20and%20areas%20for%20future%20research%20in%20chondrosarcoma%20%3A%20a%20report%20from%20the%20Birmingham%20Orthopaedic%20Oncology%20Meeting%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%20M.%22%2C%22lastName%22%3A%22Jeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%20V.%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vineet%20J.%22%2C%22lastName%22%3A%22Kurisunkal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Botello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%22%2C%22lastName%22%3A%22Boyle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Walid%22%2C%22lastName%22%3A%22Ebeid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%20T.%22%2C%22lastName%22%3A%22Houdek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajay%22%2C%22lastName%22%3A%22Puri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pietro%22%2C%22lastName%22%3A%22Ruggieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernadette%22%2C%22lastName%22%3A%22Brennan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22BOOM%20Consensus%20Meeting%20Participants%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Minna%20K.%22%2C%22lastName%22%3A%22Laitinen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%22%2C%22lastName%22%3A%22Abad%20Repiso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hesham%22%2C%22lastName%22%3A%22Abdelbary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandro%22%2C%22lastName%22%3A%22Abiad%20Mejia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%20A.%22%2C%22lastName%22%3A%22Abood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20C.%22%2C%22lastName%22%3A%22Abril%20Martin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adesegun%22%2C%22lastName%22%3A%22Abudu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayman%22%2C%22lastName%22%3A%22Abu%20Elhamd%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marthelena%22%2C%22lastName%22%3A%22Acosta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keisuke%22%2C%22lastName%22%3A%22Ae%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manish%22%2C%22lastName%22%3A%22Agarwal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivek%22%2C%22lastName%22%3A%22Ajit%20Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toru%22%2C%22lastName%22%3A%22Akiyama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ibrahim%22%2C%22lastName%22%3A%22Alshaygy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20I.%22%2C%22lastName%22%3A%22Albergo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Alexander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricio%20A.%22%2C%22lastName%22%3A%22Alfaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bugra%22%2C%22lastName%22%3A%22Alpan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%22%2C%22lastName%22%3A%22Amaya-Valero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Megan%22%2C%22lastName%22%3A%22Anderson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimosthenis%22%2C%22lastName%22%3A%22Andreou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Annabell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christopher%22%2C%22lastName%22%3A%22Anthony%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Aoude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iraia%22%2C%22lastName%22%3A%22Arteagoitia-Colino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Apichat%22%2C%22lastName%22%3A%22Asavamongkolkul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Aston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Libe%22%2C%22lastName%22%3A%22Asua%20Mentxaka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Azzopardi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Baad-Hansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ismail%20T.%22%2C%22lastName%22%3A%22Badr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Baixauli-Garcia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gavin%22%2C%22lastName%22%3A%22Baker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tessa%22%2C%22lastName%22%3A%22Balach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giacomo%20G.%22%2C%22lastName%22%3A%22Baldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janie%22%2C%22lastName%22%3A%22Barry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georges%22%2C%22lastName%22%3A%22Basile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefano%22%2C%22lastName%22%3A%22Bastoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammad%22%2C%22lastName%22%3A%22Basuki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henrik%22%2C%22lastName%22%3A%22Bauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lee%22%2C%22lastName%22%3A%22Bayliss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ricardo%20G.%22%2C%22lastName%22%3A%22Becker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angad%22%2C%22lastName%22%3A%22Bedi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Benevenia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Bengoa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Bergh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marko%22%2C%22lastName%22%3A%22Bergovec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicholas%22%2C%22lastName%22%3A%22Bernthal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odion%22%2C%22lastName%22%3A%22Binitie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Boddie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michele%22%2C%22lastName%22%3A%22Boffano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Bonilla%20Huertas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20B.%22%2C%22lastName%22%3A%22Borgognoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rajesh%22%2C%22lastName%22%3A%22Botchu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%22%2C%22lastName%22%3A%22Bramer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rahat%22%2C%22lastName%22%3A%22Brar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harriet%22%2C%22lastName%22%3A%22Branford-White%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Demien%22%2C%22lastName%22%3A%22Broekhuis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%20E.%22%2C%22lastName%22%3A%22Broida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tymoteusz%22%2C%22lastName%22%3A%22Budny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%20D.%22%2C%22lastName%22%3A%22Burke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%22%2C%22lastName%22%3A%22Cabrolier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20A.%22%2C%22lastName%22%3A%22Calvo-Haro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%20R.%22%2C%22lastName%22%3A%22Calvo%20Tapies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodrigo%22%2C%22lastName%22%3A%22Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Carey%20Smith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20I.%22%2C%22lastName%22%3A%22Carvallo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Casales%20Fresenga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20M.%22%2C%22lastName%22%3A%22Casanova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oscar%22%2C%22lastName%22%3A%22Ceballos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20L.%22%2C%22lastName%22%3A%22Cebrian%20Parra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Chacon%20Cartaya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chung%20M.%22%2C%22lastName%22%3A%22Chan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yoon%20Joo%22%2C%22lastName%22%3A%22Cho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Choong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yang-Guk%22%2C%22lastName%22%3A%22Chung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dawid%22%2C%22lastName%22%3A%22Ciechanowicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%20A.%22%2C%22lastName%22%3A%22Clara-Altamirano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Clever%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%20M.%22%2C%22lastName%22%3A%22Colina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%22%2C%22lastName%22%3A%22Consuegra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cory%22%2C%22lastName%22%3A%22Couch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gillian%22%2C%22lastName%22%3A%22Cribb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Cuervo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%20A.%22%2C%22lastName%22%3A%22Cusick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Solomon%22%2C%22lastName%22%3A%22Dadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tanios%22%2C%22lastName%22%3A%22Dagher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dietmar%22%2C%22lastName%22%3A%22Dammerer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nerys%22%2C%22lastName%22%3A%22Davies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%20P.%22%2C%22lastName%22%3A%22de%20la%20Rosa%20Martino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%20J.%22%2C%22lastName%22%3A%22de%20Santos%20de%20la%20Fuente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marieke%22%2C%22lastName%22%3A%22de%20Vaal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Deckers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Delgado%20Obando%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaneel%22%2C%22lastName%22%3A%22Deo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Niklas%22%2C%22lastName%22%3A%22Deventer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%22%2C%22lastName%22%3A%22Di%20Bella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gregory%22%2C%22lastName%22%3A%22Domson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Davide%20M.%22%2C%22lastName%22%3A%22Donati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Desiree%20M.%22%2C%22lastName%22%3A%22Dorleijn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Du%20Toit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Debra%22%2C%22lastName%22%3A%22Dunne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodolfo%22%2C%22lastName%22%3A%22Duran%20Ciarrochi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elina%22%2C%22lastName%22%3A%22Ekman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%20M.%22%2C%22lastName%22%3A%22El%20Ghoneimy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Makoto%22%2C%22lastName%22%3A%22Endo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Levent%22%2C%22lastName%22%3A%22Eralp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%22%2C%22lastName%22%3A%22Etaiwi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%22%2C%22lastName%22%3A%22Evans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Will%22%2C%22lastName%22%3A%22Eward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%22%2C%22lastName%22%3A%22Farese%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20C.%22%2C%22lastName%22%3A%22Ferguson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20F.%22%2C%22lastName%22%3A%22Ferreira%20Cardoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Fiorenza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Flint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hector%22%2C%22lastName%22%3A%22Flores%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joao%22%2C%22lastName%22%3A%22Freitas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Fuchs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomohiro%22%2C%22lastName%22%3A%22Fujiwara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipp%20T.%22%2C%22lastName%22%3A%22Funovics%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%22%2C%22lastName%22%3A%22Galli%20Serra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zakareya%22%2C%22lastName%22%3A%22Gamie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Garces-Zarzalejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aaron%22%2C%22lastName%22%3A%22Gazendam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carsten%22%2C%22lastName%22%3A%22Gebert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jasper%20G.%22%2C%22lastName%22%3A%22Gerbers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Craig%22%2C%22lastName%22%3A%22Gerrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ghaith%22%2C%22lastName%22%3A%22Abou-Nouar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Ghert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kanishka%20M.%22%2C%22lastName%22%3A%22Ghosh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Gibbons%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luis%20C.%22%2C%22lastName%22%3A%22Gomez-Mier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesus%22%2C%22lastName%22%3A%22Gomez-Vallejo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%20R.%22%2C%22lastName%22%3A%22Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fausto%22%2C%22lastName%22%3A%22Gonzalez-Lizan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Gosheger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stuart%22%2C%22lastName%22%3A%22Goudie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krista%22%2C%22lastName%22%3A%22Goulding%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stavros%20D.%22%2C%22lastName%22%3A%22Goumenos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Griffin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashish%22%2C%22lastName%22%3A%22Gulia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjay%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amit%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maurice%22%2C%22lastName%22%3A%22Guzman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammed%22%2C%22lastName%22%3A%22Haitham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jendrik%22%2C%22lastName%22%3A%22Hardes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Hardoy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yusuf%22%2C%22lastName%22%3A%22Hasan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Georg%22%2C%22lastName%22%3A%22Hauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helard%22%2C%22lastName%22%3A%22Havard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rex%22%2C%22lastName%22%3A%22Haydon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Healey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nerea%22%2C%22lastName%22%3A%22Hernandez%20Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adriana%22%2C%22lastName%22%3A%22Hernandez-Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asle%22%2C%22lastName%22%3A%22Hesla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Hess%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Hilton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chindanai%22%2C%22lastName%22%3A%22Hongsaprabhas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Hornicek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keith%22%2C%22lastName%22%3A%22Hosking%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eleanor%22%2C%22lastName%22%3A%22Houghton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oluwaseyi%20K.%22%2C%22lastName%22%3A%22Idowu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Ippolito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Isler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shintaro%22%2C%22lastName%22%3A%22Iwata%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jake%22%2C%22lastName%22%3A%22Jagiello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neil%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Jenkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Jeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Jeys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luke%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andy%22%2C%22lastName%22%3A%22Johnston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Min%20Wook%22%2C%22lastName%22%3A%22Joo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%20C.%22%2C%22lastName%22%3A%22Jutte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kadri%22%2C%22lastName%22%3A%22Kaldas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amar%22%2C%22lastName%22%3A%22Kamat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sudhir%22%2C%22lastName%22%3A%22Kannan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bilal%22%2C%22lastName%22%3A%22Kapanci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zeeshan%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroshi%22%2C%22lastName%22%3A%22Kobayashi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yehuda%22%2C%22lastName%22%3A%22Kollender%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%22%2C%22lastName%22%3A%22Koob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Kotrych%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Kyte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20M.%22%2C%22lastName%22%3A%22Lamo%20de%20Espinosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%20L.%22%2C%22lastName%22%3A%22Lazarides%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis-Romee%22%2C%22lastName%22%3A%22Le%20Nail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pawel%22%2C%22lastName%22%3A%22Legosz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Burkhard%22%2C%22lastName%22%3A%22Lehner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22Leithner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryse%22%2C%22lastName%22%3A%22Lejoly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerae%20O.%22%2C%22lastName%22%3A%22Lewis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peng%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francisco%22%2C%22lastName%22%3A%22Linares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Santiago%20A.%22%2C%22lastName%22%3A%22Lozano-Calderon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashish%22%2C%22lastName%22%3A%22Mahendra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferdiansyah%22%2C%22lastName%22%3A%22Mahyudin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fermin%20J.%22%2C%22lastName%22%3A%22Mandia%20Mancebo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%20M.%22%2C%22lastName%22%3A%22Torrejon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Marx%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Camille%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22McCullough%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sam%22%2C%22lastName%22%3A%22McMahon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%20R.%22%2C%22lastName%22%3A%22Medellin%20Rincon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shinji%22%2C%22lastName%22%3A%22Miwa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gustavo%22%2C%22lastName%22%3A%22Molina%20Uribe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bryan%22%2C%22lastName%22%3A%22Moon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rhidian%22%2C%22lastName%22%3A%22Morgan-Jones%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diego%20J.%22%2C%22lastName%22%3A%22Moriel%20Garcesco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carol%22%2C%22lastName%22%3A%22Morris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steward%22%2C%22lastName%22%3A%22Morrison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Mottard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcio%22%2C%22lastName%22%3A%22Moura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Linde%22%2C%22lastName%22%3A%22Muster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Nakayama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prashant%22%2C%22lastName%22%3A%22Narhari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Navas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Prakash%22%2C%22lastName%22%3A%22Nayak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Neugebauer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20T.%22%2C%22lastName%22%3A%22Newman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jyrki%22%2C%22lastName%22%3A%22Nieminen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmy%22%2C%22lastName%22%3A%22Nyqvist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lukas%22%2C%22lastName%22%3A%22Nystrom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22O%27Reilly-Harbidge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gary%22%2C%22lastName%22%3A%22O%27Toole%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vania%22%2C%22lastName%22%3A%22Oliveira%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20J.%22%2C%22lastName%22%3A%22Ortiz-Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harzem%22%2C%22lastName%22%3A%22Ozger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Korhan%22%2C%22lastName%22%3A%22Ozkan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Pala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Palmerini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grant%22%2C%22lastName%22%3A%22Pang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Panayiotis%22%2C%22lastName%22%3A%22Papagelopoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Paraliticci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20C.%22%2C%22lastName%22%3A%22Parry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sam%22%2C%22lastName%22%3A%22Patton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Peake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%22%2C%22lastName%22%3A%22Peiro%20Ibanez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Israel%22%2C%22lastName%22%3A%22Perez%20Munoz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ganapathy%20R.%22%2C%22lastName%22%3A%22Perianayagam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20M.%22%2C%22lastName%22%3A%22Petersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joris%22%2C%22lastName%22%3A%22Ploegmakers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Pollock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerard%22%2C%22lastName%22%3A%22Powell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Pretell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Puetzler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Qamar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anand%22%2C%22lastName%22%3A%22Raja%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raja%20B.%22%2C%22lastName%22%3A%22Rajasekaran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dipak%22%2C%22lastName%22%3A%22Ramkumar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20L.%22%2C%22lastName%22%3A%22Randall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20S.%22%2C%22lastName%22%3A%22Rankin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%20A.%22%2C%22lastName%22%3A%22Raskin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kumaran%22%2C%22lastName%22%3A%22Rassppan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauris%22%2C%22lastName%22%3A%22Repsa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%22%2C%22lastName%22%3A%22Ropars%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Rose%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wael%22%2C%22lastName%22%3A%22Sadek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22German%22%2C%22lastName%22%3A%22Salcedo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aasim%22%2C%22lastName%22%3A%22Saleemi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Sambri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hartej%22%2C%22lastName%22%3A%22Sar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Scanferla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Schubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Schwarze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guido%22%2C%22lastName%22%3A%22Scoccianti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashley%22%2C%22lastName%22%3A%22Scrimshire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tetsuya%22%2C%22lastName%22%3A%22Sekita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmad%22%2C%22lastName%22%3A%22Shehadeh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ahmed%22%2C%22lastName%22%3A%22Shoaib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bhim%22%2C%22lastName%22%3A%22Shreemal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Shumelinsky%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geoffrey%22%2C%22lastName%22%3A%22Siegel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%22%2C%22lastName%22%3A%22Silveri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Silverwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Friedl%22%2C%22lastName%22%3A%22Sinnaeve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Sison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Slade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20A.%22%2C%22lastName%22%3A%22Smolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franz%22%2C%22lastName%22%3A%22Snyman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%22%2C%22lastName%22%3A%22Sommerville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sahil%22%2C%22lastName%22%3A%22Sood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andre%22%2C%22lastName%22%3A%22Spiguel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22St-Yves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%20L.%22%2C%22lastName%22%3A%22Staals%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Stacchiotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nikolas%22%2C%22lastName%22%3A%22Stavropoulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Steadman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20D.%22%2C%22lastName%22%3A%22Stevenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikaela%22%2C%22lastName%22%3A%22Sullivan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwen%22%2C%22lastName%22%3A%22Sys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bartlomiej%22%2C%22lastName%22%3A%22Szostakowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angela%22%2C%22lastName%22%3A%22Tamburini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yuta%22%2C%22lastName%22%3A%22Taniguchi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Temple%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Theil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joachim%22%2C%22lastName%22%3A%22Thorkildsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meagan%22%2C%22lastName%22%3A%22Tibbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%22%2C%22lastName%22%3A%22Tillman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yu%22%2C%22lastName%22%3A%22Toda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaspar%22%2C%22lastName%22%3A%22Tootsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferran%22%2C%22lastName%22%3A%22Torner%20Rubies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22Traub%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioannis%22%2C%22lastName%22%3A%22Trikoupis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Panagiotis%22%2C%22lastName%22%3A%22Tsagkozis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kim%22%2C%22lastName%22%3A%22Tsoi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hiroyuki%22%2C%22lastName%22%3A%22Tsuchiya%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veli-Matti%22%2C%22lastName%22%3A%22Vainio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Valcarcel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Valencia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annelies%22%2C%22lastName%22%3A%22Van%20Beeck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Van%20de%20Sande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Van%20Den%20Berghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ingrid%22%2C%22lastName%22%3A%22Van%20de%20Geest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lizz%22%2C%22lastName%22%3A%22Van%20der%20Heijden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Van%20der%20Wal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kirsten%22%2C%22lastName%22%3A%22Van%20Langevelde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gualter%22%2C%22lastName%22%3A%22Vaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberto%22%2C%22lastName%22%3A%22Velez%20Villa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floortje%22%2C%22lastName%22%3A%22Verspoor%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koenraad%22%2C%22lastName%22%3A%22Verstraete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julia%22%2C%22lastName%22%3A%22Visgauss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oleg%22%2C%22lastName%22%3A%22Vyrva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hazem%22%2C%22lastName%22%3A%22Wafa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%22%2C%22lastName%22%3A%22Walter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wan%20F.%22%2C%22lastName%22%3A%22Wan%20Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%20Q.%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Warnock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joel%22%2C%22lastName%22%3A%22Werier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wolfram%22%2C%22lastName%22%3A%22Weschenfelder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kwok-Chuen%22%2C%22lastName%22%3A%22Wong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjan%22%2C%22lastName%22%3A%22Woulthuyzen-Bakker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jay%22%2C%22lastName%22%3A%22Wunder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Indica%22%2C%22lastName%22%3A%22Wysinghe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norio%22%2C%22lastName%22%3A%22Yamamoto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhaoming%22%2C%22lastName%22%3A%22Ye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seung-Jae%22%2C%22lastName%22%3A%22Yoon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suraya%22%2C%22lastName%22%3A%22Zainul%20Abidin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Zamora%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierluca%22%2C%22lastName%22%3A%22Zecchetto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liuzhe%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20P.%22%2C%22lastName%22%3A%22Zumarraga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Domenico%20A.%22%2C%22lastName%22%3A%22Campanacci%22%7D%5D%2C%22abstractNote%22%3A%22AIMS%3A%20The%20Birmingham%20Orthopaedic%20Oncology%20Meeting%20%28BOOM%29%2C%20held%20in%20January%202024%2C%20convened%20309%20delegates%20from%2053%20countries%20to%20discuss%20and%20refine%2021%20consensus%20statements%20on%20the%20optimal%20management%20of%20chondrosarcoma.%5CnMETHODS%3A%20With%20representation%20from%20Europe%20%2843%25%3B%20n%20%3D%20133%29%2C%20North%20America%20%2817%25%3B%20n%20%3D%2053%29%2C%20South%20America%20%2816%25%3B%20n%20%3D%2049%29%2C%20Asia%20%2813%25%3B%20n%20%3D%2040%29%2C%20Australasia%20%285%25%3B%20n%20%3D%2016%29%2C%20the%20Middle%20East%20%284%25%3B%20n%20%3D%2012%29%2C%20and%20Africa%20%282%25%3B%20n%20%3D%206%29%2C%20the%20combined%20experience%20of%20treating%20bone%20sarcomas%20among%20attendees%20totalled%20approximately%2030%2C000%20cases%20annually%2C%20equivalent%20to%2066%20years%20of%20experience%20in%20the%20UK%20alone.%20The%20meeting%26%23039%3Bs%20process%20began%20with%20the%20formation%20of%20a%20local%20organizing%20committee%2C%20regional%20leads%2C%20and%20a%20scientific%20committee%20comprising%20representatives%20from%20150%20specialist%20units%20across%2047%20countries.%20Supported%20by%20major%20orthopaedic%20oncology%20organizations%2C%20the%20meeting%20used%20a%20modified%20Delphi%20process%20to%20develop%20consensus%20statements%20through%20online%20questionnaires%2C%20thematic%20groupings%2C%20narrative%20reviews%2C%20and%20anonymous%20pre-meeting%20polling.%5CnRESULTS%3A%20Strong%20%28%26gt%3B%2080%25%29%20consensus%20was%20achieved%20on%2019%20out%20of%2021%20statements%2C%20reflecting%20agreement%20among%20delegates.%20Key%20areas%20of%20consensus%20included%20the%20role%20of%20radiology%20in%20diagnosis%20and%20surveillance%2C%20the%20management%20of%20locally%20recurrent%20disease%2C%20and%20the%20treatment%20of%20dedifferentiated%20chondrosarcoma.%20Notably%2C%20there%20was%20agreement%20that%20routine%20chemotherapy%20has%20no%20role%20in%20chondrosarcoma%20treatment%2C%20and%20radiological%20surveillance%20is%20safe%20for%20intraosseous%20chondrosarcomas.%20Despite%20the%20overall%20consensus%2C%20areas%20of%20controversy%20remain%2C%20particularly%20regarding%20the%20treatment%20of%20atypical%20cartilage%20tumours%20and%20surgical%20margins.%20These%20unresolved%20issues%20underscore%20the%20need%20for%20further%20research%20and%20collaboration%20within%20the%20orthopaedic%20oncology%20community.%5CnCONCLUSION%3A%20BOOM%20represents%20the%20largest%20global%20consensus%20meeting%20in%20orthopaedic%20oncology%2C%20providing%20valuable%20guidance%20for%20clinicians%20managing%20chondrosarcoma%20worldwide.%20The%20consensus%20statements%20offer%20a%20reference%20for%20clinical%20practice%2C%20highlight%20key%20research%20priorities%2C%20and%20aim%20to%20improve%20patient%20outcomes%20on%20a%20global%20scale.%22%2C%22date%22%3A%222025-02-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1302%5C%2F0301-620X.107B2.BJJ-2024-0643.R1%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222049-4408%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A16%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22GW8Y862C%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rusidz%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222025-01-31%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRusidz%26%23xE9%3B%2C%20Mariam%2C%20Fran%26%23xE7%3Bois%20Poumeaud%2C%20B%26%23xE9%3Batrice%20Akiki%2C%20Thibaud%20Valentin%2C%20Gwena%26%23xEB%3Bl%20Ferron%2C%20Anne%20Ducassou%2C%20Daniel%20Pissaloux%2C%20et%20al.%20%26%23x201C%3BEWSR1%3A%3ACREM%20Rearranged%20Intra-Abdominal%20Malignant%20Epithelioid%20Neoplasm%3A%20Two%20New%20Cases%20of%20an%20Emerging%20Entity%20with%20Clinicopathological%20Characteristics%20and%20Histological%20Pitfalls.%26%23x201D%3B%20%26lt%3Bi%26gt%3BVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2031%2C%202025.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-025-04034-4%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-025-04034-4%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22EWSR1%3A%3ACREM%20rearranged%20intra-abdominal%20malignant%20epithelioid%20neoplasm%3A%20two%20new%20cases%20of%20an%20emerging%20entity%20with%20clinicopathological%20characteristics%20and%20histological%20pitfalls%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariam%22%2C%22lastName%22%3A%22Rusidz%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Poumeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9atrice%22%2C%22lastName%22%3A%22Akiki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Pissaloux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Evrard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Brousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rochaix%22%7D%5D%2C%22abstractNote%22%3A%22The%20EWSR1%3A%3ACREM%20rearranged%20intra-abdominal%20malignant%20epithelioid%20neoplasm%20is%20an%20emerging%20tumor%2C%20with%20only%20a%20few%20publications%20describing%20it%20to%20date.%20Here%2C%20we%20report%20two%20new%20cases%20of%20this%20highly%20aggressive%20tumor%2C%20primarily%20involving%20the%20peritoneal%20surface.%20The%20tumors%20presented%20as%20a%20widespread%20diffuse%20peritoneal%20lesion%20associated%20with%20a%204-cm%20pelvic%20mass%20in%20a%2028-year-old%20woman%20%28Case%201%29%20and%20as%20a%2010-cm%20intra-abdominal%20mass%20infiltrating%20the%20stomach%20with%20multiple%20hepatic%20metastases%20in%20a%2053-year-old%20woman%20%28Case%202%29.%20The%20tumors%20shared%20predominant%20epithelioid%20morphology%20with%20minimal%20nuclear%20polymorphism.%20One%20of%20them%20additionally%20harbored%20spindle%20and%20rhabdoid%20cell%20populations.%20Both%20tumors%20displayed%20immunoreactivity%20for%20pan-cytokeratins%2C%20EMA%2C%20and%20CD99%2C%20and%20variable%20positivity%20for%20MUC4%2C%20progesterone%20and%20estrogen%20receptors%2C%20pan-NTRK%2C%20and%20synaptophysin.%20This%20misleading%20histology%20and%20immunophenotype%20give%20rise%20to%20a%20wide%20spectrum%20of%20differential%20diagnoses%20and%20highlight%20the%20crucial%20role%20of%20RNA%20sequencing%20in%20diagnostic%20accuracy%20and%20thus%20in%20appropriate%20therapeutic%20approaches.%22%2C%22date%22%3A%222025-01-31%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-025-04034-4%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221432-2307%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A15%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22JS6DIDQI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Delaye%20et%20al.%22%2C%22parsedDate%22%3A%222025-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDelaye%2C%20Matthieu%2C%20Alice%20Boil%26%23xE8%3Bve%2C%20Julie%20Henriques%2C%20Antoine%20Rouault%2C%20Jane%20Rose%20Paccard%2C%20Nadim%20Fares%2C%20Eric%20Assenat%2C%20et%20al.%20%26%23x201C%3BReal-Life%20Data%20on%20Biliary%20Tract%20Cancers%20in%20France%3A%20The%20Nested%20Amber%20Study%20from%20the%20French%20ACABi%20GERCOR%20PRONOBIL%20Retro-Prospective%2C%20Observational%20Cohort.%26%23x201D%3B%20%26lt%3Bi%26gt%3BDigestive%20and%20Liver%20Disease%3A%20Official%20Journal%20of%20the%20Italian%20Society%20of%20Gastroenterology%20and%20the%20Italian%20Association%20for%20the%20Study%20of%20the%20Liver%26lt%3B%5C%2Fi%26gt%3B%2057%2C%20no.%201%20%28January%202025%29%3A%20111%26%23x2013%3B17.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.dld.2024.06.032%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.dld.2024.06.032%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Real-life%20data%20on%20biliary%20tract%20cancers%20in%20France%3A%20The%20nested%20Amber%20study%20from%20the%20French%20ACABi%20GERCOR%20PRONOBIL%20retro-prospective%2C%20observational%20cohort%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Delaye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Boil%5Cu00e8ve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Henriques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Rouault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jane%20Rose%22%2C%22lastName%22%3A%22Paccard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadim%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Assenat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Lecomte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Hautefeuille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Tougeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Edeline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Boileau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aline%22%2C%22lastName%22%3A%22Ducroux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Hollebecque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dewi%22%2C%22lastName%22%3A%22Vernerey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Turpin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cindy%22%2C%22lastName%22%3A%22Neuzillet%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20AIMS%3A%20To%20gather%20real-life%20data%20on%20biliary%20tract%20cancer%20%28BTC%29%20in%20France%2C%20an%20ambispective%20ACABi%20GERCOR%20Pronobil%20cohort%20was%20initiated.%20This%20nested%20study%2C%20Amber%2C%20utilized%20data%20from%20this%20cohort%20to%20document%20clinical%20practices%20in%20this%20setting.%5CnMETHODS%3A%20Inclusion%20criteria%20encompassed%20patients%20with%20locally%20advanced%5C%2Fmetastatic%20BTC%20managed%20between%202019%20and%202021%20in%20nine%20French%20referral%20hospitals.%20Objectives%20included%20describing%20demographic%20and%20clinical%20data%2C%20treatments%20outcomes%20%28safety%20and%20efficacy%29%2C%20and%20overall%20survival.%5CnRESULTS%3A%20Of%20the%20138%20patients%20%28median%20age%2065%20years%2C%20a%20balanced%20sex%20ratio%29%20included%2C%20most%20displayed%20ECOG%200-1%20%2883%20%25%29%2C%20at%20least%20one%20comorbidity%20%2879%20%25%29%2C%20and%20had%20intrahepatic%20%2856%20%25%29%20and%20metastatic%20%2882%20%25%29%20BTC.%20Among%20surgically-resected%20patients%2C%2060%20%25%20received%20adjuvant%20chemotherapy%2C%20mainly%20capecitabine%20%2867%20%25%29.%20CisGem%2C%20the%20primary%20first-line%20palliative%20chemotherapy%20%2869%20%25%29%2C%20showed%20a%2023%20%25%20objective%20response%20rate%2C%20a%20median%20progression-free%20survival%20of%205.3%20months%2C%20and%20a%20median%20overall%20survival%20of%2013.4%20months.%20Second-%2C%20third-%2C%20and%20fourth-line%20were%20given%20to%2075%20%25%20%28FOLFOX%3A%2035%20%25%2C%20targeted%20therapy%3A%2014%20%25%29%2C%2032%20%25%2C%20and%2013%20%25%20of%20patients.%20In%20total%2C%2067%20%25%20of%20patients%20had%20a%20molecular%20profile%20%28IDH1%20mutations%20and%20FGFR2%20fusions%3A%20accounting%20for%2021%20%25%20each%20in%20intrahepatic%20cholangiocarcinoma%29.%5CnCONCLUSION%3A%20BTC%20patients%20were%20predominantly%20treated%20according%20to%20international%20recommendations.%20The%20obtained%20demographic%2C%20tumor%2C%20and%20molecular%20data%20were%20consistent%20with%20existing%20literature.%22%2C%22date%22%3A%222025-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.dld.2024.06.032%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221878-3562%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A16%3A40Z%22%7D%7D%2C%7B%22key%22%3A%225EUXQLHL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Valery%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BValery%2C%20Marine%2C%20Julien%20Edeline%2C%20Julie%20Henriques%2C%20Leony%20Antoun%2C%20Heloise%20Bourien%2C%20Antoine%20Lebeaud%2C%20Nadim%20Fares%2C%20et%20al.%20%26%23x201C%3BManagement%20of%20Biliary%20Tract%20Cancers%20in%20Elderly%20Patients%3A%20A%20French%20Multicenter%20Retrospective%20Study%20%28PRONOBIL-ACABi%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BTherapeutic%20Advances%20in%20Medical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2017%20%282025%29%3A%2017588359251344013.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F17588359251344013%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F17588359251344013%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Management%20of%20biliary%20tract%20cancers%20in%20elderly%20patients%3A%20a%20French%20multicenter%20retrospective%20study%20%28PRONOBIL-ACABi%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Valery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Edeline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Henriques%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leony%22%2C%22lastName%22%3A%22Antoun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heloise%22%2C%22lastName%22%3A%22Bourien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Lebeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadim%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Tournigand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Lecomte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Tougeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Hautefeuille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelique%22%2C%22lastName%22%3A%22Vienot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Williet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Bachet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Malka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Smolenschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Hollebecque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jane-Rose%22%2C%22lastName%22%3A%22Paccard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Fr%5Cu00e9laut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Hammel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%22%2C%22lastName%22%3A%22Turpin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Boileve%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Biliary%20tract%20cancers%20%28BTC%29%20are%20often%20diagnosed%20after%20the%20age%20of%2070%2C%20when%20comorbidities%20and%20compromised%20performance%20status%20%28PS%29%20are%20more%20prevalent.%5CnOBJECTIVES%3A%20This%20study%20compared%20clinical%20and%20disease%20characteristics%20and%20outcomes%20in%20BTC%20patients%20aged%20%5Cu2a7d70%20and%20%26gt%3B70%5Cu2009years.%5CnDESIGN%20AND%20METHODS%3A%20PRONOBIL-ACABI%20is%20a%20cohort%20study%20including%201256%20BTC%20patients%20treated%20across%2016%20French%20centers%20from%20January%202003%20to%20June%202021.%20We%20analyzed%20demographics%2C%20clinical%20characteristics%2C%20treatment%20modalities%2C%20molecular%20profiles%2C%20overall%20survival%20%28OS%29%20as%20the%20primary%20endpoint%2C%20and%20progression-free%20survival%20%28PFS%29.%5CnRESULTS%3A%20Among%20the%201256%20BTC%20patients%20%2853%25%20male%3B%20median%20age%3A%2064.5%29%2C%2031%25%20were%20aged%20%26gt%3B70.%20Patients%20%26gt%3B70%20exhibited%20poorer%20PS%20%28PS%20%5Cu2a7e2%2C%2017%25%20vs%208%25%3B%20p%5Cu2009%26lt%3B%5Cu20090.0001%29%2C%20a%20higher%20rate%20of%20comorbidities%20%28%5Cu2a7e1%2C%2089%25%20vs%2078%25%3B%20p%5Cu2009%26lt%3B%5Cu20090.0001%29%2C%20and%20were%20less%20often%20proposed%20a%20molecular%20profile%20%2843%25%20vs%2065%25%3B%20p%5Cu2009%26lt%3B%5Cu20090.0001%29%20than%20those%20%5Cu2a7d70.%20Patients%20with%20unresectable%20BTC%20aged%20%26gt%3B70%20had%20significantly%20shorter%20OS%20compared%20to%20younger%20patients%20%28median%20OS%3A%2014.6%20vs%2017.4%5Cu2009months%2C%20p%5Cu2009%26lt%3B%5Cu20090.0001%29%2C%20despite%20similar%20PFS%20%28median%20PFS%3A%206.6%20vs%205.8%5Cu2009months%2C%20p%5Cu2009%3D%5Cu20090.61%29.%20They%20were%20also%20less%20likely%20to%20receive%20first-line%20chemotherapy%20%2887%25%20vs%2097%25%2C%20p%5Cu2009%26lt%3B%5Cu20090.0001%29.%20In%20resected%20BTC%2C%20survival%20outcomes%20were%20comparable%20across%20age%20groups%2C%20with%20a%20median%20OS%20of%2047.0%5Cu2009months%20in%20patients%20%26gt%3B70%20vs%2048.8%5Cu2009months%20in%20those%20%5Cu2a7d70.%5CnCONCLUSION%3A%20Patients%20aged%20%26gt%3B70%5Cu2009years%20with%20unresectable%20BTC%20had%20a%20significantly%20shorter%20OS%20compared%20to%20those%20aged%20%5Cu2a7d70%2C%20despite%20similar%20first-line%20PFS.%20In%20resected%20BTC%2C%20elderly%20patients%20achieved%20OS%20and%20PFS%20outcomes%20comparable%20to%20those%20aged%20%5Cu2a7d70.%22%2C%22date%22%3A%222025%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1177%5C%2F17588359251344013%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221758-8340%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A16%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22SQFIH36H%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lopez%20et%20al.%22%2C%22parsedDate%22%3A%222025%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLopez%2C%20Ana%26%23xEF%3Bs%2C%20Alexia%20Paturel%2C%20Nadim%20Fares%2C%20Floriane%20Pez%2C%20Guanxiong%20Wang%2C%20Patricia%20Gifu%2C%20Lydie%20Lefran%26%23xE7%3Bois%2C%20et%20al.%20%26%23x201C%3BFrizzled%207%20Drives%20Amplification%20of%20Cancer%20Stem-Cell%20Subpopulations%20and%20the%20Aggressiveness%20and%20Poor%20Differentiation%20of%20Human%20Hepatocellular%20Carcinoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BPloS%20One%26lt%3B%5C%2Fi%26gt%3B%2020%2C%20no.%2010%20%282025%29%3A%20e0332768.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0332768%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0332768%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Frizzled%207%20drives%20amplification%20of%20cancer%20stem-cell%20subpopulations%20and%20the%20aggressiveness%20and%20poor%20differentiation%20of%20human%20hepatocellular%20carcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%5Cu00efs%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexia%22%2C%22lastName%22%3A%22Paturel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadim%22%2C%22lastName%22%3A%22Fares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floriane%22%2C%22lastName%22%3A%22Pez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guanxiong%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patricia%22%2C%22lastName%22%3A%22Gifu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydie%22%2C%22lastName%22%3A%22Lefran%5Cu00e7ois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jihed%22%2C%22lastName%22%3A%22Chouaref%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Saintigny%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marie%22%2C%22lastName%22%3A%22Peron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Rivoire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Caron%20de%20Fromentel%22%7D%5D%2C%22abstractNote%22%3A%22FZD7%20is%20one%20of%20the%20key%20players%20in%20the%20subset%20of%20WNT-TGF%5Cu03b2-activated%20hepatocellular%20carcinomas%20%28HCC%29%2C%20but%20the%20consequences%20of%20its%20abnormal%20expression%20on%20hepatocarcinogenesis%20remain%20to%20be%20better%20understood.%20Herein%2C%20we%20aimed%20to%20investigate%20the%20role%20of%20the%20FZD7-mediated%20signaling%20in%20immature%20phenotype%20and%20aggressiveness%20of%20HCC.%20Firstly%2C%20499%20human%20HCCs%20were%20used%20for%20clinical%20and%20molecular%20comparisons%20regarding%20the%20expression%20of%20FZD7%20and%20stemness-associated%20markers.%20We%20showed%20that%20FZD7%20overexpression%20was%20associated%20with%20poor%20differentiation%20and%2C%20in%20combination%20with%20CD133%2C%20predicted%20a%20poor%20outcome%20of%20patients%20with%20aggressive%20recurrence.%20Next%2C%20the%20impact%20of%20WNT3%5C%2FFZD7%20signaling%20on%20the%20differentiation%20of%20hepatic%20cells%20was%20assessed%20in%20HCC%20cell%20lines%2C%20as%20well%20in%20the%20non-transformed%20progenitor%20HepaRG%20cell%20line%20and%20in%20primary%20human%20hepatocytes%2C%20transduced%20with%20WNT3%20and%20FZD7-expressing%20lentiviruses.%20We%20demonstrated%20that%20the%20ectopic%20expression%20of%20WNT3%20and%20FZD7%20inhibited%20the%20differentiation%20behavior%20of%20HepaRG%20cells%20and%20human%20primary%20hepatocytes%2C%20amplified%20the%20pool%20of%20EpCAM%28%2B%29%2C%20CD90%28%2B%29%20and%20CD133%28%2B%29%20subsets%20of%20HCC%20cell%20lines%2C%20and%20increased%20their%20cancer%20stem%20cell%20features.%20Moreover%2C%20we%20found%20that%20WNT3%5C%2FFZD7-mediated%20stemness%20properties%20of%20cancer%20cells%20were%20independent%20of%20the%20stemness-associated%20marker%20NANOG.%20In%20conclusion%2C%20we%20identified%20the%20FZD7%28%2B%29%5C%2FCD133%28%2B%29%20signature%20as%20a%20potential%20prognosis%20marker%20and%20molecular%20therapeutic%20target%2C%20and%20we%20strengthened%20the%20hypothesis%20for%20the%20involvement%20of%20FZD7%20in%20the%20enrichment%20of%20a%20cancer%20stem%20cell%20pool%20in%20HCC.%22%2C%22date%22%3A%222025%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0332768%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221932-6203%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222026-03-23T14%3A16%3A16Z%22%7D%7D%5D%7D
Maalouly, Georges, Tarek Itani, and Nassim Fares. “Cinnamomum Cassia Modulates Key Players of Gut-Liver Axis in Murine Lupus.” Biomedicines 14, no. 1 (December 19, 2025): 6. https://doi.org/10.3390/biomedicines14010006.
Ducrot, Coline, Derek Dinart, Mathilde Reich, Max Piffoux, Maeva Bonneau, Mathieu Larroquette, Simon Nannini, et al. “Metastatic Chondrosarcoma, Patterns of Care, and Outcomes of Patients in a Real-Life National Setting over a Decade.” International Journal of Cancer 157, no. 11 (December 1, 2025): 2325–33. https://doi.org/10.1002/ijc.70023.
Valerio, M., T. Valentin, and V. Sibaud. “Ripretinib-Related Pyoderma Gangrenosum: First Description and Pathophysiological Clues.” Annales De Dermatologie Et De Venereologie 152, no. 4 (December 2025): 103410. https://doi.org/10.1016/j.annder.2025.103410.
Daou, Rouaa, Maha Hoteit, Jad Chémali, Nikolaos Tzenios, Nassim Fares, and André El Khoury. “Assessing Kidney Injury Biomarkers and OTA Exposure in Urine of Lebanese Adolescents Amid Economic Crisis and Evolving Dietary Patterns.” Toxins 17, no. 12 (November 30, 2025): 577. https://doi.org/10.3390/toxins17120577.
Khan, Zeeshan, Zainab Aqeel Khan, Tomas Zamora, Ashish Gulia, Santiago A. Lozano-Calderon, Vineet J. Kurisunkal, Lee M. Jeys, et al. “What Is Debridement, Antibiotics, and Implant Retention in Orthopaedic Oncology? : A Global Cross-Sectional Survey of Surgeons’ Practices and Opinions.” Bone & Joint Open 6, no. 11 (November 20, 2025): 1495–1503. https://doi.org/10.1302/2633-1462.611.BJO-2025-0114.R2.
Valentin, Thibaud, Nicolas Penel, and Maud Toulmonde. “[Sarcoma: a plural entity].” La Revue Du Praticien 75, no. 9 (November 2025): 954–58.
Alouani, Emily, Julien Taieb, David Tougeron, Guillaume Roces, Antoine Hollebecque, Pauline Parent, Simon Pernot, et al. “Efficacy of Immunotherapy in Gastrointestinal (GI) Tumors with Mismatch Repair Deficient (MMRd) Unusual Phenotype: An AGEO Real-World Study.” Journal for Immunotherapy of Cancer 13, no. 10 (October 30, 2025): e011436. https://doi.org/10.1136/jitc-2024-011436.
Bompas, Emmanuelle, Loic Campion, Maud Toulmonde, Axel Le Cesne, Mélanie Saint-Jean, Céleste Lebbe, Thibaud Valentin, et al. “Outcome of 1773 Superficial Non-Dermatofibrosarcoma Sarcomas A French Sarcoma Group Study (FSG) from the NETSARC Database.” European Journal of Cancer 229 (October 16, 2025): 115788. https://doi.org/10.1016/j.ejca.2025.115788.
Blay, Jean-Yves, Maud Toulmonde, Thibaud Valentin, Nelly Firmin, Sarah Watson, Florence Duffaud, Emmanuelle Bompas, et al. “Clinical Presentation, Management and Outcome of 11,132 Patients with Liposarcoma Patients: A Population-Based Study from the NETSARC+ Registry.” The Lancet Regional Health. Europe 57 (October 2025): 101403. https://doi.org/10.1016/j.lanepe.2025.101403.
Barré, Tangui, Clémence Ramier, Linda Wittkop, Philippe Sogni, David Zucman, Raphaëlle Tardieu, Patrizia Carrieri, Fabienne Marcellin, and ANRS CO13 HEPAVIH Study Group. “Low CD4 Cell Count Is Associated With Post-Hepatitis C Virus Cure Mortality in People With HIV (ANRS CO13 HEPAVIH Cohort).” Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 81, no. 2 (September 16, 2025): e28–30. https://doi.org/10.1093/cid/ciaf016.
Fazel, Mina, Romain Varnier, Hélène Vanacker, Nicolas Penel, Sarah Watson, Benjamin Verret, Thibaud Valentin, et al. “Clinical and Biological Factors Associated with Response to Immune Checkpoint Inhibitors in Advanced Sarcomas: IMPRESARC, a French Retrospective Multicenter Cohort Study.” Cancer 131, no. 18 (September 15, 2025): e70052. https://doi.org/10.1002/cncr.70052.
Blay, J.-Y., Q. Devin, M. Toulmonde, A. Dufresne, N. Penel, A. Adenis, M. Rios, et al. “Twenty-Year Survival of Advanced Gastrointestinal Stromal Tumours Treated with Imatinib: Exploratory Long-Term Follow-up of the BFR14 Trial.” Annals of Oncology: Official Journal of the European Society for Medical Oncology 36, no. 9 (September 2025): 1035–46. https://doi.org/10.1016/j.annonc.2025.05.535.
Michot, A., A. Giraud, M. Karanian, M. Laé, M. Fau, D. Adam, R. Wernert, et al. “Radiation-Associated Angiosarcoma of the Breast: Consider Chemotherapy.” European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 51, no. 9 (September 2025): 110202. https://doi.org/10.1016/j.ejso.2025.110202.
Callegaro, Dario, Gabriele Tinè, Felix Boakye Oppong, Axelle Nzokirantevye, Saskia Litière, Stefano Percio, Andrea Carenzo, et al. “CINSARC and Sarculator in Patients with Primary Retroperitoneal Sarcoma: A Combined Analysis of Single-Institution Data and the EORTC-STBSG-62092 Trial (STRASS).” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 31, no. 15 (August 1, 2025): 3239–48. https://doi.org/10.1158/1078-0432.CCR-25-0099.
Penel, N., A. Italiano, J. Wallet, L. Chaigneau, B. Verret, N. Firmin, S. Watson, et al. “Regorafenib as Maintenance Therapy after First-Line Doxorubicin-Based Chemotherapy in Advanced Non-Adipocytic Soft Tissue Sarcomas Patients: A Double-Blind Randomised Trial.” Annals of Oncology: Official Journal of the European Society for Medical Oncology 36, no. 8 (August 2025): 944–53. https://doi.org/10.1016/j.annonc.2025.03.024.
Toulmonde, Maud, Jean-Philippe Guégan, Mariella Spalato-Ceruso, Thibaud Valentin, Rastilav Bahleda, Florent Peyraud, Christophe Rey, et al. “Reshaping the Tumor Microenvironment of Cold Soft-Tissue Sarcomas with Anti-Angiogenics: A Phase 2 Trial of Regorafenib Combined with Avelumab.” Signal Transduction and Targeted Therapy 10, no. 1 (June 27, 2025): 202. https://doi.org/10.1038/s41392-025-02278-9.
Winter, Sarah, Thibaud Valentin, Anne Ducassou, Sylvie Helfre, Pablo Berlanga, Lauriane Lemelle, Aude Marie-Cardine, Pascaline Boudou Rouquette, and Valérie Laurence. “[Extra-pulmonary metastatic Ewing sarcoma: The French GroupOs diagnostic and therapeutic recommendations].” Bulletin Du Cancer 112, no. 6 (June 2025): 619–25. https://doi.org/10.1016/j.bulcan.2024.01.014.
Valentin, Thibaud, Sarah Winter, Valentine Martin, Marie Csanyi, Perrine Marec Berard, Valérie Laurence, and Nathalie Gaspar. “Primary Cutaneous/Subcutaneous Ewings Sarcoma.” Bulletin Du Cancer 112, no. 6 (June 2025): 611–18. https://doi.org/10.1016/j.bulcan.2023.10.011.
Brahmi, Mehdi, Maud Toulmonde, Sarah Winter, Sixtine De Percin, Thibaud Valentin, Nadège Corradini, Justine Gantzer, et al. “[Recurrent or refractory Osteosarcoma and Ewing sarcoma-French guidelines from the FSG/NETSARC and GroupOs groups].” Bulletin Du Cancer 112, no. 6 (June 2025): 601–10. https://doi.org/10.1016/j.bulcan.2024.03.010.
Alouani, E., C. Canivet, B. Bournet, L. Buscail, J. Selves, B. Napoleon, L. Palazzo, et al. “Is Survival Influenced by Metastatic Site in Synchronous Metastatic Pancreatic Adenocarcinoma (PDAC)? A Prospective Real-World BACAP Study.” ESMO Gastrointestinal Oncology 8 (June 2025): 100144. https://doi.org/10.1016/j.esmogo.2025.100144.
Julieron, Morbize, Anne Gomez-Mascard, Cécile Vérité, Maud Toulmonde, Cyril Lervat, Michèle Kind, and Juliette Thariat. “[Recommendations from the group of bone tumors of the French Childhood Cancer Society and the French Sarcoma Group/Group for the Study of Bone Tumors].” Bulletin Du Cancer 112, no. 6 (June 2025): 574–91. https://doi.org/10.1016/j.bulcan.2024.03.009.
Boudou-Rouquette, Pascaline, Frédérique Larousserie, Valérie Dumaine, Anne Gomez-Mascard, Valérie Bousson, Axel Le Cesne, Gualter Vaz, et al. “[Update of the recommendations for the management and treatment of giant cell bone tumors, on behalf of GroupOS].” Bulletin Du Cancer 112, no. 6 (June 2025): 626–37. https://doi.org/10.1016/j.bulcan.2024.01.013.
Vande Perre, Pierre, Ayman Al Saati, Bastien Cabarrou, Julien Plenecassagnes, Julia Gilhodes, Nils Monselet, Norbert Lignon, et al. “Germline Sequencing of Familial and Sporadic Early-Onset Colorectal Cancer: A Novel Pattern of Genes.” International Journal of Molecular Sciences 26, no. 10 (May 14, 2025): 4672. https://doi.org/10.3390/ijms26104672.
Sargos, P., M. P. Sunyach, A. Ducassou, C. Llacer, D. Dinart, A. Michot, T. Valentin, et al. “Results of a Phase Ib Study of Olaparib with Concomitant Radiotherapy in Soft-Tissue Sarcoma: A French Sarcoma Group Study.” Annals of Oncology: Official Journal of the European Society for Medical Oncology 36, no. 5 (May 2025): 592–600. https://doi.org/10.1016/j.annonc.2025.01.016.
Allaume, Pierre, Raphaël Bourgade, Arnaud Uguen, Thierry Pécot, Sophie Prevot, Catherine Guettier, Janick Selves, et al. “[A national survey from the French Society of Pathology on research and application of artificial intelligence in pathology].” Annales De Pathologie 45, no. 3 (May 2025): 224–32. https://doi.org/10.1016/j.annpat.2024.12.008.
Zamora, Tomas, Eduardo Botello, Thomas Jenkins, Charlotte Jeys, Minna Laitinen, Ajay Puri, Lee Jeys, and BOOM consensus meeting participants. “Global and Regional Disparities in Access to Specialist Sarcoma Services.” Bone & Joint Open 6, no. 4 (April 11, 2025): 425–31. https://doi.org/10.1302/2633-1462.64.BJO-2024-0208.R1.
Dutour, Aurelie, Michela Pasello, Luke Farrow, Mahetab H. Amer, Natacha Entz-Werlé, Michaela Nathrath, Katia Scotlandi, Sibylle Mittnacht, and Anne Gomez-Mascard. “Microenvironment Matters: Insights from the FOSTER Consortium on Microenvironment-Driven Approaches to Osteosarcoma Therapy.” Cancer Metastasis Reviews 44, no. 2 (April 10, 2025): 44. https://doi.org/10.1007/s10555-025-10257-3.
PFMG2025 contributors. “PFMG2025-Integrating Genomic Medicine into the National Healthcare System in France.” The Lancet Regional Health. Europe 50 (March 2025): 101183. https://doi.org/10.1016/j.lanepe.2024.101183.
Barré, Tangui, Clémence Ramier, Karine Ory, Philippe Sogni, Hugues Aumaitre, Tounes Saidi, Patrizia Carrieri, Fabienne Marcellin, and ANRS CO13 HEPAVIH Study Group. “Transient CD4 Cell Recovery after Hepatitis C Virus Cure in HIV/Hepatitis C Virus Coinfected Patients (ANRS CO13 HEPAVIH Cohort).” HIV Medicine 26, no. 3 (March 2025): 500–503. https://doi.org/10.1111/hiv.13752.
Barré, Tangui, Clémence Ramier, Karine Ory, Tounes Saidi, Philippe Sogni, Fabien Zoulim, Morgane Bureau-Stoltmann, et al. “Liver Enzyme Elevation After Hepatitis C Virus Cure: Is There a Sex Effect? (ANRS CO13 HEPAVIH Cohort).” Journal of Viral Hepatitis 32, no. 3 (March 2025): e70007. https://doi.org/10.1111/jvh.70007.
Poumeaud, F., T. Valentin, N. Fares, B. Segier, S. Watson, B. Verret, C. Tlemsani, et al. “Sarcomas Developed in Patients with Lynch Syndrome Are Enriched in Pleomorphic Soft-Tissue Sarcomas and Are Sensitive to Immunotherapy.” European Journal of Cancer 216 (February 5, 2025): 115196. https://doi.org/10.1016/j.ejca.2024.115196.
Jeys, Lee M., Guy V. Morris, Vineet J. Kurisunkal, Eduardo Botello, Richard A. Boyle, Walid Ebeid, Matthew T. Houdek, et al. “Identifying Consensus and Areas for Future Research in Chondrosarcoma : A Report from the Birmingham Orthopaedic Oncology Meeting.” The Bone & Joint Journal 107-B, no. 2 (February 1, 2025): 246–52. https://doi.org/10.1302/0301-620X.107B2.BJJ-2024-0643.R1.
Rusidzé, Mariam, François Poumeaud, Béatrice Akiki, Thibaud Valentin, Gwenaël Ferron, Anne Ducassou, Daniel Pissaloux, et al. “EWSR1::CREM Rearranged Intra-Abdominal Malignant Epithelioid Neoplasm: Two New Cases of an Emerging Entity with Clinicopathological Characteristics and Histological Pitfalls.” Virchows Archiv: An International Journal of Pathology, January 31, 2025. https://doi.org/10.1007/s00428-025-04034-4.
Delaye, Matthieu, Alice Boilève, Julie Henriques, Antoine Rouault, Jane Rose Paccard, Nadim Fares, Eric Assenat, et al. “Real-Life Data on Biliary Tract Cancers in France: The Nested Amber Study from the French ACABi GERCOR PRONOBIL Retro-Prospective, Observational Cohort.” Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 57, no. 1 (January 2025): 111–17. https://doi.org/10.1016/j.dld.2024.06.032.
Valery, Marine, Julien Edeline, Julie Henriques, Leony Antoun, Heloise Bourien, Antoine Lebeaud, Nadim Fares, et al. “Management of Biliary Tract Cancers in Elderly Patients: A French Multicenter Retrospective Study (PRONOBIL-ACABi).” Therapeutic Advances in Medical Oncology 17 (2025): 17588359251344013. https://doi.org/10.1177/17588359251344013.
Lopez, Anaïs, Alexia Paturel, Nadim Fares, Floriane Pez, Guanxiong Wang, Patricia Gifu, Lydie Lefrançois, et al. “Frizzled 7 Drives Amplification of Cancer Stem-Cell Subpopulations and the Aggressiveness and Poor Differentiation of Human Hepatocellular Carcinoma.” PloS One 20, no. 10 (2025): e0332768. https://doi.org/10.1371/journal.pone.0332768.
PUBLICATIONS 2024
7813506
CF9MRXB4
2024
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22Z6FCLZ75%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Saucier%20et%20al.%22%2C%22parsedDate%22%3A%222024-10-10%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSaucier%2C%20Emilie%2C%20Ga%26%23xEB%3Blle%20Bougeard%2C%20Anne%20Gomez-Mascard%2C%20Catherine%20Schramm%2C%20Rachid%20Abbas%2C%20Pablo%20Berlanga%2C%20Claire%20Briandet%2C%20et%20al.%20%26%23x201C%3BLi-Fraumeni-Associated%20Osteosarcomas%3A%20The%20French%20Experience.%26%23x201D%3B%20%26lt%3Bi%26gt%3BPediatric%20Blood%20%26amp%3B%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20October%2010%2C%202024%2C%20e31362.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.31362%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.31362%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Li-Fraumeni-associated%20osteosarcomas%3A%20The%20French%20experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Saucier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Bougeard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Schramm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Abbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pablo%22%2C%22lastName%22%3A%22Berlanga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Briandet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Castex%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nad%5Cu00e8ge%22%2C%22lastName%22%3A%22Corradini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Coze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Guerrini-Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Guinebreti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Khneisser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Lervat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Mansuy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%22%2C%22lastName%22%3A%22Marec-Berard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Marie-Cardine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Saumet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Dominique%22%2C%22lastName%22%3A%22Tabone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Winter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Frebourg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Brugieres%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Describe%20clinical%20characteristics%20and%20outcome%20of%20Li-Fraumeni%20syndrome%20%28LFS%29-associated%20osteosarcomas.%5CnMETHODS%3A%20TP53%20germline%20pathogenic%5C%2Flikely%20pathogenic%20variant%20carriers%20diagnosed%20with%20osteosarcoma%20in%20France%20between%201980%20and%202019%20were%20identified%20via%20the%20French%20Li-Fraumeni%20database%20at%20Rouen%20University%20Hospital.%20Sixty-five%20osteosarcomas%20in%2052%20patients%20with%20available%20clinical%20and%20histological%20data%20were%20included.%20The%20main%20clinical%20characteristics%20were%20compared%20with%20data%20from%20National%20Cancer%20Institute%26%23039%3Bs%20SEER%20%28Surveillance%2C%20Epidemiology%2C%20and%20End%20Results%29%20for%20patients%20of%20the%20same%20age%20group.%5CnRESULTS%3A%20Median%20age%20at%20first%20osteosarcoma%20diagnosis%20was%2013.7%5Cu00a0years%20%28range%3A%205.9-36.7%29.%20Compared%20to%20unselected%20osteosarcomas%2C%20LFS-associated%20osteosarcomas%20occurred%20more%20frequently%20in%20patients%20less%20than%2010%5Cu00a0years%20of%20age%20%2823%25%20vs.%209%25%29%2C%20and%20when%20compared%20with%20osteosarcomas%20in%20patients%20less%20than%2025%5Cu00a0years%20were%20characterized%20by%20an%20excess%20of%20axial%20%2816%25%20vs.%2010%25%29%20and%20jaw%20sites%20%2815%25%20vs.%203%25%29%20and%20histology%20with%20predominant%20chondroblastic%20component%20and%20periosteal%20subtypes%20%2817%25%20vs.%201%25%29.%20Metastases%20incidence%20%2825%25%29%20was%20as%20expected%20in%20osteosarcomas.%20After%20the%20first%20osteosarcoma%20treatment%2C%20the%20rate%20of%20good%20histologic%20response%20%2862%25%29%20and%20the%205-year%20progression-free%20survival%20%2855%25%2C%2095%25%20confidence%20interval%20%5BCI%5D%3A%2042.6-71.1%29%20were%20as%20expected%20in%20unselected%20series%20of%20osteosarcomas%2C%20whereas%20the%205-year%20event-free%20survival%20was%2036.5%25%20%5B95%25%20CI%3A%2025.3-52.7%5D%20due%20to%20the%20high%20incidence%20of%20second%20malignancies%20reaching%20a%2010-year%20cumulative%20risk%20of%2043.4%25%20%5B95%25%20CI%3A%2028.5-57.5%5D.%5CnCONCLUSION%3A%20In%20osteosarcoma%2C%20young%20age%20at%20diagnosis%2C%20axial%20and%20jaw%20sites%2C%20histology%20with%20periosteal%20or%20chondroblastic%20subtype%2C%20and%20synchronous%20multifocal%20tumors%20should%20prompt%20suspicion%20of%20a%20germline%20TP53%20mutation.%20Standard%20treatments%20are%20effective%2C%20but%20multiple%20malignancies%20impair%20prognosis.%20Early%20recognition%20of%20these%20patients%20is%20crucial%20for%20tailored%20therapy%20and%20follow-up.%22%2C%22date%22%3A%222024-10-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fpbc.31362%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221545-5017%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222024-10-28T13%3A16%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22HAFEJFU8%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bastard%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBastard%2C%20Paul%2C%20Nathalie%20Cozic%2C%20R%26%23xE9%3Bgis%20Brion%2C%20Nathalie%20Gaspar%2C%20Sophie%20Piperno-Neumann%2C%20Camille%20Cordero%2C%20Estelle%20Lecul%26%23xE9%3Be-Th%26%23xE9%3Bbaud%2C%20et%20al.%20%26%23x201C%3BPrognostic%20Value%20of%20Hemogram%20Parameters%20in%20Osteosarcoma%3A%20The%20French%20OS2006%20Experience.%26%23x201D%3B%20%26lt%3Bi%26gt%3BPediatric%20Blood%20%26amp%3B%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20April%2028%2C%202024%2C%20e31029.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.31029%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fpbc.31029%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prognostic%20value%20of%20hemogram%20parameters%20in%20osteosarcoma%3A%20The%20French%20OS2006%20experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Bastard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Cozic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9gis%22%2C%22lastName%22%3A%22Brion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Cordero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Lecul%5Cu00e9e-Th%5Cu00e9baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Mascard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22R%5Cu00e9dini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonin%22%2C%22lastName%22%3A%22Marchais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raina%22%2C%22lastName%22%3A%22Ikonomova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Cleirec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Laurence%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Rigaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Abbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Verrecchia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Brugi%5Cu00e8res%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Minard-Colin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Previous%20studies%20have%20shown%20that%20neutrophil-to-lymphocyte%20%28NLR%29%20ratio%20at%20diagnosis%20and%20early%20lymphocytes%20recovery%20on%20doxorubicin-based%20chemotherapy%2C%20may%20impact%20the%20outcome%20in%20patients%20with%20osteosarcoma%20%28OST%29.%20This%20study%20aimed%20to%20evaluate%20the%20prognostic%20value%20of%20hemogram%20parameters%20in%20patients%20with%20OST%20treated%20with%20high-dose%20methotrexate%20and%20etoposide%5C%2Fifosfamide%20%28M-EI%29%20chemotherapy.%5CnMATERIALS%20AND%20METHODS%3A%20We%20retrospectively%20analyzed%20the%20prognostic%20value%20of%20various%20hemogram%20parameters%20at%20diagnosis%20and%20during%20therapy%20in%20a%20large%20consecutive%20cohort%20of%20patients%20with%20OST%20included%20in%20the%20French%20OS2006%20trial%20and%20treated%20with%20M-EI%20chemotherapy.%5CnRESULTS%3A%20A%20total%20of%20164%20patients%20were%20analyzed.%20The%20median%20age%20was%2014.7%5Cu00a0years%20%28interquartile%20range%20%5BIQR%5D%3A%2011.7-17%29.%20Median%20follow-up%20was%205.6%5Cu00a0years%20%28IQR%3A%203.3-7.7%5Cu00a0years%29.%20Three-year%20event-free%20survival%20%28EFS%29%20and%20overall%20survival%20%28OS%29%20were%2071.5%25%20%2895%25%20confidence%20interval%20%5BCI%5D%3A%2064%25-78%25%29%20and%2086.4%25%20%2895%25%20CI%3A%2080%25-91%25%29%2C%20respectively.%20In%20univariate%20analysis%2C%20blood%20count%20parameters%20at%20diagnosis%20and%20early%20lymphocyte%20recovery%20at%20Day%2014%20were%20not%20found%20prognostic%20of%20survival%20outcomes.%20By%20contrast%2C%20an%20increase%20of%20NLR%20ratio%20at%20Day%201%20of%20the%20first%20EI%20chemotherapy%20%28NLR-W4%29%20was%20associated%20with%20reduced%20OS%20in%20univariate%20%28p%5Cu00a0%3D%5Cu00a0.0044%29%20and%20multivariate%20analysis%20%28hazards%20ratio%20%5BHR%5D%5Cu00a0%3D%5Cu00a01.3%2C%2095%25%20CI%3A%201.1-1.5%3B%20p%5Cu00a0%3D%5Cu00a0.002%29%2C%20although%20not%20with%20EFS.%20After%20adjustment%20on%20histological%20response%20and%20metastatic%20status%2C%20an%20increase%20of%20the%20ratio%20NLR-W4%20of%201%20was%20associated%20with%20an%20increased%20risk%20of%20death%20of%2030%25.%5CnCONCLUSIONS%3A%20We%20identified%20NLR-W4%20as%20a%20potential%20early%20biomarker%20for%20survival%20in%20patients%20with%20OST%20treated%20with%20M-EI%20chemotherapy.%20Further%20studies%20are%20required%20to%20confirm%20the%20prognostic%20value%20of%20NLR%20and%20better%20identify%20immune%20mechanisms%20involved%20in%20disease%20surveillance.%22%2C%22date%22%3A%222024-04-28%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fpbc.31029%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221545-5017%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222024-05-13T16%3A50%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22NK4DV4HY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Del%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDel%2C%20Mathilde%2C%20Claire%20Illac%2C%20Mathilde%20Morisseau%2C%20Martina%20Aida%20Angeles%2C%20Anne%20Ducassou%2C%20Sarah%20Betrian%2C%20Guillaume%20Bataillon%2C%20et%20al.%20%26%23x201C%3BIntraepithelial%20Tumor-Infiltrating%20Lymphocytes%20Shape%20Loco-Regional%20PET%5C%2FCT%20Spread%20of%20Locally%20Advanced%20Cervical%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2034%2C%20no.%204%20%28April%201%2C%202024%29%3A%20490%26%23x2013%3B96.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2023-004677%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2023-004677%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Intraepithelial%20tumor-infiltrating%20lymphocytes%20shape%20loco-regional%20PET%5C%2FCT%20spread%20of%20locally%20advanced%20cervical%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Del%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Illac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Morisseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Ducassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Betrian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Bataillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Chantalat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erwan%22%2C%22lastName%22%3A%22Gabiache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Data%20suggest%20an%20association%20between%20positron%20emission%20tomography%5C%2FCT%20%28PET%5C%2FCT%29%20metabolic%20metrics%20and%20tumor%20microenvironment%20in%20several%20malignancies%2C%20and%20a%20potential%20role%20of%20PET%5C%2FCT%20to%20monitor%20response%20to%20immunotherapy.%5CnOBJECTIVE%3A%20To%20evaluate%20the%20correlation%20between%20tumor%20loco-regional%20extension%20and%20tumor-infiltrating%20lymphocyte%20infiltration%20in%20locally%20advanced%20cervical%20cancer%20prior%20to%20concurrent%20chemo-radiotherapy.The%20secondary%20objective%20was%20to%20assess%20the%20association%20between%20tumor-infiltrating%20lymphocytes%20and%20PET%5C%2FCT%20metabolic%20metrics.%5CnMETHODS%3A%20Patients%20with%20locally%20advanced%20cervical%20cancer%20and%20negative%20para-aortic%20extensions%20on%20PET%5C%2FCT%20were%20included.%20Two%20senior%20nuclear%20medicine%20physicians%20specializing%20in%20gynecologic%20oncology%20reviewed%20all%20PET%5C%2FCT%20exams%2C%20and%20extracted%20tumor%20maximum%20standardized%20uptake%20value%2C%20metabolic%20tumor%20volume%2C%20and%20total%20lesion%20glycolysis%2C%20as%20well%20as%20pelvic%20lymph%20node%20involvement.%20One%20senior%20gynecologic%20oncology%20pathologist%20assessed%20intraepithelial%20tumor-infiltrating%20lymphocytes%20and%20stromal%20tumor-infiltrating%20lymphocytes.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20categorized%20following%20previous%20studies%20as%20%26lt%3B1%25%20and%20%26gt%3B1%25.%20The%20cut-off%20for%20stromal%20tumor-infiltrating%20lymphocytes%20was%20chosen%20empirically%3A%20intermediate%20%26lt%3B60%25%20and%20high%20%26gt%3B60%25.%5CnRESULTS%3A%2086%20patients%20were%20included.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20not%20significantly%20associated%20with%20tumor%20metabolic%20metrics.%20Intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20not%20significantly%20associated%20with%20maximum%20standard%20uptake%20value%20%28p%3D0.16%29%2C%20or%20metabolic%20tumor%20volume%20%28p%3D0.19%29.%20Tumors%20with%20%26lt%3B1%25%20intraepithelial%20tumor-infiltrating%20lymphocytes%20score%20were%20associated%20with%20a%20higher%20MRI%20tumor%20size%20%28%5Cu2265%20median%29%20%2863.3%25%20vs%2039.3%25%2C%20p%3D0.04%29.%20Patients%20with%20pelvic%20lymph%20node%20uptake%20were%20significantly%20more%20frequent%20in%20patients%20with%20high%20stromal%20tumor-infiltrating%20lymphocytes%20score%20%28%5Cu226560%25%29%20%2861.5%25%20vs%2031.7%25%2C%20p%3D0.009%29.%5CnCONCLUSIONS%3A%20Poor%20or%20absent%20intraepithelial%20tumor-infiltrating%20lymphocytes%20were%20associated%20with%20more%20advanced%20disease%20at%20diagnosis%20and%20larger%20tumor%20size.%20Tumor-infiltrating%20lymphocytes%20were%20not%20associated%20with%20tumor%20metabolic%20activity.%20Intraepithelial%20and%20stroma%20tumor-infiltrating%20lymphocytes%20are%20not%20redundant%20and%20should%20be%20assessed%20separately.%20Further%20work%20is%20needed%20to%20evaluate%20the%20association%20between%20tumor%20metabolic%20profile%20and%20immune%20populations%2C%20including%20different%20T-cell%20subtypes%20for%20patient%20selection%20for%20immunotherapy%20strategies.%22%2C%22date%22%3A%222024-04-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2023-004677%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222024-06-07T08%3A05%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22P3CRM7KI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ricotta%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRicotta%2C%20Giulio%2C%20Elodie%20Gauroy%2C%20Anne-Sophie%20Navarro%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BHow%20to%20Reduce%20Anterior%20Resection%20Syndrome%20and%20Post-Operative%20Complication%20after%20Rectosigmoid%20Resection.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2028%2C%202024%2C%20ijgc%26%23x2013%3B2024%26%23x2013%3B005306.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2024-005306%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2024-005306%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20to%20reduce%20anterior%20resection%20syndrome%20and%20post-operative%20complication%20after%20rectosigmoid%20resection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giulio%22%2C%22lastName%22%3A%22Ricotta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Gauroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Navarro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-03-28%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2024-005306%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222024-04-02T14%3A14%3A34Z%22%7D%7D%5D%7D
Saucier, Emilie, Gaëlle Bougeard, Anne Gomez-Mascard, Catherine Schramm, Rachid Abbas, Pablo Berlanga, Claire Briandet, et al. “Li-Fraumeni-Associated Osteosarcomas: The French Experience.” Pediatric Blood & Cancer, October 10, 2024, e31362. https://doi.org/10.1002/pbc.31362.
Bastard, Paul, Nathalie Cozic, Régis Brion, Nathalie Gaspar, Sophie Piperno-Neumann, Camille Cordero, Estelle Leculée-Thébaud, et al. “Prognostic Value of Hemogram Parameters in Osteosarcoma: The French OS2006 Experience.” Pediatric Blood & Cancer, April 28, 2024, e31029. https://doi.org/10.1002/pbc.31029.
Del, Mathilde, Claire Illac, Mathilde Morisseau, Martina Aida Angeles, Anne Ducassou, Sarah Betrian, Guillaume Bataillon, et al. “Intraepithelial Tumor-Infiltrating Lymphocytes Shape Loco-Regional PET/CT Spread of Locally Advanced Cervical Cancer.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 34, no. 4 (April 1, 2024): 490–96. https://doi.org/10.1136/ijgc-2023-004677.
Ricotta, Giulio, Elodie Gauroy, Anne-Sophie Navarro, Alejandra Martinez, and Gwenael Ferron. “How to Reduce Anterior Resection Syndrome and Post-Operative Complication after Rectosigmoid Resection.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, March 28, 2024, ijgc–2024–005306. https://doi.org/10.1136/ijgc-2024-005306.
PUBLICATIONS 2023
7813506
CF9MRXB4
2023
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22555A2C8N%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Frezza%20et%20al.%22%2C%22parsedDate%22%3A%222023-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFrezza%2C%20Anna%20Maria%2C%20Silvia%20Stacchiotti%2C%20Frederic%20Chibon%2C%20Jean-Michelle%20Coindre%2C%20Antoine%20Italiano%2C%20Cleofe%20Romagnosa%2C%20Silvia%20Bagu%26%23xE9%3B%2C%20et%20al.%20%26%23x201C%3BCINSARC%20in%20High-Risk%20Soft%20Tissue%20Sarcoma%20Patients%20Treated%20with%20Neoadjuvant%20Chemotherapy%3A%20Results%20from%20the%20ISG-STS%201001%20Study.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%202%20%28January%202023%29%3A%201350%26%23x2013%3B57.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.5015%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.5015%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CINSARC%20in%20high-risk%20soft%20tissue%20sarcoma%20patients%20treated%20with%20neoadjuvant%20chemotherapy%3A%20Results%20from%20the%20ISG-STS%201001%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%20Maria%22%2C%22lastName%22%3A%22Frezza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Stacchiotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michelle%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cleofe%22%2C%22lastName%22%3A%22Romagnosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Bagu%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelo%20Paolo%22%2C%22lastName%22%3A%22Dei%20Tos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luca%22%2C%22lastName%22%3A%22Braglia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Palmerini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vittorio%22%2C%22lastName%22%3A%22Quagliuolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%20Martin%22%2C%22lastName%22%3A%22Broto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Lopez%20Pousa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giovanni%22%2C%22lastName%22%3A%22Grignani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonella%22%2C%22lastName%22%3A%22Brunello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20Diaz%22%2C%22lastName%22%3A%22Beveridge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iwona%22%2C%22lastName%22%3A%22Lugowska%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roberta%22%2C%22lastName%22%3A%22Maestro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franco%20Domenico%22%2C%22lastName%22%3A%22Merlo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%20Giovanni%22%2C%22lastName%22%3A%22Casali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Gronchi%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20Complexity%20INdex%20in%20SARComas%20%28CINSARC%29%20is%20a%20transcriptional%20signature%20derived%20from%20the%20expression%20of%2067%20genes%20involved%20in%20mitosis%20control%20and%20chromosome%20integrity.%20This%20study%20aims%20to%20assess%20CINSARC%20value%20of%20in%20an%20independent%20series%20of%20high-risk%20patients%20with%20localized%20soft%20tissue%20sarcoma%20%28STS%29%20treated%20with%20preoperative%20chemotherapy%20within%20a%20prospective%2C%20randomized%2C%20phase%20III%20study%20%28ISG-STS%201001%29.%5CnPATIENTS%20AND%20METHODS%3A%20Patients%20with%20available%20pre-treatment%20samples%2C%20treated%20with%203%20cycles%20of%20either%20standard%20%28ST%29%20preoperative%20or%20histotype-tailored%20%28HT%29%20chemotherapy%2C%20were%20scored%20according%20to%20CINSARC%20%28low-risk%2C%20C1%3B%20high-risk%2C%20C2%29.%20The%2010-year%20overall%20survival%20probability%20%28pr-OS%29%20according%20to%20SARCULATOR%20was%20calculated%2C%20and%20patients%20were%20classified%20accordingly%20%28low-risk%2C%20Sarc-LR%2C%2010-year%20pr-OS%26gt%3B60%25%3B%20high-risk%2C%20Sarc-HR%2C%2010-year%20pr-OS%26lt%3B60%25%29.%20Survival%20functions%20were%20estimated%20using%20the%20Kaplan-Meier%20method%20and%20compared%20using%20log-rank%20test.%5CnRESULTS%3A%20Eighty-six%20patients%20were%20included%2C%2030%20C1%20and%2056%20C2%2C%2049%20Sarc-LR%20and%2037%20Sarc-HR.%20A%20low%20level%20of%20agreement%20between%20CINSARC%20and%20SARCULATOR%20was%20observed%20%28Cohen%26%23039%3Bs%20Kappa%5Cu00a0%3D%5Cu00a00.174%29.%20The%205-year%20relapse-free%20survival%20in%20C1%20and%20C2%20were%200.57%20and%200.55%20%28p%5Cu00a0%3D%5Cu20090.481%29%3B%205-year%20metastases-free%20survival%200.63%20and%200.64%20%28p%5Cu00a0%3D%5Cu20090.740%29%3B%205-year%20OS%200.80%20and%200.72%20%28p%5Cu00a0%3D%5Cu20090.460%29.%20The%205-year%20OS%20in%20C1%20treated%20with%20ST%20and%20HT%20chemotherapy%20was%200.84%20and%200.76%20%28p%5Cu00a0%3D%5Cu20090.251%29%20respectively%3B%20in%20C2%20treated%20it%20was%200.72%20and%200.70%20%28p%5Cu00a0%3D%5Cu20090.349%29.%20The%205-year%20OS%20in%20Sarc-LR%20treated%20with%20S%20and%20HT%20chemotherapy%20was%200.80%20and%200.82%20%28p%5Cu00a0%3D%5Cu20090.502%29%20respectively%3B%20in%20Sarc-HR%20it%20was%200.70%20and%200.61%20%28p%5Cu00a0%3D%5Cu20090.233%29.%5CnCONCLUSIONS%3A%20Our%20results%2C%20although%20constrained%20by%20the%20small%20size%20of%20the%20series%2C%20suggest%20that%20CINSARC%20has%20weak%20prognostic%20power%20in%20high-risk%2C%20localized%20STS%20treated%20with%20neoadjuvant%20chemotherapy.%22%2C%22date%22%3A%222023-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fcam4.5015%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222045-7634%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222023-02-07T13%3A36%3A07Z%22%7D%7D%5D%7D
Frezza, Anna Maria, Silvia Stacchiotti, Frederic Chibon, Jean-Michelle Coindre, Antoine Italiano, Cleofe Romagnosa, Silvia Bagué, et al. “CINSARC in High-Risk Soft Tissue Sarcoma Patients Treated with Neoadjuvant Chemotherapy: Results from the ISG-STS 1001 Study.” Cancer Medicine 12, no. 2 (January 2023): 1350–57. https://doi.org/10.1002/cam4.5015.
PUBLICATIONS 2022
7813506
CF9MRXB4
2022
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22A5QIFHFI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brunac%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrunac%2C%20Anne-C%26%23xE9%3Bcile%2C%20Joanna%20Fourquet%2C%20Ga%26%23xEB%3Blle%20Perot%2C%20Marion%20Jaffrelot%2C%20Julie%20Meilleroux%2C%20Marie%20Danjoux%2C%20Thomas%20Filleron%2C%20et%20al.%20%26%23x201C%3BCINSARC%20Signature%20Outperforms%20Gold-Standard%20TNM%20Staging%20and%20Consensus%20Molecular%20Subtypes%20for%20Clinical%20Outcome%20in%20Stage%20II-III%20Colorectal%20Carcinoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BModern%20Pathology%3A%20An%20Official%20Journal%20of%20the%20United%20States%20and%20Canadian%20Academy%20of%20Pathology%2C%20Inc%26lt%3B%5C%2Fi%26gt%3B%2C%20October%206%2C%202022.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-022-01166-9%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-022-01166-9%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CINSARC%20signature%20outperforms%20gold-standard%20TNM%20staging%20and%20consensus%20molecular%20subtypes%20for%20clinical%20outcome%20in%20stage%20II-III%20colorectal%20carcinoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-C%5Cu00e9cile%22%2C%22lastName%22%3A%22Brunac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joanna%22%2C%22lastName%22%3A%22Fourquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Perot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Jaffrelot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Meilleroux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Danjoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Nicola%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rosine%22%2C%22lastName%22%3A%22Guimbaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samira%22%2C%22lastName%22%3A%22Icher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadim%22%2C%22lastName%22%3A%22Far%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janick%22%2C%22lastName%22%3A%22Selves%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22The%20outcome%20of%20stage%20II-III%20colorectal%20cancer%20%28CRC%29%20is%20highly%20variable%20and%20therapeutic%20choice%20is%20currently%20based%20on%20TNM%20staging%20with%20a%20few%20additional%20biomarkers.%20However%2C%20studies%20show%20that%20some%20stage%20III%20patients%20have%20a%20better%20prognosis%20than%20some%20stage%20II%20patients.%20A%20promising%20consensus%20molecular%20%28CMS%29%20classification%20with%20prognostic%20relevance%20has%20been%20developed%2C%20but%20it%20is%20not%20used%20in%20daily%20practice.%20Our%20team%20developed%20CINSARC%2C%20a%2067-gene%20expression%20prognostic%20signature%2C%20whose%20prognostic%20value%20has%20been%20demonstrated%20in%20many%20cancer%20types.%20It%20is%20applicable%20to%20formalin-fixed%2C%20paraffin-embedded%20%28FFPE%29%20blocks%20using%20NanoString%5Cu00ae%20technology.%20We%20investigated%20whether%20it%20could%20predict%20outcome%20in%20stage%20II-III%20CRC.%20We%20established%20the%20CINSARC%20classification%20on%20the%20TCGA%20retrospective%20cohort%20comprising%20297%20stage%20II-III%20CRC%20patients%20using%20RNA%20sequencing%20and%20on%20a%20second%20independent%20cohort%20comprising%20169%20cases%20using%20NanoString%5Cu00ae%20technology.%20We%20compared%20its%20recurrence-free%20and%20overall%20survival%20prognostic%20value%20with%20TNM%20staging%20and%20CMS%20classification.%20In%20the%20TCGA%20cohort%2C%20we%20showed%20that%20CINSARC%20significantly%20splits%20the%20population%20of%20stage%20II-III%20CRC%20into%20two%20groups%20with%20different%20progression-free%20interval%20%28P%5Cu2009%3D%5Cu20091.68%5Cu2009%5Cu00d7%5Cu200910-2%3B%20HR%5Cu2009%3D%5Cu20091.87%20%5B1.11-3.16%5D%29%20and%20overall%20survival%20%28P%5Cu2009%3D%5Cu20093.73%5Cu2009%5Cu00d7%5Cu200910-3%3B%20HR%5Cu2009%3D%5Cu20092.45%20%5B1.31-4.59%5D%29%20and%20is%20a%20strong%20prognostic%20factor%20in%20multivariate%20analysis%2C%20outperforming%20TNM%20staging%20and%20CMS%20classification.%20We%20validated%20these%20results%20in%20the%20second%20cohort%20by%20applying%20CINSARC%20on%20FFPE%20samples%20with%20Nanostring%5Cu00ae%20technology.%20CINSARC%20is%20a%20ready-to-use%20tool%20with%20a%20robust%20independent%20prognostic%20value%20in%20stage%20II-III%20CRC.%22%2C%22date%22%3A%222022-10-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41379-022-01166-9%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221530-0285%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-10-25T19%3A12%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22MXLCE4LK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Angeles%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAngeles%2C%20Martina%20Aida%2C%20Alicia%20Hern%26%23xE1%3Bndez%2C%20Asunci%26%23xF3%3Bn%20P%26%23xE9%3Brez-Benavente%2C%20Bastien%20Cabarrou%2C%20Emanuela%20Spagnolo%2C%20Agnieszka%20Rychlik%2C%20Amel%20Daboussi%2C%20et%20al.%20%26%23x201C%3BThe%20Effect%20of%20Major%20Postoperative%20Complications%20on%20Recurrence%20and%20Long-Term%20Survival%20after%20Cytoreductive%20Surgery%20for%20Ovarian%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%20166%2C%20no.%201%20%28July%202022%29%3A%208%26%23x2013%3B17.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.05.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.05.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20effect%20of%20major%20postoperative%20complications%20on%20recurrence%20and%20long-term%20survival%20after%20cytoreductive%20surgery%20for%20ovarian%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asunci%5Cu00f3n%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Benavente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Spagnolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnieszka%22%2C%22lastName%22%3A%22Rychlik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amel%22%2C%22lastName%22%3A%22Daboussi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Migliorelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22B%5Cu00e9trian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Gil-Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20To%20assess%20the%20impact%20on%20survival%20of%20major%20postoperative%20complications%20and%20to%20identify%20the%20factors%20associated%20with%20these%20complications%20in%20patients%20with%20advanced%20ovarian%20cancer%20after%20cytoreductive%20surgery.%5CnMETHODS%3A%20We%20designed%20a%20retrospective%20multicenter%20study%20collecting%20data%20from%20patients%20with%20IIIC-IV%20FIGO%20Stage%20ovarian%20cancer%20who%20had%20undergone%20either%20primary%20debulking%20surgery%20%28PDS%29%2C%20early%20interval%20debulking%20surgery%20%28IDS%29%20after%203-4%20cycles%20of%20neoadjuvant%20chemotherapy%2C%20or%20delayed%20debulking%20surgery%20%28DDS%29%20after%206%20cycles%2C%20with%20minimal%20or%20no%20residual%20disease%2C%20from%20January%202008%20to%20December%202015.%20Univariable%20and%20multivariable%20analyses%20were%20conducted%20to%20identify%20factors%20associated%20with%20major%20surgical%20complications%20%28%5Cu2265Grade%203%29.%20We%20assessed%20disease-free%20survival%20%28DFS%29%20and%20overall%20survival%20%28OS%29%20rates%20according%20to%20the%20occurrence%20of%20major%20postoperative%20complications.%5CnRESULTS%3A%20549%20women%20were%20included.%20The%20overall%20rate%20of%20major%20surgical%20complications%20was%2022.4%25.%20Patients%20who%20underwent%20PDS%20had%20a%20higher%20rate%20of%20major%20complications%20%2828.6%25%29%20than%20patients%20who%20underwent%20either%20early%20IDS%20%2823.2%25%29%20or%20DDS%20%2814.0%25%29.%20Multivariable%20analysis%20revealed%20that%20extensive%20peritonectomy%20and%20surgical%20timing%20were%20associated%20with%20the%20occurrence%20of%20major%20complications.%20Median%20DFS%20and%20OS%20were%2016.9%20months%20%2895%25CI%20%3D%20%5B13.7-18.4%5D%29%20and%2048.0%20months%20%2895%25CI%20%3D%20%5B37.2-73.1%5D%29%20for%20the%20group%20of%20patients%20with%20major%20complications%2C%20and%2020.1%20months%20%2895%25CI%20%3D%20%5B18.6-22.4%5D%29%20and%2056.7%20months%20%2895%25CI%20%3D%20%5B51.2-70.4%5D%29%20for%20the%20group%20without%20major%20complications.%20Multivariable%20analysis%20revealed%20that%20major%20surgical%20complications%20were%20significantly%20associated%20with%20DFS%2C%20but%20not%20with%20OS.%5CnCONCLUSIONS%3A%20Patients%20who%20experienced%20major%20surgical%20complications%20had%20reduced%20DFS%2C%20compared%20with%20patients%20without%20major%20morbidity.%20Extensive%20peritonectomy%20and%20surgical%20timing%20were%20predictive%20factors%20of%20postoperative%20morbidity.%22%2C%22date%22%3A%222022-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ygyno.2022.05.002%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221095-6859%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-06-28T07%3A46%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22E6EECT24%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fayet%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-25%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFayet%2C%20Yohan%2C%20Christine%20Chevreau%2C%20Gauthier%20Decanter%2C%20C%26%23xE9%3Bcile%20Dalban%2C%20Pierre%20Meeus%2C%20S%26%23xE9%3Bbastien%20Carr%26%23xE8%3Bre%2C%20Leila%20Haddag-Miliani%2C%20et%20al.%20%26%23x201C%3BNo%20Geographical%20Inequalities%20in%20Survival%20for%20Sarcoma%20Patients%20in%20France%3A%20A%20Reference%20Networks%26%23x2019%3B%20Outcome%3F%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2014%2C%20no.%2011%20%28May%2025%2C%202022%29%3A%202620.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14112620%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers14112620%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22No%20Geographical%20Inequalities%20in%20Survival%20for%20Sarcoma%20Patients%20in%20France%3A%20A%20Reference%20Networks%27%20Outcome%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohan%22%2C%22lastName%22%3A%22Fayet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gauthier%22%2C%22lastName%22%3A%22Decanter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Dalban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Meeus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Carr%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leila%22%2C%22lastName%22%3A%22Haddag-Miliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Causeret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Orbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michelle%22%2C%22lastName%22%3A%22Kind%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis-Rom%5Cu00e9e%22%2C%22lastName%22%3A%22Le%20Nail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwena%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Labrosse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Chaigneau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Bertucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Ruzic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Le%20Brun%20Ly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fadila%22%2C%22lastName%22%3A%22Farsi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Bompas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Noal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Vozy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnes%22%2C%22lastName%22%3A%22Ducoulombier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Chabaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Ducimeti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Tlemsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Micka%5Cu00ebl%22%2C%22lastName%22%3A%22Ropars%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Collard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Michelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Gantzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Dubray-Longeras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Rios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Soibinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Duffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Gouin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rapha%5Cu00ebl%22%2C%22lastName%22%3A%22T%5Cu00e9treau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Honor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Ray-Coquard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%5D%2C%22abstractNote%22%3A%22The%20national%20reference%20network%20NETSARC%2B%20provides%20remote%20access%20to%20specialized%20diagnosis%20and%20the%20Multidisciplinary%20Tumour%20Board%20%28MTB%29%20to%20improve%20the%20management%20and%20survival%20of%20sarcoma%20patients%20in%20France.%20The%20IG%5Cu00e9AS%20research%20program%20aims%20to%20assess%20the%20potential%20of%20this%20innovative%20organization%20to%20address%20geographical%20inequalities%20in%20cancer%20management.%20Using%20the%20IG%5Cu00e9AS%20cohort%20built%20from%20the%20nationwide%20NETSARC%2B%20database%2C%20the%20individual%2C%20clinical%2C%20and%20geographical%20determinants%20of%20the%203-year%20overall%20survival%20of%20sarcoma%20patients%20in%20France%20were%20analyzed.%20The%20survival%20analysis%20was%20focused%20on%20patients%20diagnosed%20in%202013%20%28n%20%3D%202281%29%20to%20ensure%20sufficient%20hindsight%20to%20collect%20patient%20follow-up.%20Our%20study%20included%20patients%20with%20bone%20%2816.8%25%29%2C%20soft-tissue%20%2869%25%29%2C%20and%20visceral%20%2814.2%25%29%20sarcomas%2C%20with%20a%20median%20age%20of%2061.8%20years.%20The%20overall%20survival%20was%20not%20associated%20with%20geographical%20variables%20after%20adjustment%20for%20individual%20and%20clinical%20factors.%20The%20lower%20survival%20in%20precarious%20population%20districts%20%5BHR%201.23%2C%2095%25%20CI%201.02%20to%201.48%5D%20in%20comparison%20to%20wealthy%20metropolitan%20areas%20%28HR%20%3D%201%29%20found%20in%20univariable%20analysis%20was%20due%20to%20the%20worst%20clinical%20presentation%20at%20diagnosis%20of%20patients.%20The%20place%20of%20residence%20had%20no%20impact%20on%20sarcoma%20patients%26%23039%3B%20survival%2C%20in%20the%20context%20of%20the%20national%20organization%20driven%20by%20the%20reference%20network.%20Following%20previous%20findings%2C%20this%20suggests%20the%20ability%20of%20this%20organization%20to%20go%20through%20geographical%20barriers%20usually%20impeding%20the%20optimal%20management%20of%20cancer%20patients.%22%2C%22date%22%3A%222022-05-25%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers14112620%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-06-13T08%3A38%3A47Z%22%7D%7D%2C%7B%22key%22%3A%225CUD6LFS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Krantschenko%20et%20al.%22%2C%22parsedDate%22%3A%222022-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BKrantschenko%2C%20Emma%2C%20Paul%20Khayat%2C%20Aurore%20Siegfried%2C%20Nathalie%20Van%20Acker%2C%20and%20Anne%20Gomez-Brouchet.%20%26%23x201C%3B%5BBone-forming%20lesions%20and%20rearrangements%20of%20FOS%20genes%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnales%20De%20Pathologie%26lt%3B%5C%2Fi%26gt%3B%2042%2C%20no.%203%20%28April%202022%29%3A%20208%26%23x2013%3B13.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2022.01.013%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.annpat.2022.01.013%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BBone-forming%20lesions%20and%20rearrangements%20of%20FOS%20genes%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emma%22%2C%22lastName%22%3A%22Krantschenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Khayat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Van%20Acker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-04%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.annpat.2022.01.013%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220242-6498%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-06-13T10%3A39%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22B9WBALIX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daix%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-21%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDaix%2C%20Manon%2C%20Carlos%20Martinez%20Gomez%2C%20Martina%20Aida%20Angeles%2C%20St%26%23xE9%3Bphanie%20Tock%2C%20Laurence%20Gladieff%2C%20Erwan%20Gabiache%2C%20Eliane%20Mery%2C%20Alejandra%20Martinez%2C%20David%20Cibula%2C%20and%20Gw%26%23xE9%3Bna%26%23xEB%3Bl%20Ferron.%20%26%23x201C%3BExtended%20Pelvic%20Resection%20for%20Gynecological%20Malignancies%3A%20A%20Review%20of%20out-of-the-Box%20Surgery.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2C%20March%2021%2C%202022%2C%20S0090-8258%2822%2900174-3.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.03.002%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ygyno.2022.03.002%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Extended%20pelvic%20resection%20for%20gynecological%20malignancies%3A%20A%20review%20of%20out-of-the-box%20surgery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Martinez%20Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Tock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gladieff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erwan%22%2C%22lastName%22%3A%22Gabiache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Cibula%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22The%20term%20%26%23039%3Bout-of-the-box%20surgery%26%23039%3B%20in%20gynecologic%20oncology%20was%20recently%20coined%20to%20describe%20the%20resection%20of%20tumor%20growing%20out%20of%20the%20endopelvic%20cavity.%20In%20the%20specific%20case%20of%20pelvic%20sidewall%20involvement%2C%20a%20laterally%20extended%20pelvic%20resection%20may%20be%20required.%20As%20previously%20defined%20by%20H%5Cu00f6ckel%2C%20this%20resection%20requires%20the%20en%20bloc%20removal%20of%20structures%20including%20the%20pelvic%20sidewall%20muscles%2C%20bones%2C%20nerves%2C%20and%5C%2For%20major%20vessels.%20This%20complex%20radical%20procedure%20leads%20to%20tumor-free%20margins%20in%20more%20than%2075%25%20of%20the%20patients%2C%20with%20reliable%20functional%20results.%20The%20rate%20of%20recurrence%20and%20overall%20survival%20are%20directly%20correlated%20with%20clear%20resection%20margins.%20Progress%20in%20imaging%2C%20surgical%20techniques%2C%20and%20perioperative%20care%20currently%20offer%20the%20opportunity%20to%20attempt%20surgical%20curative%20resection%20in%20selected%20patients%20for%20whom%20palliative%20therapy%20was%20the%20only%20alternative.%20However%2C%20the%20procedure%20is%20associated%20with%20a%20high%20rate%20of%20major%20postoperative%20complications%20affecting%20up%20to%2060%25%20of%20patients.%20Multidisciplinary%20expert%20centers%20are%20the%20most%20likely%20to%20achieve%20this%20complex%20surgery%20with%20favorable%20oncological%20outcomes.%20The%20aim%20of%20this%20review%20is%20to%20summarize%20the%20key%20issues%20of%20out-of-the-box%20surgery%20in%20gynecologic%20cancer.%22%2C%22date%22%3A%222022-03-21%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ygyno.2022.03.002%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221095-6859%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A10%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22U3V2CBBY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marchais%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-25%22%2C%22numChildren%22%3A9%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMarchais%2C%20Antonin%2C%20Maria%20Eugenia%20Marques%20Da%20Costa%2C%20Bastien%20Job%2C%20Rachid%20Abbas%2C%20Damien%20Drubay%2C%20Sophie%20Piperno-Neumann%2C%20Olivia%20Fromigu%26%23xE9%3B%2C%20et%20al.%20%26%23x201C%3BImmune%20Infiltrate%20and%20Tumor%20Microenvironment%20Transcriptional%20Programs%20Stratify%20Pediatric%20Osteosarcoma%20into%20Prognostic%20Groups%20at%20Diagnosis.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2025%2C%202022%2C%20canres.CAN-20-4189-A.2020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-20-4189%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-20-4189%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Immune%20infiltrate%20and%20tumor%20microenvironment%20transcriptional%20programs%20stratify%20pediatric%20osteosarcoma%20into%20prognostic%20groups%20at%20diagnosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonin%22%2C%22lastName%22%3A%22Marchais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Eugenia%22%2C%22lastName%22%3A%22Marques%20Da%20Costa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Job%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachid%22%2C%22lastName%22%3A%22Abbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Drubay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivia%22%2C%22lastName%22%3A%22Fromigu%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9dini%22%2C%22lastName%22%3A%22Fran%5Cu00e7oise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Droit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Lervat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Entz-Werle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Pacquement%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Devoldere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Cupissol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Bodet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Gandemer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%20G.%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Perrine%20Marec%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Jimenez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Vassal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Birgit%22%2C%22lastName%22%3A%22Geoerger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Brugieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Gaspar%22%7D%5D%2C%22abstractNote%22%3A%22The%20outcomes%20of%20adolescents%5C%2Fyoung%20adults%20with%20osteosarcoma%20have%20not%20improved%20in%20decades.%20The%20chaotic%20karyotype%20of%20this%20rare%20tumor%20has%20precluded%20the%20identification%20of%20prognostic%20biomarkers%20and%20patient%20stratification.%20We%20reasoned%20that%20transcriptomic%20studies%20should%20overcome%20this%20genetic%20complexity.%20RNA%20sequencing%20of%2079%20osteosarcoma%20diagnostic%20biopsies%20identified%20stable%20independent%20components%20that%20recapitulate%20the%20tumor%20and%20microenvironment%20cell%20composition.%20Unsupervised%20classification%20of%20the%20independent%20components%20stratified%20this%20cohort%20into%20favorable%20%28G1%29%20and%20unfavorable%20%28G2%29%20prognostic%20tumors%20in%20terms%20of%20overall%20survival.%20Multivariate%20survival%20analysis%20ranked%20this%20stratification%20as%20the%20most%20influential%20variable.%20Functional%20characterization%20associated%20G1%20tumors%20with%20innate%20immunity%20and%20G2%20tumors%20with%20angiogenic%2C%20osteoclastic%2C%20and%20adipogenic%20activities%20as%20well%20as%20PPAR%5Cu03b3%20pathway%20upregulation.%20A%20focused%20gene%20signature%20that%20predicted%20G1%5C%2FG2%20tumors%20from%20RNA-seq%20data%20was%20developed%20and%20validated%20within%20an%20independent%20cohort%20of%2082%20osteosarcomas.%20This%20signature%20was%20further%20validated%20with%20a%20custom%20NanoString%20panel%20in%2096%20additional%20osteosarcomas.%20This%20study%20thus%20proposes%20new%20biomarkers%20to%20detect%20high-risk%20patients%20and%20new%20therapeutic%20options%20for%20osteosarcoma.%22%2C%22date%22%3A%222022-01-25%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1158%5C%2F0008-5472.CAN-20-4189%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221538-7445%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%223U3NWA3K%22%2C%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A11%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22RAE2P5XW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daix%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A8%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDaix%2C%20Manon%2C%20Martina%20Aida%20Angeles%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Leray%2C%20Kelig%20Vergriete%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BAnterior%20Pelvic%20Exenteration%20and%20Laterally%20Extended%20Pelvic%20Resection%3A%20A%20Step%20by%20Step%20Procedure.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%201%20%28January%202022%29%3A%20107%26%23x2013%3B8.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-003047%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-003047%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anterior%20pelvic%20exenteration%20and%20laterally%20extended%20pelvic%20resection%3A%20a%20step%20by%20step%20procedure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelig%22%2C%22lastName%22%3A%22Vergriete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2021-003047%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%223U3NWA3K%22%2C%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22BIL6RBHV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Akladios%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAkladios%2C%20C.%2C%20%26%23xC9%3B%20Dara%26%23xEF%3B%2C%20F.%20Golfier%2C%20F.%20Lecuru%2C%20P.%20Collinet%2C%20C.%20Uzan%2C%20V.%20Lavou%26%23xE9%3B%2C%20F.%20Guyon%2C%20G.%20Ferron%2C%20and%20D.%20Querleu.%20%26%23x201C%3B%5BA%20curriculum%20based%20certification%20of%20competence%20in%20gynaecologic%20surgical%20oncology%5D.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGynecologie%2C%20Obstetrique%2C%20Fertilite%20%26amp%3B%20Senologie%26lt%3B%5C%2Fi%26gt%3B%2050%2C%20no.%201%20%28January%202022%29%3A%2026%26%23x2013%3B32.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.gofs.2021.07.003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.gofs.2021.07.003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BA%20curriculum%20based%20certification%20of%20competence%20in%20gynaecologic%20surgical%20oncology%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Akladios%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c9%22%2C%22lastName%22%3A%22Dara%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Golfier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Lecuru%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Collinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Uzan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Lavou%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Querleu%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20In%20France%2C%20we%20are%20lacking%20an%20identified%20pathway%20for%20training%20in%20gynaecological%20cancer%20surgery.%20The%20four%20competent%20French%20learned%20societies%2C%20the%20SFOG%2C%20the%20CNGOF%2C%20the%20SFCO%20and%20the%20SCGP%2C%20supported%20by%20the%20CNU%20of%20Obstetrics%20%26amp%3BGynaecology-%20and%20UNICANCER%2C%20agreed%20to%20materialize%20this%20course%20and%20attest%20it%20by%20a%20certification%20awarded%20by%20a%20national%20jury.%5CnMATERIAL%20AND%20METHODS%3A%20The%20national%20committee%20of%20certification%20in%20gynaecological%20oncology%20made%20up%20of%2010%5Cu00a0members%2C%20representing%20the%206%5Cu00a0concerned%20organizations%2C%20set%20itself%205%5Cu00a0objectives%3A%20the%20definition%20of%20the%20eligibility%20criteria%20for%20training%20centres%3B%20the%20determination%20of%20a%20check-list%20to%20be%20filled%20by%20the%20candidate%3B%20the%20determination%20of%20a%20targeted%20curriculum%20for%20the%20training%20in%20gynecological%20oncological%20surgery%3B%20the%20determination%20of%20the%20assets%20necessary%20for%20the%20certification%20of%20a%20candidate%20already%20in%20practice%3B%20and%20the%20practical%20organization%20of%20the%20certification.%5CnRESULTS%3A%20Criteria%20for%20approval%20of%20centres%20for%20training%20included%20150%5Cu00a0gynaecological%20cancer%20cases%20per%20year%2C%20among%20which%20100%5Cu00a0excisional%20surgeries%2C%20including%2020%5Cu00a0advanced-stage%20ovarian%20cancers.%20For%20certification%20of%20candidate%20who%20followed%20the%20curriculum%20established%20by%20the%20committee%20or%20by%20validation%20of%20prior%20experience%20for%20an%20actual%20practitioner%2C%20a%20candidate%20must%20validate%20a%20logbook%20and%20fill%20out%20a%20checklist%20including%204%5Cu00a0parts%3A%20theoretical%20and%20practical%20training%3B%20research%20and%20publications%3B%20teaching%20and%20subscription%20to%20a%20continuing%20education%20program.%20The%20accomplished%20elements%20of%20the%20logbook%20and%20the%20checklist%20will%20be%20evaluated%20by%20a%20score.%20The%20first%20certification%20session%20is%20planned%20for%20the%20end%20of%202021.%5CnCONCLUSION%3A%20The%20optimisation%20of%20the%20surgical%20management%20of%20patients%20treated%20for%20gynaecological%20cancer%20is%20achieved%20through%20the%20identification%20of%20a%20training%20course%20and%20the%20certification%2C%20by%20a%20national%20jury%2C%20of%20the%20skills%20of%20surgeons%20who%20have%20completed%20it.%22%2C%22date%22%3A%222022-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.gofs.2021.07.003%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222468-7189%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A09%3A07Z%22%7D%7D%5D%7D
Brunac, Anne-Cécile, Joanna Fourquet, Gaëlle Perot, Marion Jaffrelot, Julie Meilleroux, Marie Danjoux, Thomas Filleron, et al. “CINSARC Signature Outperforms Gold-Standard TNM Staging and Consensus Molecular Subtypes for Clinical Outcome in Stage II-III Colorectal Carcinoma.” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, October 6, 2022. https://doi.org/10.1038/s41379-022-01166-9.
Angeles, Martina Aida, Alicia Hernández, Asunción Pérez-Benavente, Bastien Cabarrou, Emanuela Spagnolo, Agnieszka Rychlik, Amel Daboussi, et al. “The Effect of Major Postoperative Complications on Recurrence and Long-Term Survival after Cytoreductive Surgery for Ovarian Cancer.” Gynecologic Oncology 166, no. 1 (July 2022): 8–17. https://doi.org/10.1016/j.ygyno.2022.05.002.
Fayet, Yohan, Christine Chevreau, Gauthier Decanter, Cécile Dalban, Pierre Meeus, Sébastien Carrère, Leila Haddag-Miliani, et al. “No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks’ Outcome?” Cancers 14, no. 11 (May 25, 2022): 2620. https://doi.org/10.3390/cancers14112620.
Krantschenko, Emma, Paul Khayat, Aurore Siegfried, Nathalie Van Acker, and Anne Gomez-Brouchet. “[Bone-forming lesions and rearrangements of FOS genes].” Annales De Pathologie 42, no. 3 (April 2022): 208–13. https://doi.org/10.1016/j.annpat.2022.01.013.
Daix, Manon, Carlos Martinez Gomez, Martina Aida Angeles, Stéphanie Tock, Laurence Gladieff, Erwan Gabiache, Eliane Mery, Alejandra Martinez, David Cibula, and Gwénaël Ferron. “Extended Pelvic Resection for Gynecological Malignancies: A Review of out-of-the-Box Surgery.” Gynecologic Oncology, March 21, 2022, S0090-8258(22)00174-3. https://doi.org/10.1016/j.ygyno.2022.03.002.
Marchais, Antonin, Maria Eugenia Marques Da Costa, Bastien Job, Rachid Abbas, Damien Drubay, Sophie Piperno-Neumann, Olivia Fromigué, et al. “Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis.” Cancer Research, January 25, 2022, canres.CAN-20-4189-A.2020. https://doi.org/10.1158/0008-5472.CAN-20-4189.
Daix, Manon, Martina Aida Angeles, Hélène Leray, Kelig Vergriete, Alejandra Martinez, and Gwenael Ferron. “Anterior Pelvic Exenteration and Laterally Extended Pelvic Resection: A Step by Step Procedure.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 32, no. 1 (January 2022): 107–8. https://doi.org/10.1136/ijgc-2021-003047.
Akladios, C., É Daraï, F. Golfier, F. Lecuru, P. Collinet, C. Uzan, V. Lavoué, F. Guyon, G. Ferron, and D. Querleu. “[A curriculum based certification of competence in gynaecologic surgical oncology].” Gynecologie, Obstetrique, Fertilite & Senologie 50, no. 1 (January 2022): 26–32. https://doi.org/10.1016/j.gofs.2021.07.003.
PUBLICATIONS 2021
7813506
CF9MRXB4
2021
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%2244MCBTVI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Angeles%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAngeles%2C%20Martina%20Aida%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Leray%2C%20Federico%20Migliorelli%2C%20Manon%20Daix%2C%20Alejandra%20Martinez%2C%20and%20Gwenael%20Ferron.%20%26%23x201C%3BSurgical%20Approach%20of%20the%20Left%20Upper%20Quadrant%20for%20Ovarian%20Cancer%20in%2010%20Steps.%26%23x201D%3B%20%26lt%3Bi%26gt%3BInternational%20Journal%20of%20Gynecological%20Cancer%3A%20Official%20Journal%20of%20the%20International%20Gynecological%20Cancer%20Society%26lt%3B%5C%2Fi%26gt%3B%2031%2C%20no.%2011%20%28November%202021%29%3A%201488%26%23x2013%3B89.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-002963%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fijgc-2021-002963%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Surgical%20approach%20of%20the%20left%20upper%20quadrant%20for%20ovarian%20cancer%20in%2010%20steps%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Migliorelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Daix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gwenael%22%2C%22lastName%22%3A%22Ferron%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1136%5C%2Fijgc-2021-002963%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221525-1438%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%2C%22FGRJFWV3%22%5D%2C%22dateModified%22%3A%222022-01-27T15%3A12%3A35Z%22%7D%7D%2C%7B%22key%22%3A%223PDW6E2I%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Angeles%20et%20al.%22%2C%22parsedDate%22%3A%222021-11%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAngeles%2C%20Martina%20Aida%2C%20Bastien%20Cabarrou%2C%20Antonio%20Gil-Moreno%2C%20Asunci%26%23xF3%3Bn%20P%26%23xE9%3Brez-Benavente%2C%20Emanuela%20Spagnolo%2C%20Agnieszka%20Rychlik%2C%20Carlos%20Mart%26%23xED%3Bnez-G%26%23xF3%3Bmez%2C%20et%20al.%20%26%23x201C%3BEffect%20of%20Tumor%20Burden%20and%20Radical%20Surgery%20on%20Survival%20Difference%20between%20Upfront%2C%20Early%20Interval%20or%20Delayed%20Cytoreductive%20Surgery%20in%20Ovarian%20Cancer.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Gynecologic%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2032%2C%20no.%206%20%28November%202021%29%3A%20e78.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3802%5C%2Fjgo.2021.32.e78%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3802%5C%2Fjgo.2021.32.e78%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20tumor%20burden%20and%20radical%20surgery%20on%20survival%20difference%20between%20upfront%2C%20early%20interval%20or%20delayed%20cytoreductive%20surgery%20in%20ovarian%20cancer%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%20Aida%22%2C%22lastName%22%3A%22Angeles%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antonio%22%2C%22lastName%22%3A%22Gil-Moreno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Asunci%5Cu00f3n%22%2C%22lastName%22%3A%22P%5Cu00e9rez-Benavente%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuela%22%2C%22lastName%22%3A%22Spagnolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agnieszka%22%2C%22lastName%22%3A%22Rychlik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-G%5Cu00f3mez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ignacio%22%2C%22lastName%22%3A%22Zapardiel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Illac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Federico%22%2C%22lastName%22%3A%22Migliorelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22B%5Cu00e9trian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gw%5Cu00e9na%5Cu00ebl%22%2C%22lastName%22%3A%22Ferron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alicia%22%2C%22lastName%22%3A%22Hern%5Cu00e1ndez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alejandra%22%2C%22lastName%22%3A%22Martinez%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20We%20sought%20to%20evaluate%20the%20impact%20on%20survival%20of%20tumor%20burden%20and%20surgical%20complexity%20in%20relation%20to%20the%20number%20of%20cycles%20of%20neoadjuvant%20chemotherapy%20%28NACT%29%20in%20patients%20with%20advanced%20ovarian%20cancer%20%28OC%29%20with%20minimal%20%28CC-1%29%20or%20no%20residual%20disease%20%28CC-0%29.%5CnMETHODS%3A%20This%20retrospective%20study%20included%20patients%20with%20International%20Federation%20of%20Gynaecology%20and%20Obstetrics%20IIIC-IV%20stage%20OC%20who%20underwent%20debulking%20surgery%20at%204%20high-volume%20institutions%20between%20January%202008%20and%20December%202015.%20We%20assessed%20the%20overall%20survival%20%28OS%29%20of%20primary%20debulking%20surgery%20%28PDS%20group%29%2C%20early%20interval%20debulking%20surgery%20after%203-4%20cycles%20of%20NACT%20%28early%20IDS%20group%29%20and%20delayed%20debulking%20surgery%20after%206%20cycles%20%28DDS%20group%29%20with%20CC-0%20or%20CC-1%20according%20to%20peritoneal%20cancer%20index%20%28PCI%29%20and%20Aletti%20score.%5CnRESULTS%3A%20Five%20hundred%20forty-nine%20women%20were%20included%3A%20175%20%2831.9%25%29%20had%20PDS%2C%20224%20%2840.8%25%29%20early%20IDS%20and%20150%20%2827.3%25%29%20DDS.%20Regardless%20of%20Aletti%20score%2C%20median%20OS%20after%20PDS%20was%20significantly%20higher%20than%20after%20early%20IDS%20or%20DDS%2C%20but%20the%20survival%20difference%20was%20higher%20in%20women%20with%20an%20Aletti%20score%20%26lt%3B8.%20Among%20patients%20with%20PCI%20%5Cu226410%2C%20median%20OS%20after%20PDS%20was%20significantly%20higher%20than%20after%20early%20IDS%20or%20DDS.%20In%20women%20with%20PCI%20%26gt%3B10%2C%20there%20were%20no%20differences%20between%20PDS%20and%20early%20IDS%2C%20but%20DDS%20was%20associated%20with%20decreased%20OS.%5CnCONCLUSION%3A%20The%20benefit%20of%20complete%20PDS%20compared%20with%20NACT%20was%20maximal%20in%20patients%20with%20a%20low%20complexity%20score.%20In%20patients%20with%20low%20tumor%20burden%2C%20there%20was%20a%20survival%20benefit%20of%20PDS%20over%20early%20IDS%20or%20DDS.%20In%20women%20with%20high%20tumor%20load%2C%20DDS%20impaired%20the%20oncological%20outcome.%22%2C%22date%22%3A%222021-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3802%5C%2Fjgo.2021.32.e78%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222005-0399%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-01-14T15%3A43%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22NHQK465D%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brito%20et%20al.%22%2C%22parsedDate%22%3A%222021-07-28%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrito%2C%20Ariadna%2C%20Candice%20Merle%2C%20Pauline%20Lagarde%2C%20Benjamin%20Faustin%2C%20Anne%20Devin%2C%20Lydia%20Lartigue%2C%20and%20Frederic%20Chibon.%20%26%23x201C%3BCell%20Fusion%20Enhances%20Energy%20Metabolism%20of%20Mesenchymal%20Tumor%20Hybrid%20Cells%20to%20Sustain%20Their%20Proliferation%20and%20Invasion.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2021%2C%20no.%201%20%28July%2028%2C%202021%29%3A%20863.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-08561-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-08561-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cell%20fusion%20enhances%20energy%20metabolism%20of%20mesenchymal%20tumor%20hybrid%20cells%20to%20sustain%20their%20proliferation%20and%20invasion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariadna%22%2C%22lastName%22%3A%22Brito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Faustin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Devin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cell-to-cell%20fusion%20is%20emerging%20as%20a%20key%20element%20of%20the%20metastatic%20process%20in%20various%20cancer%20types.%20We%20recently%20showed%20that%20hybrids%20made%20from%20the%20spontaneous%20merging%20of%20pre-malignant%20%28IMR90%20E6E7%2C%20i.e.%20E6E7%29%20and%20malignant%20%28IMR90%20E6E7%20RST%2C%20i.e.%20RST%29%20mesenchymal%20cells%20recapitulate%20the%20main%20features%20of%20human%20undifferentiated%20pleomorphic%20sarcoma%20%28UPS%29%2C%20with%20a%20highly%20rearranged%20genome%20and%20increased%20spreading%20capacities.%20To%20better%20characterize%20the%20intrinsic%20properties%20of%20these%20hybrids%2C%20we%20investigated%20here%20their%20metabolic%20energy%20profile%20compared%20to%20their%20parents.%5CnRESULTS%3A%20Our%20results%20unveiled%20that%20hybrids%20harbored%20a%20Warburg-like%20metabolism%2C%20like%20their%20RST%20counterparts.%20However%2C%20hybrids%20displayed%20a%20much%20greater%20metabolic%20activity%2C%20enhancing%20glycolysis%20to%20proliferate.%20Interestingly%2C%20modifying%20the%20metabolic%20environmental%20conditions%20through%20the%20use%20of%205-aminoimidazole-4-carbox-amide-1-%5Cu03b2-D-ribofuranoside%20%28AICAR%29%2C%20an%20activator%20of%20the%205%26%23039%3B-adenosine%20monophosphate%20%28AMP%29-activated%20protein%20kinase%20%28AMPK%29%2C%20specifically%20reduced%20the%20growth%20of%20hybrids%2C%20and%20also%20abrogated%20the%20invasive%20capacity%20of%20hybrids%20displaying%20enhanced%20glycolysis.%20Furthermore%2C%20AICAR%20efficiently%20blocked%20the%20tumoral%20features%20related%20to%20the%20aggressiveness%20of%20human%20UPS%20cell%20lines.%5CnCONCLUSION%3A%20Altogether%2C%20our%20findings%20strongly%20suggest%20that%20hybrids%20rely%20on%20higher%20energy%20flux%20to%20proliferate%20and%20that%20a%20drug%20altering%20this%20metabolic%20equilibrium%20could%20impair%20their%20survival%20and%20be%20potentially%20considered%20as%20a%20novel%20therapeutic%20strategy.%22%2C%22date%22%3A%222021-07-28%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-021-08561-6%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221471-2407%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A31%3A29Z%22%7D%7D%2C%7B%22key%22%3A%22S4ZM5NII%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Beddok%20et%20al.%22%2C%22parsedDate%22%3A%222021-05-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBeddok%2C%20Arnaud%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Sophie%20Le%20Guellec%2C%20No%26%23xE9%3Bmie%20Thebault%2C%20Alexandre%20Coutte%2C%20Henri%20Sevestre%2C%20Bruno%20Chauffert%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BGerminal%20GLT8D1%2C%20GATAD2A%20and%20SLC25A39%20Mutations%20in%20a%20Patient%20with%20a%20Glomangiopericytal%20Tumor%20and%20Five%20Different%20Sarcomas%20over%20a%2010-Year%20Period.%26%23x201D%3B%20%26lt%3Bi%26gt%3BScientific%20Reports%26lt%3B%5C%2Fi%26gt%3B%2011%2C%20no.%201%20%28May%207%2C%202021%29%3A%209765.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-88671-0%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-021-88671-0%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Germinal%20GLT8D1%2C%20GATAD2A%20and%20SLC25A39%20mutations%20in%20a%20patient%20with%20a%20glomangiopericytal%20tumor%20and%20five%20different%20sarcomas%20over%20a%2010-year%20period%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Beddok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Thebault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Coutte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Henri%22%2C%22lastName%22%3A%22Sevestre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Chauffert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Soft%20tissue%20sarcoma%20represents%20about%201%25%20of%20all%20adult%20cancers.%20Occurrence%20of%20multiple%20sarcomas%20in%20a%20same%20individual%20cannot%20be%20fortuitous.%20A%2072-year-old%20patient%20had%20between%202007%20and%202016%20a%20glomangiopericytal%20tumor%20of%20the%20right%20forearm%20and%20a%20succession%20of%20sarcomas%20of%20the%20extremities%3A%20a%20leiomyosarcoma%20of%20the%20left%20buttock%2C%20a%20myxofibrosarcoma%20%28MFS%29%20of%20the%20right%20forearm%2C%20a%5Cu00a0MFS%20of%20the%20left%20scapula%2C%20a%20left%20latero-thoracic%20MFS%20and%20two%20undifferentiated%20sarcomas%20on%20the%20left%20forearm.%20Pathological%20examination%20of%20the%20six%20locations%20was%20not%20in%20favor%20of%20disease%20with%20local%5C%2Fdistant%20recurrences%20but%20could%20not%20confirm%20different%20diseases.%20An%20extensive%20molecular%20analysis%20including%20DNA-array%2C%20RNA-sequencing%20and%20DNA-Sanger-sequencing%2C%20was%20thus%20performed%20to%20determine%20the%20link%20between%20them.%20The%20genomic%20profile%20of%20the%20glomangiopericytal%20tumor%20and%20the%20six%20sarcomas%20revealed%20that%20five%20sarcomas%20were%20different%20diseases%20and%20one%20was%20the%20local%20recurrence%20of%20the%20glomangiopericytal%20tumor.%20While%20the%20chromosomal%20alterations%20in%20the%20six%20tumors%20were%20different%2C%20a%20common%20somatic%20CDKN2A%5C%2FCDKN2B%20deletion%20was%20identified.%20RNA-sequencing%20of%20five%20tumors%20identified%20mutations%20in%20GLT8D1%2C%20GATAD2A%20and%20SLC25A39%20in%20all%20samples.%20The%20germline%20origin%20of%20these%20mutations%20was%20confirmed%20by%20Sanger-sequencing.%20Innovative%20molecular%20analysis%20methods%20have%20made%20possible%20a%20better%20understanding%20of%20the%20complex%20tumorigenesis%20of%20multiple%20sarcomas.%22%2C%22date%22%3A%222021-05-07%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-021-88671-0%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222045-2322%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-16T12%3A26%3A47Z%22%7D%7D%2C%7B%22key%22%3A%22G3FX4ST6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Darmusey%20et%20al.%22%2C%22parsedDate%22%3A%222021-04-29%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDarmusey%2C%20Lucie%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20No%26%23xE9%3Bmie%20Th%26%23xE9%3Bbault%2C%20Sophie%20Le%20Guellec%2C%20Nelly%20Desplat%2C%20La%26%23xEB%3Btitia%20Gaston%2C%20Lucile%20Delespaul%2C%20et%20al.%20%26%23x201C%3BATRX%20Alteration%20Contributes%20to%20Tumor%20Growth%20and%20Immune%20Escape%20in%20Pleomorphic%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2013%2C%20no.%209%20%28April%2029%2C%202021%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13092151%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13092151%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22ATRX%20Alteration%20Contributes%20to%20Tumor%20Growth%20and%20Immune%20Escape%20in%20Pleomorphic%20Sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Darmusey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Th%5Cu00e9bault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Desplat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22La%5Cu00ebtitia%22%2C%22lastName%22%3A%22Gaston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Darbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Gomez-Brouchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Richard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Whole%20genome%20and%20transcriptome%20sequencing%20of%20a%20cohort%20of%2067%20leiomyosarcomas%20has%20been%20revealed%20ATRX%20to%20be%20one%20of%20the%20most%20frequently%20mutated%20genes%20in%20leiomyosarcomas%20after%20TP53%20and%20RB1.%20While%20its%20function%20is%20well%20described%20in%20the%20alternative%20lengthening%20of%20telomeres%20mechanism%2C%20we%20wondered%20whether%20its%20alteration%20could%20have%20complementary%20effects%20on%20sarcoma%20oncogenesis.%20ATRX%20alteration%20is%20associated%20with%20the%20down-expression%20of%20genes%20linked%20to%20differentiation%20in%20leiomyosarcomas%2C%20and%20to%20immunity%20in%20an%20additional%20cohort%20of%2060%20poorly%20differentiated%20pleomorphic%20sarcomas.%20In%20vitro%20and%20in%20vivo%20models%20showed%20that%20ATRX%20down-expression%20increases%20tumor%20growth%20rate%20and%20immune%20escape%20by%20decreasing%20the%20immunity%20load%20of%20active%20mast%20cells%20in%20sarcoma%20tumors.%20These%20data%20indicate%20that%20an%20alternative%20to%20unsuccessful%20targeting%20of%20the%20adaptive%20immune%20system%20in%20sarcoma%20could%20target%20the%20innate%20system.%20This%20might%20lead%20to%20a%20better%20outcome%20for%20sarcoma%20patients%20in%20terms%20of%20ATRX%20status.%22%2C%22date%22%3A%222021-04-29%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13092151%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A53%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22PKFEBRGX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brahmi%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrahmi%2C%20M.%2C%20T.%20Lesluyes%2C%20A.%20Dufresne%2C%20M.%20Toulmonde%2C%20A.%20Italiano%2C%20O.%20Mir%2C%20A.%20Le%20Cesne%2C%20et%20al.%20%26%23x201C%3BExpression%20and%20Prognostic%20Significance%20of%20PDGF%20Ligands%20and%20Receptors%20across%20Soft%20Tissue%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BESMO%20Open%26lt%3B%5C%2Fi%26gt%3B%206%2C%20no.%201%20%28February%202021%29%3A%20100037.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2020.100037%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.esmoop.2020.100037%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Expression%20and%20prognostic%20significance%20of%20PDGF%20ligands%20and%20receptors%20across%20soft%20tissue%20sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Mir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Penel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-M.%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-Y.%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20While%20the%20anti-PDGFRA%20antibody%20olaratumab%20failed%20to%20confirm%20an%20impact%20on%20survival%20in%20unselected%20advanced%20soft%20tissue%20sarcoma%20%28STS%29%20patients%2C%20the%20level%20of%20expression%20and%20the%20prognosis%20of%20platelet-derived%20growth%20factor%20%28PDGF%29%20receptors%20and%20ligands%20in%20STS%20remain%20unclear.%5CnPATIENTS%20AND%20METHODS%3A%20We%20analyzed%20PDGF%20ligands%20and%20receptors%26%23039%3B%20expression%20levels%20in%20a%20series%20of%20255%20patients%20with%20different%20histologies%20of%20STS%20%5Bgastrointestinal%20stromal%20tumor%20%28GIST%29%2C%20myxoid%20liposarcoma%20%28MLPS%29%2C%20sarcoma%20with%20complex%20genomics%2C%20synovial%20sarcoma%20%28SyS%29%5D%20with%20Agilent%20single-color%20micro-arrays.%20We%20explored%20expression%20levels%20as%20prognostic%20values%20in%20univariate%20and%20multivariate%20analysis%20using%20R%20software%20%28version%203.4.2%29.%5CnRESULTS%3A%20Complex%20patterns%20of%20correlation%20of%20expression%20between%20ligands%20and%20receptors%20were%20observed%20for%20each%20histotype.%20PDGFA%20levels%20were%20highest%20in%20SyS%20and%20lowest%20in%20MLPS%20%28P%20%26lt%3B%204%5Cu00a0%5Cu00d7%2010-9%29%2C%20PDGFB%20and%20C%20levels%20were%20lower%20in%20GIST%20%28P%20%26lt%3B%202%5Cu00a0%5Cu00d7%2010-15%20and%20P%20%26lt%3B%203%5Cu00a0%5Cu00d7%2010-9%29%20while%20PDGFD%20expression%20was%20similar%20across%20histological%20subtypes.%20PDGF%20receptor%20%28PDGFR%29%20A%20expression%20was%20lowest%20in%20MLPS%20%28P%20%26lt%3B%200.002%29%2C%20whereas%20PDGFRB%20and%20L%20expressions%20were%20lowest%20in%20GIST%20and%20SyS%20%28P%20%26lt%3B%200.0004%29.%20Interestingly%2C%20high%20PDGFA%20expression%20levels%20were%20associated%20with%20higher%20risk%20of%20metastasis%20%28P%5Cu00a0%3D%200.006%29%2C%20whereas%20PDGFD%20levels%20above%20average%20were%20associated%20with%20a%20reduced%20risk%20of%20metastasis%20%28P%5Cu00a0%3D%200.01%29%20in%20univariate%20and%20multivariate%20analysis.%5CnCONCLUSIONS%3A%20The%20expression%20of%20PDGF%20ligands%20and%20receptors%20varies%20across%20sarcoma%20histological%20subtypes.%20PDGFA%20and%20D%20expression%20levels%20independently%20and%20inversely%20correlate%20with%20the%20risk%20of%20metastatic%20relapse.%22%2C%22date%22%3A%222021-02%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.esmoop.2020.100037%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222059-7029%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-16T10%3A26%3A12Z%22%7D%7D%2C%7B%22key%22%3A%22CAQMXBP4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Merle%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMerle%2C%20Candice%2C%20Pauline%20Lagarde%2C%20Lydia%20Lartigue%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BAcquisition%20of%20Cancer%20Stem%20Cell%20Capacities%20after%20Spontaneous%20Cell%20Fusion.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2021%2C%20no.%201%20%282021%29%3A%20241.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-07979-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-021-07979-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Acquisition%20of%20cancer%20stem%20cell%20capacities%20after%20spontaneous%20cell%20fusion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Background%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Cancer%20stem%5C%2FInitiating%20cell%20%28CS%5C%2FIC%29%20hypothesis%20argues%20that%20CS%5C%2FICs%20are%20responsible%20of%20tumour%20initiation%2C%20drug%20resistance%2C%20metastasis%20or%20disease%20relapse.%20Their%20detection%20in%20several%20cancers%20supports%20this%20concept.%20However%2C%20their%20origin%20is%20still%20misunderstood.%20Cell%20fusion%20is%20shown%20to%20take%20part%20in%20the%20formation%20of%20CS%5C%2FICs%2C%20i.e.%20fusion%20between%20mesenchymal%20stem%20cell%20and%20cancer%20cell.%20In%20a%20previous%20paper%2C%20we%20described%20that%20fusion%20leads%20to%20hybrids%20with%20metastatic%20capacity.%20This%20process%20triggered%20genomic%20rearrangements%20in%20hybrid%20cells%20together%20with%20increased%20metastasis%20development.%20Here%2C%20we%20hypothesize%20that%20cell%20fusion%20could%20be%20strong%20enough%20to%20provoke%20a%20cellular%20reprogramming%20and%20the%20acquisition%20of%20CS%5C%2FIC%20properties%2C%20promoting%20metastasis%20formation.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20After%20spontaneous%20cell%20fusion%20between%20E6E7%20%28IMR90%20with%20the%20oncogenes%20E6%20and%20E7%29%20and%20RST%20%28IMR90%20fully%20transformed%29%20cell%20lines%2C%20hybrid%20cells%20were%20selected%20by%20dual%20antibiotic%20selection.%20Cancer%20stem%20cells%20capacities%20were%20evaluated%20regarding%20capacity%20to%20form%20spheres%2C%20expression%20of%20stem%20cell%20markers%20and%20the%20presence%20of%20ALDH%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20high%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20cells.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Our%20data%20show%20that%20after%20cell%20fusion%2C%20all%20hybrids%20contain%20a%20percentage%20of%20cells%20with%20CS%5C%2FICs%20properties%2C%20regarding.%20Importantly%2C%20we%20lastly%20showed%20that%20NANOG%20inhibition%20in%20H1%20hybrid%20decreases%20this%20migration%20capacity%20while%20having%20no%20effect%20on%20the%20corresponding%20parental%20cells.%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Conclusions%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20Altogether%20these%20results%20indicate%20that%20the%20combination%20of%20CS%5C%2FICs%20properties%20and%20genomic%20rearrangement%20in%20hybrids%20is%20likely%20to%20be%20key%20to%20tumour%20progression.%22%2C%22date%22%3A%2212%5C%2F2021%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-021-07979-2%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbmccancer.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs12885-021-07979-2%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221471-2407%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222022-01-28T15%3A06%3A24Z%22%7D%7D%5D%7D
Angeles, Martina Aida, Hélène Leray, Federico Migliorelli, Manon Daix, Alejandra Martinez, and Gwenael Ferron. “Surgical Approach of the Left Upper Quadrant for Ovarian Cancer in 10 Steps.” International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society 31, no. 11 (November 2021): 1488–89. https://doi.org/10.1136/ijgc-2021-002963.
Angeles, Martina Aida, Bastien Cabarrou, Antonio Gil-Moreno, Asunción Pérez-Benavente, Emanuela Spagnolo, Agnieszka Rychlik, Carlos Martínez-Gómez, et al. “Effect of Tumor Burden and Radical Surgery on Survival Difference between Upfront, Early Interval or Delayed Cytoreductive Surgery in Ovarian Cancer.” Journal of Gynecologic Oncology 32, no. 6 (November 2021): e78. https://doi.org/10.3802/jgo.2021.32.e78.
Brito, Ariadna, Candice Merle, Pauline Lagarde, Benjamin Faustin, Anne Devin, Lydia Lartigue, and Frederic Chibon. “Cell Fusion Enhances Energy Metabolism of Mesenchymal Tumor Hybrid Cells to Sustain Their Proliferation and Invasion.” BMC Cancer 21, no. 1 (July 28, 2021): 863. https://doi.org/10.1186/s12885-021-08561-6.
Beddok, Arnaud, Gaëlle Pérot, Sophie Le Guellec, Noémie Thebault, Alexandre Coutte, Henri Sevestre, Bruno Chauffert, and Frédéric Chibon. “Germinal GLT8D1, GATAD2A and SLC25A39 Mutations in a Patient with a Glomangiopericytal Tumor and Five Different Sarcomas over a 10-Year Period.” Scientific Reports 11, no. 1 (May 7, 2021): 9765. https://doi.org/10.1038/s41598-021-88671-0.
Darmusey, Lucie, Gaëlle Pérot, Noémie Thébault, Sophie Le Guellec, Nelly Desplat, Laëtitia Gaston, Lucile Delespaul, et al. “ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas.” Cancers 13, no. 9 (April 29, 2021). https://doi.org/10.3390/cancers13092151.
Brahmi, M., T. Lesluyes, A. Dufresne, M. Toulmonde, A. Italiano, O. Mir, A. Le Cesne, et al. “Expression and Prognostic Significance of PDGF Ligands and Receptors across Soft Tissue Sarcomas.” ESMO Open 6, no. 1 (February 2021): 100037. https://doi.org/10.1016/j.esmoop.2020.100037.
Merle, Candice, Pauline Lagarde, Lydia Lartigue, and Frédéric Chibon. “Acquisition of Cancer Stem Cell Capacities after Spontaneous Cell Fusion.” BMC Cancer 21, no. 1 (2021): 241. https://doi.org/10.1186/s12885-021-07979-2.
PUBLICATIONS 2020
7813506
CF9MRXB4
2020
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22TABWS96W%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Croce%20and%20Chibon%22%2C%22parsedDate%22%3A%222020-11-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCroce%2C%20Sabrina%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BMolecular%20Prognostication%20of%20Uterine%20Smooth%20Muscle%20Neoplasms%3A%20From%20%26lt%3Bspan%20style%3D%26quot%3Bfont-variant%3Asmall-caps%3B%26quot%3B%26gt%3BCGH%26lt%3B%5C%2Fspan%26gt%3B%20Array%20to%20%26lt%3Bspan%20style%3D%26quot%3Bfont-variant%3Asmall-caps%3B%26quot%3B%26gt%3BCINSARC%26lt%3B%5C%2Fspan%26gt%3B%20Signature%20and%20Beyond.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGenes%2C%20Chromosomes%20and%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20November%2011%2C%202020%2C%20gcc.22906.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22906%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22906%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20prognostication%20of%20uterine%20smooth%20muscle%20neoplasms%3A%20From%20%3Cspan%20style%3D%5C%22font-variant%3Asmall-caps%3B%5C%22%3ECGH%3C%5C%2Fspan%3E%20array%20to%20%3Cspan%20style%3D%5C%22font-variant%3Asmall-caps%3B%5C%22%3ECINSARC%3C%5C%2Fspan%3E%20signature%20and%20beyond%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Croce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-11-11%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fgcc.22906%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2F10.1002%5C%2Fgcc.22906%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221045-2257%2C%201098-2264%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A52Z%22%7D%7D%2C%7B%22key%22%3A%223V3C7KTP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lesluyes%20and%20Chibon%22%2C%22parsedDate%22%3A%222020-10-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLesluyes%2C%20Tom%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BA%20Global%20and%20Integrated%20Analysis%20of%20CINSARC-Associated%20Genetic%20Defects.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2C%20October%206%2C%202020%2C%20canres.0512.2020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-20-0512%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F0008-5472.CAN-20-0512%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20global%20and%20integrated%20analysis%20of%20CINSARC-associated%20genetic%20defects%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-10-06%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1158%5C%2F0008-5472.CAN-20-0512%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fcancerres.aacrjournals.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1158%5C%2F0008-5472.CAN-20-0512%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%220008-5472%2C%201538-7445%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A43Z%22%7D%7D%2C%7B%22key%22%3A%225SZSN86F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ciss%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222020-06-10%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCiss%26%23xE9%3B%2C%20Madi%20Y.%2C%20Samuel%20Pyrdziak%2C%20Nelly%20Firmin%2C%20Laurie%20Gayte%2C%20Maud%20Heuillet%2C%20Floriant%20Bellvert%2C%20Maryse%20Fuentes%2C%20et%20al.%20%26%23x201C%3BTargeting%20MDM2-Dependent%20Serine%20Metabolism%20as%20a%20Therapeutic%20Strategy%20for%20Liposarcoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BScience%20Translational%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%20547%20%28June%2010%2C%202020%29%3A%20eaay2163.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.aay2163%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.aay2163%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeting%20MDM2-dependent%20serine%20metabolism%20as%20a%20therapeutic%20strategy%20for%20liposarcoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Madi%20Y.%22%2C%22lastName%22%3A%22Ciss%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Pyrdziak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nelly%22%2C%22lastName%22%3A%22Firmin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurie%22%2C%22lastName%22%3A%22Gayte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maud%22%2C%22lastName%22%3A%22Heuillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floriant%22%2C%22lastName%22%3A%22Bellvert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maryse%22%2C%22lastName%22%3A%22Fuentes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Delpech%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Riscal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Giuseppe%22%2C%22lastName%22%3A%22Arena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Gellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Maran-Gonzalez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22Chateau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Theillet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Carrere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Charles%22%2C%22lastName%22%3A%22Portais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Le%20Cam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%20K.%22%2C%22lastName%22%3A%22Linares%22%7D%5D%2C%22abstractNote%22%3A%22Well-differentiated%20and%20dedifferentiated%20liposarcomas%20%28LPSs%29%20are%20characterized%20by%20a%20systematic%20amplification%20of%20the%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20MDM2%5Cn%20%20%20%20%20%20%20%20%20%20%20%20%20%20oncogene%2C%20which%20encodes%20a%20key%20negative%20regulator%20of%20the%20p53%20pathway.%20The%20molecular%20mechanisms%20underlying%20MDM2%20overexpression%20while%20sparing%20wild-type%20p53%20in%20LPS%20remain%20poorly%20understood.%20Here%2C%20we%20show%20that%20the%20p53-independent%20metabolic%20functions%20of%20chromatin-bound%20MDM2%20are%20exacerbated%20in%20LPS%20and%20mediate%20an%20addiction%20to%20serine%20metabolism%20that%20sustains%20nucleotide%20synthesis%20and%20tumor%20growth.%20Treatment%20of%20LPS%20cells%20with%20Nutlin-3A%2C%20a%20pharmacological%20inhibitor%20of%20the%20MDM2-p53%20interaction%2C%20stabilized%20p53%20but%20unexpectedly%20enhanced%20MDM2-mediated%20control%20of%20serine%20metabolism%20by%20increasing%20its%20recruitment%20to%20chromatin%2C%20likely%20explaining%20the%20poor%20clinical%20efficacy%20of%20this%20class%20of%20MDM2%20inhibitors.%20In%20contrast%2C%20genetic%20or%20pharmacological%20inhibition%20of%20chromatin-bound%20MDM2%20by%20SP141%2C%20a%20distinct%20MDM2%20inhibitor%20triggering%20its%20degradation%2C%20or%20interfering%20with%20de%20novo%20serine%20synthesis%2C%20impaired%20LPS%20growth%20both%20in%20vitro%20and%20in%20clinically%20relevant%20patient-derived%20xenograft%20models.%20Our%20data%20indicate%20that%20targeting%20MDM2%20functions%20in%20serine%20metabolism%20represents%20a%20potential%20therapeutic%20strategy%20for%20LPS.%22%2C%22date%22%3A%222020-06-10%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1126%5C%2Fscitranslmed.aay2163%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fstm.sciencemag.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1126%5C%2Fscitranslmed.aay2163%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221946-6234%2C%201946-6242%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22CCJT38SX%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Merle%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-19%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMerle%2C%20Candice%2C%20No%26%23xE9%3Bmie%20Th%26%23xE9%3Bbault%2C%20Sophie%20LeGuellec%2C%20Jessica%20Baud%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Tom%20Lesluyes%2C%20Lucile%20Delespaul%2C%20Lydia%20Lartigue%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BTetraploidization%20of%20Immortalized%20Myoblasts%20Induced%20by%20Cell%20Fusion%20Drives%20Myogenic%20Sarcoma%20Development%20with%20DMD%20Deletion.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%205%20%28May%2019%2C%202020%29%3A%201281.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12051281%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12051281%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Tetraploidization%20of%20Immortalized%20Myoblasts%20Induced%20by%20Cell%20Fusion%20Drives%20Myogenic%20Sarcoma%20Development%20with%20DMD%20Deletion%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Th%5Cu00e9bault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22LeGuellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Whole-genome%20doubling%20is%20the%20second%20most%20frequent%20genomic%20event%2C%20after%20TP53%20alterations%2C%20in%20advanced%20solid%20tumors%20and%20is%20associated%20with%20poor%20prognosis.%20Tetraploidization%20step%20will%20lead%20to%20aneuploidy%20and%20chromosomic%20rearrangements.%20The%20mechanism%20leading%20to%20tetraploid%20cells%20is%20important%20since%20endoreplication%2C%20abortive%20cytokinesis%20and%20cell%20fusion%20could%20have%20distinct%20consequences.%20Unlike%20processes%20based%20on%20duplication%2C%20cell%20fusion%20involves%20the%20merging%20of%20two%20different%20genomes%2C%20epigenomes%20and%20cellular%20states.%20Since%20it%20is%20involved%20in%20muscle%20differentiation%2C%20we%20hypothesized%20that%20it%20could%20play%20a%20role%20in%20the%20oncogenesis%20of%20myogenic%20cancers.%20Spontaneous%20hybrids%2C%20but%20not%20their%20non-fused%20immortalized%20myoblast%20counterparts%20they%20are%20generated%20from%2C%20induced%20tumors%20in%20mice.%20Unstable%20upon%20fusion%2C%20the%20hybrid%20genome%20evolved%20from%20initial%20mitosis%20to%20tumors%20with%20a%20highly%20rearranged%20genome.%20This%20genome%20remodeling%20finally%20produced%20targeted%20DMD%20deletions%20associated%20with%20replicative%20stress%2C%20isoform%20relocalization%20and%20metastatic%20spreading%2C%20exactly%20as%20observed%20in%20human%20myogenic%20sarcomas.%20In%20conclusion%2C%20these%20results%20draw%20a%20model%20of%20myogenic%20oncogenesis%20in%20which%20cell%20fusion%20and%20oncogene%20activation%20combine%20to%20produce%20pleomorphic%20aggressive%20sarcomas.%22%2C%22date%22%3A%222020-05-19%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12051281%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F5%5C%2F1281%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22MSEX8BXI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lartigue%20et%20al.%22%2C%22parsedDate%22%3A%222020-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLartigue%2C%20Lydia%2C%20Candice%20Merle%2C%20Pauline%20Lagarde%2C%20Lucile%20Delespaul%2C%20Tom%20Lesluyes%2C%20Sophie%20Le%20Guellec%2C%20Gaelle%20P%26%23xE9%3Brot%2C%20Laura%20Leroy%2C%20Jean-Michel%20Coindre%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BGenome%20Remodeling%20upon%20Mesenchymal%20Tumor%20Cell%20Fusion%20Contributes%20to%20Tumor%20Progression%20and%20Metastatic%20Spread.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncogene%26lt%3B%5C%2Fi%26gt%3B%2039%2C%20no.%2021%20%28May%202020%29%3A%204198%26%23x2013%3B4211.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-020-1276-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-020-1276-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Genome%20remodeling%20upon%20mesenchymal%20tumor%20cell%20fusion%20contributes%20to%20tumor%20progression%20and%20metastatic%20spread%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaelle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Cell%20fusion%20in%20tumor%20progression%20mostly%20refers%20to%20the%20merging%20of%20a%20cancer%20cell%20with%20a%20cell%20that%20has%20migration%20and%20immune%20escape%20capabilities%20such%20as%20macrophages.%20Here%20we%20show%20that%20spontaneous%20hybrids%20made%20from%20the%20fusion%20of%20transformed%20mesenchymal%20cells%20with%20partners%20from%20the%20same%20lineage%20undergo%20nonrecurrent%20large-scale%20genomic%20rearrangements%2C%20leading%20to%20the%20creation%20of%20highly%20aneuploid%20cells%20with%20novel%20phenotypic%20traits%2C%20including%20metastatic%20spreading%20capabilities.%20Moreover%2C%20in%20contrast%20to%20their%20parents%2C%20hybrids%20were%20the%20only%20cells%20able%20to%20recapitulate%20in%20vivo%20all%20features%20of%20human%20pleomorphic%20sarcomas%2C%20a%20rare%20and%20genetically%20complex%20mesenchymal%20tumor.%20Hybrid%20tumors%20not%20only%20displayed%20specific%20mesenchymal%20markers%2C%20but%20also%20combined%20a%20complex%20genetic%20profile%20with%20a%20highly%20metastatic%20behavior%2C%20like%20their%20human%20counterparts.%20Finally%2C%20we%20provide%20evidence%20that%20patient-derived%20pleomorphic%20sarcoma%20cells%20are%20inclined%20to%20spontaneous%20cell%20fusion.%20The%20resulting%20hybrids%20also%20gain%20in%20aggressiveness%2C%20exhibiting%20superior%20growth%20capacity%20in%20mouse%20models.%20Altogether%2C%20these%20results%20indicate%20that%20cell%20fusion%20has%20the%20potential%20to%20promote%20cancer%20progression%20by%20increasing%20growth%20and%5C%2For%20metastatic%20capacities%2C%20regardless%20of%20the%20nature%20of%20the%20companion%20cell.%20Moreover%2C%20such%20events%20likely%20occur%20upon%20sarcoma%20development%2C%20paving%20the%20way%20for%20better%20understanding%20of%20the%20biology%2C%20and%20aggressiveness%20of%20these%20tumors.%22%2C%22date%22%3A%22May%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41388-020-1276-6%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221476-5594%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22M7Y7A7GS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mattei%20et%20al.%22%2C%22parsedDate%22%3A%222020-03-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMattei%2C%20Jean%20Camille%2C%20Corinne%20Bouvier-Labit%2C%20Doriane%20Barets%2C%20Nicolas%20Macagno%2C%20Mathieu%20Chocry%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon%2C%20Philippe%20Morando%2C%20et%20al.%20%26%23x201C%3BPan%20Aurora%20Kinase%20Inhibitor%3A%20A%20Promising%20Targeted-Therapy%20in%20Dedifferentiated%20Liposarcomas%20With%20Differential%20Efficiency%20Depending%20on%20Sarcoma%20Molecular%20Profile.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2012%2C%20no.%203%20%28March%203%2C%202020%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12030583%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12030583%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pan%20Aurora%20Kinase%20Inhibitor%3A%20A%20Promising%20Targeted-Therapy%20in%20Dedifferentiated%20Liposarcomas%20With%20Differential%20Efficiency%20Depending%20on%20Sarcoma%20Molecular%20Profile%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Camille%22%2C%22lastName%22%3A%22Mattei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Bouvier-Labit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doriane%22%2C%22lastName%22%3A%22Barets%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Macagno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Chocry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Morando%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20Alexandre%22%2C%22lastName%22%3A%22Rochwerger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Duffaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylviane%22%2C%22lastName%22%3A%22Olschwang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Salas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Jiguet-Jiglaire%22%7D%5D%2C%22abstractNote%22%3A%22Soft%20tissue%20sarcoma%20%28STS%29%20are%20rare%20and%20aggressive%20tumours.%20Their%20classification%20includes%20numerous%20histological%20subtypes%20of%20frequent%20poor%20prognosis.%20Liposarcomas%20%28LPS%29%20are%20the%20most%20frequent%20type%20among%20them%2C%20and%20the%20aggressiveness%20and%20deep%20localization%20of%20dedifferentiated%20LPS%20are%20linked%20to%20high%20levels%20of%20recurrence.%20Current%20treatments%20available%20today%20lead%20to%20five-year%20overall%20survival%20has%20remained%20stuck%20around%2060%25-70%25%20for%20the%20past%20three%20decades.%20Here%2C%20we%20highlight%20a%20correlation%20between%20Aurora%20kinasa%20A%20%28AURKA%29%20and%20AURKB%20mRNA%20overexpression%20and%20a%20low%20metastasis%20-%20free%20survival.%20AURKA%20and%20AURKB%20expression%20analysis%20at%20genomic%20and%20protein%20level%20on%20a%209-STS%20cell%20lines%20panel%20highlighted%20STS%20heterogeneity%2C%20especially%20in%20LPS%20subtype.%20AURKA%20and%20AURKB%20inhibition%20by%20RNAi%20and%20drug%20targeting%20with%20AMG%20900%2C%20a%20pan%20Aurora%20Kinase%20inhibitor%2C%20in%20four%20LPS%20cell%20lines%20reduces%20cell%20survival%20and%20clonogenic%20proliferation%2C%20inducing%20apoptosis%20and%20polyploidy.%20When%20combined%20with%20doxorubicin%2C%20the%20standard%20treatment%20in%20STS%2C%20aurora%20kinases%20inhibitor%20can%20be%20considered%20as%20an%20enhancer%20of%20standard%20treatment%20or%20as%20an%20independent%20drug.%20Kinome%20analysis%20suggested%20its%20effect%20was%20linked%20to%20the%20inhibition%20of%20the%20MAP-kinase%20pathway%2C%20with%20differential%20drug%20resistance%20profiles%20depending%20on%20molecular%20characteristics%20of%20the%20tumor.%20Aurora%20Kinase%20inhibition%20by%20AMG%20900%20could%20be%20a%20promising%20therapy%20in%20STS.%22%2C%22date%22%3A%22Mar%2003%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12030583%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22DZ6IZI2A%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jakob%20et%20al.%22%2C%22parsedDate%22%3A%222020-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJakob%2C%20Jens%2C%20Tom%20Lesluyes%2C%20Anna%20Simeonova-Chergou%2C%20Frederik%20Wenz%2C%20Peter%20Hohenberger%2C%20Frederic%20Chibon%2C%20and%20Sophie%20Le%20Guellec.%20%26%23x201C%3BImpact%20of%20Preoperative%20Treatment%20on%20the%20CINSARC%20Prognostic%20Signature%3A%20Translational%20Research%20Results%20from%20a%26%23xA0%3BPhase%26%23xA0%3B1%20Trial%20of%20the%20German%20Interdisciplinary%20Sarcoma%20Group%20%28GISG%2003%29.%26%23x201D%3B%20%26lt%3Bi%26gt%3BStrahlentherapie%20Und%20Onkologie%3A%20Organ%20Der%20Deutschen%20Rontgengesellschaft%20...%20%5Bet%20Al%5D%26lt%3B%5C%2Fi%26gt%3B%20196%2C%20no.%203%20%28March%202020%29%3A%20280%26%23x2013%3B85.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00066-019-01543-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00066-019-01543-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20preoperative%20treatment%20on%20the%20CINSARC%20prognostic%20signature%3A%20translational%20research%20results%20from%20a%5Cu00a0phase%5Cu00a01%20trial%20of%20the%20German%20Interdisciplinary%20Sarcoma%20Group%20%28GISG%2003%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jens%22%2C%22lastName%22%3A%22Jakob%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Simeonova-Chergou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederik%22%2C%22lastName%22%3A%22Wenz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Hohenberger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20CINSARC%20%28Complexity%20INdex%20in%20SARComas%29%20is%20a%5Cu00a0prognostic%20signature%20for%20soft%20tissue%20sarcoma%20that%20determines%20the%20risk%20for%20recurrence%20and%20may%20serve%20to%20guide%20the%20decision%20for%20adjuvant%20chemotherapy.%20The%20aim%20of%20this%20study%20was%20to%20compare%20the%20CINSARC%20signature%20of%20pre-%20and%20posttreatment%20biopsies%20of%20sarcoma%20patients%20treated%20within%20a%5Cu00a0phase%5Cu00a0I%20trial%20evaluating%20preoperative%20sunitinib%20and%20irradiation.%5CnMETHODS%3A%20We%20retrieved%2014%5Cu00a0pairs%20of%20formalin-fixed%20paraffin-embedded%20blocks%20from%20pretreatment%20biopsies%20and%20posttreatment%20resection%20specimens%20and%20performed%20expression%20profiling%20of%20the%2067%5Cu00a0CINSARC%20signature%20genes.%5CnRESULTS%3A%20In%205%5C%2F14%5Cu00a0patients%2C%20both%20probes%20were%20unsuitable%20for%20expression%20analysis%20because%20there%20was%20no%20%28vital%29%20tissue%20left%20in%20biopsies%20or%20resection%20specimens.%20Comparing%20the%20CINSARC%20risk%20classification%20before%20and%20after%20treatment%20in%20the%20remaining%20patients%2C%202%5C%2F9%5Cu00a0shifted%20from%20a%5Cu00a0high-%20to%20a%5Cu00a0low-risk%20classification%20for%20metastatic%20disease%20after%20preoperative%20treatment%20with%20radiation%20therapy%20plus%20sunitinib%20and%207%5C%2F9%5Cu00a0pairs%20of%20pre-%20and%20posttreatment%20biopsies%20revealed%20identical%20results.%5CnCONCLUSION%3A%20Concurrent%20radiation%20therapy%20and%20sunitinib%20leads%20to%20diverging%20results%20of%20prognostic%20gene%20array%20testing%20in%20a%5Cu00a0relevant%20proportion%20of%20sarcoma%20patients.%20These%20changes%20may%20reflect%20tumor%20heterogeneity%2C%20local%20treatment%20effects%2C%20or%20prognostic%20changes%20of%20the%20disease.%20Caution%20is%20advised%20in%20the%20selection%20of%20samples%20and%20interpretation%20of%20test%20results.%22%2C%22date%22%3A%22Mar%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00066-019-01543-5%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221439-099X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A28%3A30Z%22%7D%7D%2C%7B%22key%22%3A%222K4CKQ3I%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Salas%20and%20Chibon%22%2C%22parsedDate%22%3A%222020-01-16%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSalas%2C%20S%26%23xE9%3Bbastien%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BBiology%20and%20signaling%20pathways%20involved%20in%20the%20oncogenesis%20of%20desmoid%20tumors.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBulletin%20Du%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2C%20January%2016%2C%202020.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2019.12.003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.bulcan.2019.12.003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Biology%20and%20signaling%20pathways%20involved%20in%20the%20oncogenesis%20of%20desmoid%20tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Salas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Desmoid%20tumors%20%28TDs%29%20are%20derived%20from%20mesenchymal%20stem%20cells%20and%20their%20pathogenesis%20is%20strongly%20linked%20to%20the%20Wingless%5C%2FWnt%20cascade%20where%20the%20deregulation%20of%20%5Cu03b2-catenin%20plays%20a%20major%20role.%20A%20mutation%20of%20the%20CTNNB1%20encoding%20%5Cu03b2-catenin%20is%20found%20in%20the%20majority%20of%20sporadic%20TD%20cases%20and%20constitutional%20mutations%20of%20APC%20have%20been%20described%20in%20heritable%20forms%20in%20patients%20with%20familial%20adenomatous%20polyposis%20%28FAP%29.%20Estrogens%20could%20also%20play%20a%20role%20in%20pathogenesis%20and%20this%20is%20the%20basis%20for%20the%20use%20of%20hormone%20therapy.%20Other%20signaling%20pathways%20have%20been%20involved%20in%20the%20development%20of%20TDs%20such%20as%20Notch%2C%20Hedgehog%2C%20JAK%5C%2FSTAT%2C%20PI3%20Kinase%5C%2FAKT%20and%20mTOR.%20Metalloproteases%20are%20expressed%20in%20TDs%20and%20play%20a%20role%20in%20invasiveness.%20TGF-%5Cu00df%2C%20as%20a%20growth%20factor%2C%20stimulates%20the%20transcriptional%20activity%20of%20%5Cu03b2-catenin.%20Future%20studies%20will%20need%20to%20focus%20on%20better%20describing%20and%20understanding%20the%20immune%20environment%20of%20TDs.%20One%20of%20the%20major%20difficulties%20for%20the%20experimental%20study%20of%20TDs%20is%20the%20virtual%20absence%20of%20a%20preclinical%20model%2C%20either%20in%20vitro%20or%20in%20vivo.%20This%20is%20partly%20why%20the%20interactions%20between%20the%20different%20signaling%20pathways%20presented%20here%20and%20their%20consequences%20for%20the%20development%20of%20TDs%20are%20still%20poorly%20understood.%22%2C%22date%22%3A%22Jan%2016%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.bulcan.2019.12.003%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221769-6917%22%2C%22language%22%3A%22fre%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A36%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22S66C8KEI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dufresne%20et%20al.%22%2C%22parsedDate%22%3A%222020-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDufresne%2C%20A.%2C%20T.%20Lesluyes%2C%20C.%20M%26%23xE9%3Bn%26%23xE9%3Btrier-Caux%2C%20M.%20Brahmi%2C%20E.%20Darbo%2C%20M.%20Toulmonde%2C%20A.%20Italiano%2C%20et%20al.%20%26%23x201C%3BSpecific%20Immune%20Landscapes%20and%20Immune%20Checkpoint%20Expressions%20in%20Histotypes%20and%20Molecular%20Subtypes%20of%20Sarcoma.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncoImmunology%26lt%3B%5C%2Fi%26gt%3B%209%2C%20no.%201%20%28January%201%2C%202020%29%3A%201792036.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2020.1792036%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F2162402X.2020.1792036%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Specific%20immune%20landscapes%20and%20immune%20checkpoint%20expressions%20in%20histotypes%20and%20molecular%20subtypes%20of%20sarcoma%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Dufresne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22M%5Cu00e9n%5Cu00e9trier-Caux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Brahmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Darbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Toulmonde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Italiano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Mir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.M.%22%2C%22lastName%22%3A%22Robin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J-M%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Caux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.Y.%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-01-01%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1080%5C%2F2162402X.2020.1792036%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.tandfonline.com%5C%2Fdoi%5C%2Ffull%5C%2F10.1080%5C%2F2162402X.2020.1792036%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222162-402X%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22THDAINSI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Delespaul%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDelespaul%2C%20Lucile%2C%20Caroline%20G%26%23xE9%3Blabert%2C%20Tom%20Lesluyes%2C%20Sophie%20Le%20Guellec%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Laura%20Leroy%2C%20Jessica%20Baud%2C%20Candice%20Merle%2C%20Lydia%20Lartigue%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BCell%26%23x2013%3BCell%20Fusion%20of%20Mesenchymal%20Cells%20with%20Distinct%20Differentiations%20Triggers%20Genomic%20and%20Transcriptomic%20Remodelling%20toward%20Tumour%20Aggressiveness.%26%23x201D%3B%20%26lt%3Bi%26gt%3BScientific%20Reports%26lt%3B%5C%2Fi%26gt%3B%2010%2C%20no.%201%20%282020%29%3A%2021634.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-78502-z%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41598-020-78502-z%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cell%5Cu2013cell%20fusion%20of%20mesenchymal%20cells%20with%20distinct%20differentiations%20triggers%20genomic%20and%20transcriptomic%20remodelling%20toward%20tumour%20aggressiveness%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22G%5Cu00e9labert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Cell%5Cu2013cell%20fusion%20is%20a%20physiological%20process%20that%20is%20hijacked%20during%20oncogenesis%20and%20promotes%20tumour%20evolution.%20The%20main%20known%20impact%20of%20cell%20fusion%20is%20to%20promote%20the%20formation%20of%20metastatic%20hybrid%20cells%20following%20fusion%20between%20mobile%20leucocytes%20and%20proliferating%20tumour%20cells.%20We%20show%20here%20that%20cell%20fusion%20between%20immortalized%20myoblasts%20and%20transformed%20fibroblasts%2C%20through%20genomic%20instability%20and%20expression%20of%20a%20specific%20transcriptomic%20profile%2C%20leads%20to%20emergence%20of%20hybrid%20cells%20acquiring%20dissemination%20properties.%20This%20is%20associated%20with%20acquisition%20of%20clonogenic%20ability%20by%20fused%20cells.%20In%20addition%2C%20by%20inheriting%20parental%20properties%2C%20hybrid%20tumours%20were%20found%20to%20mimic%20the%20histological%20characteristics%20of%20a%20specific%20histotype%20of%20sarcomas%3A%20undifferentiated%20pleomorphic%20sarcomas%20with%20incomplete%20muscular%20differentiation.%20This%20finding%20suggests%20that%20cell%20fusion%2C%20as%20macroevolution%20event%2C%20favours%20specific%20sarcoma%20development%20according%20to%20the%20differentiation%20lineage%20of%20parent%20cells.%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41598-020-78502-z%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41598-020-78502-z%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222045-2322%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A22%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22VVJJF69F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Filleron%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFilleron%2C%20Thomas%2C%20Sophie%20Le%20Guellec%2C%20Christine%20Chevreau%2C%20Bastien%20Cabarrou%2C%20Tom%20Lesluyes%2C%20Sabrina%20Lodin%2C%20Ang%26%23xE9%3Blique%20Massoubre%2C%20et%20al.%20%26%23x201C%3BValue%20of%20Peri-Operative%20Chemotherapy%20in%20Patients%20with%20CINSARC%20High-Risk%20Localized%20Grade%201%20or%202%20Soft%20Tissue%20Sarcoma%3A%20Study%20Protocol%20of%20the%20Target%20Selection%20Phase%20III%20CHIC-STS%20Trial.%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2020%2C%20no.%201%20%282020%29%3A%20716.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-020-07207-3%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12885-020-07207-3%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Value%20of%20peri-operative%20chemotherapy%20in%20patients%20with%20CINSARC%20high-risk%20localized%20grade%201%20or%202%20soft%20tissue%20sarcoma%3A%20study%20protocol%20of%20the%20target%20selection%20phase%20III%20CHIC-STS%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Chevreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Lodin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ang%5Cu00e9lique%22%2C%22lastName%22%3A%22Massoubre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Mounier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Poublanc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2212%5C%2F2020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12885-020-07207-3%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fbmccancer.biomedcentral.com%5C%2Farticles%5C%2F10.1186%5C%2Fs12885-020-07207-3%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221471-2407%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22TA6SVWFL%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gu%5Cu00e9rin%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGu%26%23xE9%3Brin%2C%20Amandine%2C%20Delphine%20Martire%2C%20Eva%20Trenquier%2C%20Tom%20Lesluyes%2C%20S%26%23xE9%3Bbastien%20Sagnol%2C%20Marine%20Pratlong%2C%20Elise%20Lefebvre%2C%20Fr%26%23xE9%3Bderic%20Chibon%2C%20Pascal%20Santa%20Barbara%2C%20and%20Sandrine%20Faure.%20%26%23x201C%3BLIX1%20Regulates%20YAP%20Activity%20and%20Controls%20Gastrointestinal%20Cancer%20Cell%20Plasticity.%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Cellular%20and%20Molecular%20Medicine%26lt%3B%5C%2Fi%26gt%3B%2024%2C%20no.%2016%20%282020%29%3A%209244%26%23x2013%3B54.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjcmm.15569%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjcmm.15569%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LIX1%20regulates%20YAP%20activity%20and%20controls%20gastrointestinal%20cancer%20cell%20plasticity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amandine%22%2C%22lastName%22%3A%22Gu%5Cu00e9rin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Martire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Trenquier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Sagnol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Pratlong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Santa%20Barbara%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Faure%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2208%5C%2F2020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1111%5C%2Fjcmm.15569%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fjcmm.15569%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221582-1838%2C%201582-4934%22%2C%22language%22%3A%22en%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22B8534R9G%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Croce%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCroce%2C%20Sabrina%2C%20Tom%20Lesluyes%2C%20Carine%20Valle%2C%20Loubna%20M%26%23x2019%3BHamdi%2C%20No%26%23xE9%3Bmie%20Th%26%23xE9%3Bbault%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Eberhard%20Stoeckle%2C%20et%20al.%20%26%23x201C%3BThe%20Nanocind%20Signature%20Is%20an%20Independent%20Prognosticator%20of%20Recurrence%20and%20Death%20in%20Uterine%20Leiomyosarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Cancer%20Research%3A%20An%20Official%20Journal%20of%20the%20American%20Association%20for%20Cancer%20Research%26lt%3B%5C%2Fi%26gt%3B%2026%2C%20no.%204%20%2815%202020%29%3A%20855%26%23x2013%3B61.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-19-2891%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-19-2891%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Nanocind%20Signature%20Is%20an%20Independent%20Prognosticator%20of%20Recurrence%20and%20Death%20in%20Uterine%20Leiomyosarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Croce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Valle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loubna%22%2C%22lastName%22%3A%22M%27Hamdi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Th%5Cu00e9bault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eberhard%22%2C%22lastName%22%3A%22Stoeckle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22No%5Cu00ebl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Quitterie%22%2C%22lastName%22%3A%22Fontanges%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mojgan%22%2C%22lastName%22%3A%22Devouassoux-Shisheboran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Floquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Chakiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Mayeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flora%22%2C%22lastName%22%3A%22Rebier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00ebtan%20Marie%22%2C%22lastName%22%3A%22MacGrogan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Soubeyran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Uterine%20leiomyosarcoma%2C%20which%20accounts%20for%207%25%20of%20all%20soft-tissue%20sarcomas%20and%201%25-3%25%20of%20all%20uterine%20malignancies%2C%20is%20an%20aggressive%20tumor%20responsible%20for%20a%20significant%20proportion%20of%20uterine%20cancer-related%20deaths.%20While%20Federation%20Internationale%20des%20Gynaecologistes%20et%20Obstetristes%20%28FIGO%29%20stage%20is%20the%20most%20important%20prognostic%20factor%2C%20metastatic%20and%20relapse%20rates%20at%20stage%20I%20exceed%2050%25%20so%20it%20is%20currently%20impossible%20to%20predict%20the%20clinical%20outcome%20of%20stage%20I%20leiomyosarcomas.%20In%202010%2C%20our%20team%20published%20a%20transcriptomic%20signature%20composed%20of%2067%20genes%20related%20to%20chromosome%20biogenesis%2C%20mitosis%20control%2C%20and%20chromosome%20segregation.%20It%20has%20demonstrated%20its%20prognostic%20value%20in%20many%20cancer%20types%20and%20was%20recently%20successfully%20applied%20to%20formalin-fixed%2C%20paraffin-embedded%20sarcomas%20by%20NanoCind%20on%20NanoString%20technology%2C%20making%20another%20step%20forward%20toward%20its%20use%20in%20routine%20practice.%5CnEXPERIMENTAL%20DESIGN%3A%20Sixty%20uterine%20leiomyosarcomas%20at%20any%20stage%2C%20including%2040%20localized%20in%20the%20uterus%20%28stage%20I%29%2C%20were%20analyzed%20with%20the%20NanoCind%20%28CINSARC%20with%20NanoString%29%20signature.%20Its%20prognostic%20value%20was%20evaluated%20for%20overall%20survival%20and%20relapse-free%20survival%20and%20compared%20in%20multivariate%20analysis%20with%20other%20prognostic%20markers%20like%20FIGO%20staging%20and%20genomic%20index.%5CnRESULTS%3A%20The%20NanoCind%20signature%20was%20able%20to%20split%20the%20heterogeneous%20group%20of%20uterine%20leiomyosarcomas%20of%20any%20stage%20including%20stage%20I%20into%20two%20distinct%20groups%20with%20different%20relapse-free%20survival%20and%20overall%20survival.%20These%20results%20were%20validated%20on%20an%20independent%20cohort%20of%20uterine%20leiomyosarcomas%20in%20The%20Cancer%20Genome%20Atlas%20consortium.%5CnCONCLUSIONS%3A%20The%20NanoCind%20signature%20is%20a%20powerful%20prognosticator%20that%20outperforms%20FIGO%20staging%20and%20the%20genomic%20index.%20The%20CINSARC%20signature%20is%20platform%20independent%20and%20%26quot%3Bready%20to%20use%26quot%3B%20and%20should%20now%20be%20used%20for%20randomization%20in%20future%20therapeutic%20trials.%22%2C%22date%22%3A%2202%2015%2C%202020%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-19-2891%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221078-0432%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A26%3A19Z%22%7D%7D%5D%7D
Croce, Sabrina, and Frédéric Chibon. “Molecular Prognostication of Uterine Smooth Muscle Neoplasms: From CGH Array to CINSARC Signature and Beyond.” Genes, Chromosomes and Cancer, November 11, 2020, gcc.22906. https://doi.org/10.1002/gcc.22906.
Lesluyes, Tom, and Frédéric Chibon. “A Global and Integrated Analysis of CINSARC-Associated Genetic Defects.” Cancer Research, October 6, 2020, canres.0512.2020. https://doi.org/10.1158/0008-5472.CAN-20-0512.
Cissé, Madi Y., Samuel Pyrdziak, Nelly Firmin, Laurie Gayte, Maud Heuillet, Floriant Bellvert, Maryse Fuentes, et al. “Targeting MDM2-Dependent Serine Metabolism as a Therapeutic Strategy for Liposarcoma.” Science Translational Medicine 12, no. 547 (June 10, 2020): eaay2163. https://doi.org/10.1126/scitranslmed.aay2163.
Merle, Candice, Noémie Thébault, Sophie LeGuellec, Jessica Baud, Gaëlle Pérot, Tom Lesluyes, Lucile Delespaul, Lydia Lartigue, and Frédéric Chibon. “Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion.” Cancers 12, no. 5 (May 19, 2020): 1281. https://doi.org/10.3390/cancers12051281.
Lartigue, Lydia, Candice Merle, Pauline Lagarde, Lucile Delespaul, Tom Lesluyes, Sophie Le Guellec, Gaelle Pérot, Laura Leroy, Jean-Michel Coindre, and Frédéric Chibon. “Genome Remodeling upon Mesenchymal Tumor Cell Fusion Contributes to Tumor Progression and Metastatic Spread.” Oncogene 39, no. 21 (May 2020): 4198–4211. https://doi.org/10.1038/s41388-020-1276-6.
Mattei, Jean Camille, Corinne Bouvier-Labit, Doriane Barets, Nicolas Macagno, Mathieu Chocry, Frédéric Chibon, Philippe Morando, et al. “Pan Aurora Kinase Inhibitor: A Promising Targeted-Therapy in Dedifferentiated Liposarcomas With Differential Efficiency Depending on Sarcoma Molecular Profile.” Cancers 12, no. 3 (March 3, 2020). https://doi.org/10.3390/cancers12030583.
Jakob, Jens, Tom Lesluyes, Anna Simeonova-Chergou, Frederik Wenz, Peter Hohenberger, Frederic Chibon, and Sophie Le Guellec. “Impact of Preoperative Treatment on the CINSARC Prognostic Signature: Translational Research Results from a Phase 1 Trial of the German Interdisciplinary Sarcoma Group (GISG 03).” Strahlentherapie Und Onkologie: Organ Der Deutschen Rontgengesellschaft ... [et Al] 196, no. 3 (March 2020): 280–85. https://doi.org/10.1007/s00066-019-01543-5.
Salas, Sébastien, and Frédéric Chibon. “Biology and signaling pathways involved in the oncogenesis of desmoid tumors.” Bulletin Du Cancer, January 16, 2020. https://doi.org/10.1016/j.bulcan.2019.12.003.
Dufresne, A., T. Lesluyes, C. Ménétrier-Caux, M. Brahmi, E. Darbo, M. Toulmonde, A. Italiano, et al. “Specific Immune Landscapes and Immune Checkpoint Expressions in Histotypes and Molecular Subtypes of Sarcoma.” OncoImmunology 9, no. 1 (January 1, 2020): 1792036. https://doi.org/10.1080/2162402X.2020.1792036.
Delespaul, Lucile, Caroline Gélabert, Tom Lesluyes, Sophie Le Guellec, Gaëlle Pérot, Laura Leroy, Jessica Baud, Candice Merle, Lydia Lartigue, and Frédéric Chibon. “Cell–Cell Fusion of Mesenchymal Cells with Distinct Differentiations Triggers Genomic and Transcriptomic Remodelling toward Tumour Aggressiveness.” Scientific Reports 10, no. 1 (2020): 21634. https://doi.org/10.1038/s41598-020-78502-z.
Filleron, Thomas, Sophie Le Guellec, Christine Chevreau, Bastien Cabarrou, Tom Lesluyes, Sabrina Lodin, Angélique Massoubre, et al. “Value of Peri-Operative Chemotherapy in Patients with CINSARC High-Risk Localized Grade 1 or 2 Soft Tissue Sarcoma: Study Protocol of the Target Selection Phase III CHIC-STS Trial.” BMC Cancer 20, no. 1 (2020): 716. https://doi.org/10.1186/s12885-020-07207-3.
Guérin, Amandine, Delphine Martire, Eva Trenquier, Tom Lesluyes, Sébastien Sagnol, Marine Pratlong, Elise Lefebvre, Fréderic Chibon, Pascal Santa Barbara, and Sandrine Faure. “LIX1 Regulates YAP Activity and Controls Gastrointestinal Cancer Cell Plasticity.” Journal of Cellular and Molecular Medicine 24, no. 16 (2020): 9244–54. https://doi.org/10.1111/jcmm.15569.
Croce, Sabrina, Tom Lesluyes, Carine Valle, Loubna M’Hamdi, Noémie Thébault, Gaëlle Pérot, Eberhard Stoeckle, et al. “The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 26, no. 4 (15 2020): 855–61. https://doi.org/10.1158/1078-0432.CCR-19-2891.
PUBLICATIONS 2019
7813506
CF9MRXB4
2019
1
chicago-fullnote-bibliography
50
date
desc
39101
https://www.crct-inserm.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22A4LLPCUM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Delespaul%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDelespaul%2C%20Lucile%2C%20Candice%20Merle%2C%20Tom%20Lesluyes%2C%20Pauline%20Lagarde%2C%20Sophie%20Le%20Guellec%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Jessica%20Baud%2C%20et%20al.%20%26%23x201C%3BFusion-Mediated%20Chromosomal%20Instability%20Promotes%20Aneuploidy%20Patterns%20That%20Resemble%20Human%20Tumors.%26%23x201D%3B%20%26lt%3Bi%26gt%3BOncogene%26lt%3B%5C%2Fi%26gt%3B%2C%20July%203%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-019-0859-6%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41388-019-0859-6%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fusion-mediated%20chromosomal%20instability%20promotes%20aneuploidy%20patterns%20that%20resemble%20human%20tumors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Merle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martina%22%2C%22lastName%22%3A%22Carlotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coralie%22%2C%22lastName%22%3A%22Danet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murielle%22%2C%22lastName%22%3A%22F%5Cu00e8vre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Rousseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Durrieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Teichmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Oncogenesis%20is%20considered%20to%20result%20from%20chromosomal%20instability%2C%20in%20addition%20to%20oncogene%20and%20tumor-suppressor%20alterations.%20Intermediate%20to%20aneuploidy%20and%20chromosomal%20instability%2C%20genome%20doubling%20is%20a%20frequent%20event%20in%20tumor%20development%20but%20the%20mechanisms%20driving%20tetraploidization%20and%20its%20impact%20remain%20unexplored.%20Cell%20fusion%2C%20one%20of%20the%20pathways%20to%20tetraploidy%2C%20is%20a%20physiological%20process%20involved%20in%20mesenchymal%20cell%20differentiation.%20Besides%20simple%20genome%20doubling%2C%20cell%20fusion%20results%20in%20the%20merging%20of%20two%20different%20genomes%20that%20can%20be%20destabilized%20upon%20proliferation.%20By%20testing%20whether%20cell%20fusion%20is%20involved%20in%20mesenchymal%20oncogenesis%2C%20we%20provide%20evidence%20that%20it%20induces%20genomic%20instability%20and%20mediates%20tumor%20initiation.%20After%20a%20latency%20period%2C%20the%20tumor%20emerges%20with%20the%20cells%20most%20suited%20for%20its%20development.%20Furthermore%2C%20hybrid%20tumor%20genomes%20were%20stabilized%20after%20this%20selection%20process%20and%20were%20very%20close%20to%20those%20of%20human%20pleomorphic%20mesenchymal%20tumors.%20Thus%20genome%20restructuring%20triggered%20by%20cell%20fusion%20may%20account%20for%20the%20chromosomal%20instability%20involved%20in%20oncogenesis.%22%2C%22date%22%3A%22Jul%2003%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41388-019-0859-6%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221476-5594%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22JRZG7GIG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mauduit%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMauduit%2C%20Olivier%2C%20Vanessa%20Delcroix%2C%20Tom%20Lesluyes%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Pauline%20Lagarde%2C%20Lydia%20Lartigue%2C%20Jean-Yves%20Blay%2C%20and%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%20Chibon.%20%26%23x201C%3BRecurrent%20DMD%20Deletions%20Highlight%20Specific%20Role%20of%20Dp71%20Isoform%20in%20Soft-Tissue%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2011%2C%20no.%207%20%28July%201%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11070922%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11070922%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Recurrent%20DMD%20Deletions%20Highlight%20Specific%20Role%20of%20Dp71%20Isoform%20in%20Soft-Tissue%20Sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Mauduit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Delcroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Soft-tissue%20sarcomas%20%28STS%29%20are%20rare%20tumors%20whose%20oncogenesis%20remains%20unknown%20and%20for%20which%20no%20common%20therapeutic%20target%20has%20yet%20been%20identified.%20Analysis%20of%20318%20STS%20by%20CGH%20array%20evidenced%20a%20frequent%20deletion%20affecting%20the%20DMD%20gene%20%28encoding%20dystrophin%20isoforms%29%20in%2016.5%25%20of%20STS%2C%20including%20sarcomas%20with%20complex%20genomics%2C%20gastrointestinal%20tumors%20%28GIST%29%2C%20and%20synovial%20sarcomas%20%28SS%29.%20These%20deletions%20are%20significantly%20associated%20with%20metastatic%20progression%2C%20thus%20suggesting%20the%20role%20of%20DMD%20downregulation%20in%20the%20acquisition%20of%20aggressive%20phenotypes.%20We%20observed%20that%20targeted%20deletions%20of%20DMD%20were%20restricted%20to%20the%205%26%23039%3B%20region%20of%20the%20gene%2C%20which%20is%20responsible%20for%20the%20transcription%20of%20Dp427.%20Analysis%20of%20STS%20tumors%20and%20cell%20lines%20by%20RNA%20sequencing%20revealed%20that%20only%20the%20Dp71%20isoform%20was%20widely%20expressed.%20Dp427%20depletion%20had%20no%20effect%20on%20cell%20growth%20or%20migration.%20However%2C%20Dp71%20inhibition%20by%20shRNA%20dramatically%20reduced%20the%20cell%20proliferation%20and%20clonogenicity%20of%20three%20STS%20cell%20lines%2C%20likely%20by%20altering%20the%20cell%20cycle%20progression%20through%20the%20G2%5C%2FM-phase.%20Our%20work%20demonstrates%20that%20DMD%20deletions%20are%20not%20restricted%20to%20myogenic%20tumors%20and%20could%20be%20used%20as%20a%20biomarker%20for%20metastatic%20evolution%20in%20STS.%20Dp71%20seems%20to%20play%20an%20essential%20role%20in%20tumor%20growth%2C%20thus%20providing%20a%20potential%20target%20for%20future%20STS%20treatments.%22%2C%22date%22%3A%22Jul%2001%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers11070922%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A24Z%22%7D%7D%2C%7B%22key%22%3A%2264AD9ZGM%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lesluyes%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLesluyes%2C%20Tom%2C%20Jessica%20Baud%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20C%26%23xE9%3Bline%20Charon-Barra%2C%20Axel%20You%2C%20Isabelle%20Valo%2C%20C%26%23xE9%3Bline%20Bazille%2C%20et%20al.%20%26%23x201C%3BGenomic%20and%20Transcriptomic%20Comparison%20of%20Post-Radiation%20versus%20Sporadic%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BModern%20Pathology%3A%20An%20Official%20Journal%20of%20the%20United%20States%20and%20Canadian%20Academy%20of%20Pathology%2C%20Inc%26lt%3B%5C%2Fi%26gt%3B%2C%20June%2026%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-019-0300-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41379-019-0300-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Genomic%20and%20transcriptomic%20comparison%20of%20post-radiation%20versus%20sporadic%20sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Charon-Barra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22You%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Valo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Bazille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Mishellany%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Leroux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Renard-Oldrini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Terrier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Le%20Cesne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marick%22%2C%22lastName%22%3A%22La%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Piperno-Neumann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Bonvalot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Neuville%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Collin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Maingon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Post-radiation%20sarcomas%20are%20rare%20secondary%20cancers%20arising%20from%20radiation%20therapies.%20To%20date%2C%20few%20genetic%20specificities%20have%20been%20described%20for%20such%20malignancies%20and%20the%20oncogenesis%20of%20sarcomas%20with%20complex%20genetics%20%28both%20sporadic%20and%20post-radiation%29%20remains%20largely%20misunderstood.%20We%20performed%20genomic%20and%20transcriptomic%20analyses%20on%2077%20post-radiation%20sarcomas%20using%20DNA-array%20and%20RNA%20sequencing.%20Consequently%2C%20we%20were%20able%20to%20investigate%20changes%20in%20copy%20number%20variations%2C%20transcriptome%20profiling%2C%20fusion%20gene%20expression%2C%20and%20mutational%20landscapes.%20We%20compare%20these%20data%20to%20a%20reference%20cohort%20of%2093%20sporadic%20sarcomas.%20At%20genomic%20level%2C%20similar%20chromosomal%20complexity%20was%20observed%20both%20in%20post-radiation%20and%20sporadic%20sarcomas%20with%20complex%20genetics.%20We%20found%20more%20frequent%20CDKN2A%20and%20CDKN2B%20%28coding%20for%20p14%5C%2Fp16%20and%20p15%20proteins%2C%20respectively%3B%20at%209p21.3%29%20losses%20in%20post-radiation%20%2871%25%29%20than%20in%20sporadic%20tumors%20%2839%25%3B%20P%5Cu2009%3D%5Cu20096.92e-3%29.%20Among%20all%20detected%20fusion%20genes%20and%20punctual%20variations%2C%20few%20specificities%20were%20observed%20between%20these%20groups%20and%20such%20alterations%20are%20not%20able%20to%20drive%20a%20strong%20and%20specific%20oncogenesis.%20Recurrent%20MYC%20amplifications%20%2896%25%29%20and%20KDR%20variants%20%288%25%29%20were%20detected%20in%20post-radiation%20angiosarcomas%2C%20in%20agreement%20with%20the%20literature.%20Transcriptomic%20analysis%20of%20such%20angiosarcomas%20revealed%20two%20distinct%20groups%20harboring%20different%20genomic%20imbalances%20%28in%20particular%20gains%20of%2017q24.2-17qter%29%20with%20different%20clinical%20courses%20according%20to%20patient%26%23039%3Bs%20vital%20status.%20Differential%20gene%20expression%20analysis%20permitted%20to%20focus%20on%20the%20immune%20response%20as%20a%20potential%20actor%20to%20tumor%20aggressiveness.%20Histochemistry%20validated%20a%20lower%20inflammation%20and%20lower%20immune%20infiltrate%20at%20tumor%20periphery%20for%20highly%20aggressive%20angiosarcomas.%20Our%20results%20provide%20new%20genomic%20and%20transcriptomic%20information%20about%20post-radiation%20sarcomas.%20The%20techniques%20we%20used%20%28RNA-seq%20and%20DNA-arrays%29%20did%20not%20highlight%20major%20differences%20in%20sarcomas%20with%20complex%20genetics%20depending%20on%20the%20radiation%20context%2C%20revealing%20similar%20patterns%20of%20transcriptomic%20profiles%20and%20chromosomal%20copy%20number%20variations.%20Additional%20characterizations%2C%20particularly%20whole%20genome%20sequencing%2C%20could%20measure%20changes%20in%20DNA%20following%20radiation%20therapy%20in%20such%20malignancies%20and%20may%20precise%20their%20oncogenesis.%22%2C%22date%22%3A%22Jun%2026%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41379-019-0300-2%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221530-0285%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22DM9486JU%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chibon%20et%20al.%22%2C%22parsedDate%22%3A%222019-04-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChibon%2C%20Fr%26%23xE9%3Bd%26%23xE9%3Bric%2C%20Elodie%20Darbo%2C%20and%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot.%20%26%23x201C%3BLeiomyosarcomas%3A%20Whole%20Genome%20Sequencing%20for%20a%20Whole%20Biology%20Characterization.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCurrent%20Opinion%20in%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2C%20April%2024%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FCCO.0000000000000550%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FCCO.0000000000000550%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Leiomyosarcomas%3A%20whole%20genome%20sequencing%20for%20a%20whole%20biology%20characterization%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Darbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%20OF%20REVIEW%3A%20Leiomyosarcoma%20%28LMS%29%20is%20among%20the%20more%20aggressive%20sarcomas%20and%20still%20suffers%20from%20the%20lack%20of%20efficient%20systemic%20treatment%20after%2C%20or%20before%2C%20surgery.%20During%20the%20last%20decades%2C%20one%20provider%20of%20therapeutic%20improvement%20has%20been%20the%20targeting%20of%20genome%20alterations.%20Efforts%20have%20thus%20been%20done%20to%20apply%20next-generation%20sequencing%20approaches%20to%20those%20tumours%20to%20decipher%20their%20oncogenesis%20and%20find%20out%20such%20targets.%5CnRECENT%20FINDINGS%3A%20Sequencing%20performed%20so%20far%2C%20based%20on%20exome%2C%20mostly%20confirmed%20that%20p53%20and%20RB1%20are%20the%20two%20main%20pathways%20altered%20in%20LMS%20oncogenesis.%20There%20are%20few%20point%20mutations%20in%20LMS%20genome%2C%20which%20is%20mainly%20characterized%20by%20numerous%20chromosomal%20rearrangements.%20Data%20from%20whole%20genome%20sequencing%20are%20now%20mandatory%20to%20decipher%20mechanisms%20triggering%20chromosomal%20instability%20and%20mutational%20process.%5CnSUMMARY%3A%20Although%20each%20LMS%20appears%20to%20have%20quite%20private%20genetic%20alterations%20leading%20to%20oncogenesis%2C%20it%20is%20likely%20that%20the%20altered%20biological%20pathways%20are%20relatively%20homogeneous%20within%20each%20of%20the%20LMS%20subgroups.%20Understanding%20this%20oncogenesis%2C%20thanks%20to%20integrated%20approaches%20involving%20whole%20genome%20and%20transcriptome%20sequencing%20together%20with%20functional%20and%20clinical%20characterizations%20will%20certainly%20give%20us%20the%20keys%20to%20relevant%20and%20effective%20new%20therapeutic%20approaches.%22%2C%22date%22%3A%22Apr%2024%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FCCO.0000000000000550%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221531-703X%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A14Z%22%7D%7D%2C%7B%22key%22%3A%224IRDFZL5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Loarer%20et%20al.%22%2C%22parsedDate%22%3A%222019-03-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLe%20Loarer%2C%20Fran%26%23xE7%3Bois%2C%20Sophie%20Laffont%2C%20Tom%20Lesluyes%2C%20Franck%20Tirode%2C%20Cristina%20Antonescu%2C%20Anne-Catherine%20Baglin%2C%20Lucile%20Delespaul%2C%20et%20al.%20%26%23x201C%3BClinicopathologic%20and%20Molecular%20Features%20of%20a%20Series%20of%2041%20Biphenotypic%20Sinonasal%20Sarcomas%20Expanding%20Their%20Molecular%20Spectrum.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20American%20Journal%20of%20Surgical%20Pathology%26lt%3B%5C%2Fi%26gt%3B%2C%20March%201%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001238%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FPAS.0000000000001238%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinicopathologic%20and%20Molecular%20Features%20of%20a%20Series%20of%2041%20Biphenotypic%20Sinonasal%20Sarcomas%20Expanding%20Their%20Molecular%20Spectrum%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Le%20Loarer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Laffont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%22%2C%22lastName%22%3A%22Tirode%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Antonescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Catherine%22%2C%22lastName%22%3A%22Baglin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Soubeyran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Hostein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Karanian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Costes-Martineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Castain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Eimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Le%20Bail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Wassef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%5D%2C%22abstractNote%22%3A%22Biphenotypic%20sinonasal%20sarcoma%20%28BSNS%29%20is%20a%20locally%20aggressive%20tumor%20occurring%20in%20the%20sinonasal%20region.%20It%20harbors%20both%20myogenic%20and%20neural%20differentiation%20and%20is%20characterized%20by%20PAX3%20rearrangement%20with%20MAML3%20as%20the%20most%20frequent%20fusion%20partner%2C%20but%20the%20partner%20of%20PAX3%20remains%20unidentified%20in%20a%20subset%20of%20cases.%20About%2070%20cases%20have%20been%20reported%20so%20far.%20In%20this%20study%2C%20we%20report%20a%20series%20of%2041%20cases%20with%20clinical%2C%20pathologic%2C%20and%20molecular%20description.%20Twenty-five%20%2861%25%29%20patients%20were%20female%20individuals%2C%20and%20the%20median%20age%20was%2049%20years.%20Tumors%20arose%20predominantly%20in%20the%20nasal%20cavity%20and%20ethmoidal%20sinuses.%20Local%20recurrences%20occurred%20in%208%20cases%20of%20the%2025%20%2832%25%29.%20Histologic%20features%20were%20characteristic%20of%20BSNS%2C%20with%205%20cases%20showing%20focal%20rhabdomyoblastic%20differentiation.%20Immunohistochemistry%20showed%20a%20constant%20positivity%20of%20S100%20protein%20and%20PAX3%20and%20negativity%20of%20SOX10.%20MyoD1%20was%20focally%20positive%20in%2091%25%20of%20cases%2C%20whereas%20only%2020%25%20were%20positive%20for%20myogenin.%20Molecular%20analysis%20showed%20a%20PAX3-MAML3%20transcript%20in%2037%20cases%20%2890%25%29.%20RNA%20sequencing%20was%20performed%20in%20the%204%20negative%20cases%20for%20PAX3-MAML3%20fusion%2C%20and%20it%20showed%20that%201%20case%20harbored%20a%20PAX3-FOXO1%20fusion%2C%20as%20previously%20described%20in%20the%20literature%2C%20and%202%20novel%20fusions%3A%20PAX3-WWTR1%20fusion%20in%202%20cases%20and%20PAX3-NCOA2%20fusion%20in%201%20case.%20RNA%20sequencing%20results%20were%20confirmed%20by%20fluorescence%20in%20situ%20hybridization%2C%20reverse%20transcription-polymerase%20chain%20reaction%2C%20and%20Sanger%20sequencing.%20The%20PAX3-NCOA2-positive%20case%20showed%20focal%20rhabdomyoblastic%20differentiation.%20In%20conclusion%2C%20we%20report%202%20novel%20fusions%20%28PAX3-WWTR1%20and%20PAX3-NCOA2%29%20in%20BSNS%20and%20show%20that%20MyoD1%20is%20more%20sensitive%20than%20myogenin%20for%20demonstrating%20myogenic%20differentiation%20in%20this%20tumor.%22%2C%22date%22%3A%22Mar%2001%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1097%5C%2FPAS.0000000000001238%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221532-0979%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A04Z%22%7D%7D%2C%7B%22key%22%3A%222USM3MYE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vitiello%20et%20al.%22%2C%22parsedDate%22%3A%222019-02-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVitiello%2C%20Gerardo%20A.%2C%20Timothy%20G.%20Bowler%2C%20Mengyuan%20Liu%2C%20Benjamin%20D.%20Medina%2C%20Jennifer%20Q.%20Zhang%2C%20Nesteene%20J.%20Param%2C%20Jennifer%20K.%20Loo%2C%20et%20al.%20%26%23x201C%3BDifferential%20Immune%20Profiles%20Distinguish%20the%20Mutational%20Subtypes%20of%20Gastrointestinal%20Stromal%20Tumor.%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Journal%20of%20Clinical%20Investigation%26lt%3B%5C%2Fi%26gt%3B%2C%20February%2014%2C%202019.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI124108%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1172%5C%2FJCI124108%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Differential%20immune%20profiles%20distinguish%20the%20mutational%20subtypes%20of%20gastrointestinal%20stromal%20tumor%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerardo%20A.%22%2C%22lastName%22%3A%22Vitiello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20G.%22%2C%22lastName%22%3A%22Bowler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mengyuan%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%20D.%22%2C%22lastName%22%3A%22Medina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20Q.%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nesteene%20J.%22%2C%22lastName%22%3A%22Param%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%20K.%22%2C%22lastName%22%3A%22Loo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20L.%22%2C%22lastName%22%3A%22Goldfeder%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ferdinand%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shan%22%2C%22lastName%22%3A%22Zeng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ronald%20P.%22%2C%22lastName%22%3A%22DeMatteo%22%7D%5D%2C%22abstractNote%22%3A%22Gastrointestinal%20stromal%20tumor%20%28GIST%29%20is%20the%20most%20common%20human%20sarcoma%2C%20frequently%20characterized%20by%20an%20oncogenic%20mutation%20in%20the%20KIT%20or%20platelet-derived%20growth%20factor%20receptor%20alpha%20%28PDGFRA%29%20genes.%20We%20performed%20RNA%20sequencing%20of%2075%20human%20GIST%20tumors%20from%2075%20patients%2C%20comprising%20the%20largest%20cohort%20of%20GISTs%20sequenced%20to%20date%2C%20in%20order%20to%20discover%20differences%20in%20the%20immune%20infiltrates%20of%20KIT%20and%20PDGFRA-mutant%20GIST.%20Through%20bioinformatics%2C%20immunohistochemistry%2C%20and%20flow%20cytometry%2C%20we%20found%20that%20PDGFRA-mutant%20GISTs%20harbored%20more%20immune%20cells%20with%20increased%20cytolytic%20activity%20when%20compared%20to%20KIT-mutant%20GISTs.%20PDGFRA-mutant%20GISTs%20expressed%20many%20chemokines%2C%20such%20as%20CXCL14%2C%20at%20a%20significantly%20higher%20level%20when%20compared%20to%20KIT-mutant%20GISTs%20and%20exhibited%20more%20diverse%20driver-derived%20neoepitope%3AHLA%20binding%2C%20both%20of%20which%20may%20contribute%20to%20PDGFRA-mutant%20GIST%20immunogenicity.%20Through%20machine%20learning%2C%20we%20generated%20gene%20expression-based%20immune%20profiles%20capable%20of%20differentiating%20KIT%20and%20PDGFRA-mutant%20GISTs%2C%20and%20also%20identified%20additional%20immune%20features%20of%20high%20PD-1%20and%20PD-L1%20expressing%20tumors%20across%20all%20GIST%20mutational%20subtypes%2C%20which%20may%20provide%20insight%20into%20immunotherapeutic%20opportunities%20and%20limitations%20in%20GIST.%22%2C%22date%22%3A%22Feb%2014%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1172%5C%2FJCI124108%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221558-8238%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22TVXWM6WZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mauduit%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMauduit%2C%20Olivier%2C%20C%26%23xE9%3Bline%20Brulard%2C%20Tom%20Lesluyes%2C%20Vanessa%20Delcroix%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Nina%20Choublier%2C%20Mickael%20Michaud%2C%20et%20al.%20%26%23x201C%3BRCBTB1%20Deletion%20Is%20Associated%20with%20Metastatic%20Outcome%20and%20Contributes%20to%20Docetaxel%20Resistance%20in%20Nontranslocation-Related%20Pleomorphic%20Sarcomas.%26%23x201D%3B%20%26lt%3Bi%26gt%3BCancers%26lt%3B%5C%2Fi%26gt%3B%2011%2C%20no.%201%20%28January%2011%2C%202019%29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11010081%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers11010081%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22RCBTB1%20Deletion%20Is%20Associated%20with%20Metastatic%20Outcome%20and%20Contributes%20to%20Docetaxel%20Resistance%20in%20Nontranslocation-Related%20Pleomorphic%20Sarcomas%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Mauduit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Brulard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vanessa%22%2C%22lastName%22%3A%22Delcroix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nina%22%2C%22lastName%22%3A%22Choublier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%22%2C%22lastName%22%3A%22Michaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jessica%22%2C%22lastName%22%3A%22Baud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alain%22%2C%22lastName%22%3A%22Aurias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Michel%22%2C%22lastName%22%3A%22Coindre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Lartigue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Blay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Half%20of%20soft-tissue%20sarcomas%20are%20tumors%20with%20complex%20genomics%2C%20which%20display%20no%20specific%20genetic%20alterations%20and%20respond%20poorly%20to%20treatment.%20It%20is%20therefore%20necessary%20to%20find%20new%20therapeutic%20targets%20for%20these%20sarcomas.%20Despite%20genetic%20heterogeneity%20across%20samples%2C%20oncogenesis%20may%20be%20driven%20by%20common%20pathway%20alterations.%20Therefore%2C%20genomic%20and%20transcriptomic%20profiles%20of%20106%20sarcomas%20with%20complex%20genomics%20were%20analyzed%20to%20identify%20common%20pathways%20with%20altered%20genes.%20This%20brought%20out%20a%20gene%20belonging%20to%20the%20%26quot%3Bcell%20cycle%26quot%3B%20biological%20pathway%2C%20RCBTB1%20%28RCC1%20And%20BTB%20Domain%20Containing%20Protein%201%29%2C%20which%20is%20lost%20and%20downregulated%20in%2062.5%25%20of%20metastatic%20tumors%20against%2034%25%20of%20non-metastatic%20tumors.%20A%20retrospective%20study%20of%20three%20sarcoma%20cohorts%20revealed%20that%20low%20RCBTB1%20expression%20is%20prognostic%20for%20metastatic%20progression%2C%20specifically%20in%20patients%20that%20received%20chemotherapy.%20In%20vitro%20and%20in%20vivo%2C%20RCBTB1%20overexpression%20in%20leiomyosarcoma%20cells%20specifically%20sensitized%20to%20docetaxel-induced%20apoptosis.%20This%20was%20associated%20with%20increased%20mitotic%20rate%20in%20vitro%20and%20higher%20growth%20rate%20of%20xenografts.%20By%20contrast%2C%20RCBTB1%20inhibition%20decreased%20cell%20proliferation%20and%20protected%20sarcoma%20cells%20from%20apoptosis%20induced%20by%20docetaxel.%20Collectively%2C%20these%20data%20evidenced%20that%20RCBTB1%20is%20frequently%20deleted%20in%20sarcomas%20with%20complex%20genomics%20and%20that%20its%20downregulation%20is%20associated%20with%20a%20higher%20risk%20of%20developing%20metastasis%20for%20patients%20receiving%20chemotherapy%2C%20likely%20due%20to%20their%20higher%20resistance%20to%20docetaxel.%22%2C%22date%22%3A%22Jan%2011%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers11010081%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%222072-6694%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A22%3A56Z%22%7D%7D%2C%7B%22key%22%3A%22TIS82J4D%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Valentin%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BValentin%2C%20T.%2C%20T.%20Lesluyes%2C%20S.%20Le%20Guellec%2C%20and%20F.%20Chibon.%20%26%23x201C%3BChemotherapy%20in%20Localized%20Soft%20Tissue%20Sarcoma%3A%20Will%20We%20Soon%20Have%20to%20Treat%20Grade%201%20Tumors%3F%20Update%20on%20CINSARC%20Performances.%26%23x201D%3B%20%26lt%3Bi%26gt%3BAnnals%20of%20Oncology%3A%20Official%20Journal%20of%20the%20European%20Society%20for%20Medical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2030%2C%20no.%201%20%28January%201%2C%202019%29%3A%20153%26%23x2013%3B55.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fannonc%5C%2Fmdy465%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fannonc%5C%2Fmdy465%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Chemotherapy%20in%20localized%20soft%20tissue%20sarcoma%3A%20will%20we%20soon%20have%20to%20treat%20grade%201%20tumors%3F%20Update%20on%20CINSARC%20performances%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Jan%2001%2C%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fannonc%5C%2Fmdy465%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221569-8041%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A36%3A21Z%22%7D%7D%2C%7B%22key%22%3A%2237NR77WY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Timbergen%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTimbergen%2C%20Milea%20J.%20M.%2C%20Matthijs%20L.%20Janssen%2C%20Cornelis%20Verhoef%2C%20Dirk%20J.%20Gr%26%23xFC%3Bnhagen%2C%20Frederic%20Chibon%2C%20Marcel%20Smid%2C%20Stefan%20Sleijfer%2C%20and%20Erik%20A.%20C.%20Wiemer.%20%26%23x201C%3BWnt%20Targets%20Genes%20Are%20Not%20Differentially%20Expressed%20in%20Desmoid%20Tumors%20Bearing%20Different%20Activating%20%26%23x3B2%3B-Catenin%20Mutations.%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Surgical%20Oncology%3A%20The%20Journal%20of%20the%20European%20Society%20of%20Surgical%20Oncology%20and%20the%20British%20Association%20of%20Surgical%20Oncology%26lt%3B%5C%2Fi%26gt%3B%2045%2C%20no.%204%20%282019%29%3A%20691%26%23x2013%3B98.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2018.09.019%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.ejso.2018.09.019%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Wnt%20targets%20genes%20are%20not%20differentially%20expressed%20in%20desmoid%20tumors%20bearing%20different%20activating%20%5Cu03b2-catenin%20mutations%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Milea%20J.%20M.%22%2C%22lastName%22%3A%22Timbergen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthijs%20L.%22%2C%22lastName%22%3A%22Janssen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cornelis%22%2C%22lastName%22%3A%22Verhoef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%20J.%22%2C%22lastName%22%3A%22Gr%5Cu00fcnhagen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcel%22%2C%22lastName%22%3A%22Smid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Sleijfer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20A.%20C.%22%2C%22lastName%22%3A%22Wiemer%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Sporadic%20desmoid-type%20fibromatosis%20%28DTF%29%20is%20a%20rare%20soft%20tissue%20tumor%20of%20mesenchymal%20origin.%20It%20is%20characterized%20by%20local%20invasive%20growth%20and%20unpredictable%20growth%20behavior.%20Three%20distinct%20mutations%20involving%20the%20CTNNB1%20%28%5Cu03b2-catenin%29%20gene%20have%20been%20identified%20in%20the%20vast%20majority%20of%20DTF%20tumors%2C%20which%20cause%20activation%20of%20the%20Wnt%20signaling%20pathway%20and%20impact%20prognosis.%20This%20study%20examines%20whether%20the%20different%20CTNNB1%20mutants%20%28T41A%2C%20S45F%29%20occurring%20in%20DTF%20tumors%20differentially%20affect%20Wnt%20signaling%20activity%2C%20which%20might%20explain%20the%20different%20disease%20course%20between%20DTF%20patients%20harboring%20different%20CTNNB1%20mutations.%5CnMATERIALS%20AND%20METHODS%3A%20Real-time%20polymerase%20chain%20reaction%20%28RT-PCR%29%20on%2061%20formalin%20fixed%20paraffin%20embedded%20DTF%20samples%20with%20known%20CTNNB1%20status%20was%20used%20to%20measure%20the%20relative%20mRNA%20expression%20level%20of%20Wnt%20target%20genes%20AXIN2%2C%20DKK1%20and%20CCND1.%20Additionally%2C%20publicly%20available%20mRNA%20expression%20data%20retrieved%20from%20the%20Gene%20Expression%20Omnibus%20of%20128%20DTF%20samples%20were%20used%20for%20an%20unsupervised%20cluster%20analyses%20based%20on%20the%20expression%20of%20a%20selection%20of%20Wnt%20targets.%5CnRESULTS%3A%20No%20statistically%20significant%20difference%20in%20relative%20expression%20levels%20of%20Wnt%20target%20genes%20AXIN2%2C%20DKK1%20and%20CCND1%20was%20identified%20between%20either%20CTNNB1%20wild-type%2C%20S45F%20or%20T41A%20mutated%20DTF%20samples.%20Moreover%2C%20the%20hierarchical%20cluster%20analyses%20using%20selected%20Wnt%20targets%20did%20not%20discriminate%20between%20different%20CTNNB1%20mutation%20types.%5CnCONCLUSIONS%3A%20No%20differences%20in%20the%20expression%20levels%20of%20Wnt%20target%20genes%20were%20observed%20between%20the%20different%20CTNNB1%20mutation%20types%20in%20DTF%20tumors.%20Further%20studies%20are%20needed%20to%20decipher%20the%20mechanism%20accounting%20for%20the%20diverse%20disease%20courses%20between%20DTF%20patients%20with%20different%20CTNNB1%20variants.%22%2C%22date%22%3A%2204%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.ejso.2018.09.019%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221532-2157%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A22%3A06Z%22%7D%7D%2C%7B%22key%22%3A%22DFUPS6V7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Croce%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCroce%2C%20Sabrina%2C%20Tom%20Lesluyes%2C%20Lucile%20Delespaul%2C%20Benjamin%20Bonhomme%2C%20Ga%26%23xEB%3Blle%20P%26%23xE9%3Brot%2C%20Val%26%23xE9%3Brie%20Velasco%2C%20Laetitia%20Mayeur%2C%20et%20al.%20%26%23x201C%3BGREB1-CTNNB1%20Fusion%20Transcript%20Detected%20by%20RNA-Sequencing%20in%20a%20Uterine%20Tumor%20Resembling%20Ovarian%20Sex%20Cord%20Tumor%20%28UTROSCT%29%3A%20A%20Novel%20CTNNB1%20Rearrangement.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGenes%2C%20Chromosomes%20%26amp%3B%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2058%2C%20no.%203%20%282019%29%3A%20155%26%23x2013%3B63.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22694%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22694%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22GREB1-CTNNB1%20fusion%20transcript%20detected%20by%20RNA-sequencing%20in%20a%20uterine%20tumor%20resembling%20ovarian%20sex%20cord%20tumor%20%28UTROSCT%29%3A%20A%20novel%20CTNNB1%20rearrangement%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabrina%22%2C%22lastName%22%3A%22Croce%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucile%22%2C%22lastName%22%3A%22Delespaul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Bonhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22P%5Cu00e9rot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Velasco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Mayeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flora%22%2C%22lastName%22%3A%22Rebier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Houda%22%2C%22lastName%22%3A%22Ben%20Rejeb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Guyon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22W.%20Glenn%22%2C%22lastName%22%3A%22McCluggage%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Floquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Querleu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Chakiba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mojgan%22%2C%22lastName%22%3A%22Devouassoux-Shisheboran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eliane%22%2C%22lastName%22%3A%22Mery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Arnould%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerlinde%22%2C%22lastName%22%3A%22Averous%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Soubeyran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Chibon%22%7D%5D%2C%22abstractNote%22%3A%22Mutations%20of%20CTNNB1%20have%20been%20implicated%20in%20tumorigenesis%20in%20many%20organs.%20However%2C%20tumors%20harboring%20a%20CTNNB1%20translocation%20are%20extremely%20rare%20and%20this%20translocation%20has%20never%20been%20reported%20in%20a%20uterine%20mesenchymal%20neoplasm.%20We%20report%20a%20novel%20translocation%20t%282%3B3%29%28p25%3Bp22%29%20involving%20the%20GREB1%20%28intron%208%29%20and%20CTNNB1%20%28exon%203%29%20in%20a%20uterine%20tumor%20resembling%20ovarian%20sex%20cord%20tumor%20%28UTROSCT%29%2C%20which%20exhibited%20extrauterine%20metastasis.%20The%20translocation%20detected%20by%20RNA-sequencing%20was%20validated%20by%20RT-PCR%2C%20and%20resulted%20in%20nuclear%20expression%20of%20%5Cu03b2-catenin.%20Juxtapositioning%20with%20GREB1%2C%20which%20is%20overexpressed%20in%20response%20to%20estrogens%2C%20resulted%20in%20overexpression%20of%20a%20truncated%20and%20hypophosphorylated%20nuclear%20%5Cu03b2-catenin%20in%20the%20primary%20and%20recurrent%20tumors.%20This%20accumulation%20of%20nuclear%20%5Cu03b2-catenin%20results%20in%20a%20constitutive%20activation%20of%20the%20Wnt%5C%2F%5Cu03b2-catenin%20signaling%20pathway%20with%20a%20major%20oncogenic%20effect.%20The%20CTNNB1%20gene%20fusion%2C%20promoted%20by%20an%20estrogen-responsive%20gene%20%28GREB1%29%2C%20could%20be%20a%20potential%20driver%20of%20tumorigenesis%20in%20this%20case%20and%20a%20therapeutic%20target%20with%20adapted%20inhibitors.%20RT-PCR%20and%20immunohistochemistry%20performed%20on%2011%20additional%20UTROSCTs%20showed%20no%20CTNNB1%20fusion%20transcript%20or%20nuclear%20%5Cu03b2-catenin%20immunoreactivity.%22%2C%22date%22%3A%2203%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fgcc.22694%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221098-2264%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A36%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22USE3GCXY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chibon%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChibon%2C%20Frederic%2C%20Tom%20Lesluyes%2C%20Thibaud%20Valentin%2C%20and%20Sophie%20Le%20Guellec.%20%26%23x201C%3BCINSARC%20Signature%20as%20a%20Prognostic%20Marker%20for%20Clinical%20Outcome%20in%20Sarcomas%20and%20Beyond.%26%23x201D%3B%20%26lt%3Bi%26gt%3BGenes%2C%20Chromosomes%20%26amp%3B%20Cancer%26lt%3B%5C%2Fi%26gt%3B%2058%2C%20no.%202%20%282019%29%3A%20124%26%23x2013%3B29.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22703%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fgcc.22703%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CINSARC%20signature%20as%20a%20prognostic%20marker%20for%20clinical%20outcome%20in%20sarcomas%20and%20beyond%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Chibon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%22%2C%22lastName%22%3A%22Lesluyes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaud%22%2C%22lastName%22%3A%22Valentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Le%20Guellec%22%7D%5D%2C%22abstractNote%22%3A%22Prognostication%20is%20a%20key%20issue%20for%20sarcoma%20patients%26%23039%3B%20care%20as%20it%20triggers%20the%20therapeutic%20approach%20including%20chemotherapy%2C%20which%20is%20still%20not%20standard%20for%20localized%20patients.%20Current%20prognostic%20evaluation%2C%20based%20on%20the%20FNCLCC%20grading%20system%2C%20has%20recently%20been%20improved%20by%20the%20CINSARC%20signature%20outperforming%20histology-based%20grading%20system%20by%20identifying%20high-risk%20patients%20in%20every%20grade%2C%20even%20in%20those%20considered%20as%20low.%20CINSARC%20is%20an%20expression-based%20signature%20related%20to%20mitosis%20and%20chromosome%20integrity%20with%20prognostic%20value%20in%20a%20wide%20range%20of%20cancers%20additional%20to%20sarcoma.%20First%20developed%20with%20frozen%20material%2C%20CINSARC%20is%20now%20coupled%20with%20NanoString%20technology%20allowing%20evaluation%20from%20FFPE%20blocks%20used%20in%20clinical%20practice.%20Consequently%2C%20CINSARC%20is%20currently%20evaluated%20in%20clinical%20trials%20with%20a%20dual%20objective%20of%20demonstrating%20the%20benefit%20of%20chemotherapy%20in%20sarcoma%20patients%20and%20testing%20its%20response%20prediction.%20Considering%20its%20overarching%20value%20in%20oncology%2C%20its%20development%20is%20welcome%20in%20any%20cancers%20where%20the%20prognostication%20needs%20to%20be%20improved.%22%2C%22date%22%3A%2202%202019%22%2C%22section%22%3A%22%22%2C%22partNumber%22%3A%22%22%2C%22partTitle%22%3A%22%22%2C%22DOI%22%3A%2210.1002%5C%2Fgcc.22703%22%2C%22citationKey%22%3A%22%22%2C%22url%22%3A%22%22%2C%22PMID%22%3A%22%22%2C%22PMCID%22%3A%22%22%2C%22ISSN%22%3A%221098-2264%22%2C%22language%22%3A%22eng%22%2C%22collections%22%3A%5B%22CF9MRXB4%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A24%3A23Z%22%7D%7D%5D%7D
Delespaul, Lucile, Candice Merle, Tom Lesluyes, Pauline Lagarde, Sophie Le Guellec, Gaëlle Pérot, Jessica Baud, et al. “Fusion-Mediated Chromosomal Instability Promotes Aneuploidy Patterns That Resemble Human Tumors.” Oncogene, July 3, 2019. https://doi.org/10.1038/s41388-019-0859-6.
Mauduit, Olivier, Vanessa Delcroix, Tom Lesluyes, Gaëlle Pérot, Pauline Lagarde, Lydia Lartigue, Jean-Yves Blay, and Frédéric Chibon. “Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas.” Cancers 11, no. 7 (July 1, 2019). https://doi.org/10.3390/cancers11070922.
Lesluyes, Tom, Jessica Baud, Gaëlle Pérot, Céline Charon-Barra, Axel You, Isabelle Valo, Céline Bazille, et al. “Genomic and Transcriptomic Comparison of Post-Radiation versus Sporadic Sarcomas.” Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc, June 26, 2019. https://doi.org/10.1038/s41379-019-0300-2.
Chibon, Frédéric, Elodie Darbo, and Gaëlle Pérot. “Leiomyosarcomas: Whole Genome Sequencing for a Whole Biology Characterization.” Current Opinion in Oncology, April 24, 2019. https://doi.org/10.1097/CCO.0000000000000550.
Le Loarer, François, Sophie Laffont, Tom Lesluyes, Franck Tirode, Cristina Antonescu, Anne-Catherine Baglin, Lucile Delespaul, et al. “Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum.” The American Journal of Surgical Pathology, March 1, 2019. https://doi.org/10.1097/PAS.0000000000001238.
Vitiello, Gerardo A., Timothy G. Bowler, Mengyuan Liu, Benjamin D. Medina, Jennifer Q. Zhang, Nesteene J. Param, Jennifer K. Loo, et al. “Differential Immune Profiles Distinguish the Mutational Subtypes of Gastrointestinal Stromal Tumor.” The Journal of Clinical Investigation, February 14, 2019. https://doi.org/10.1172/JCI124108.
Mauduit, Olivier, Céline Brulard, Tom Lesluyes, Vanessa Delcroix, Gaëlle Pérot, Nina Choublier, Mickael Michaud, et al. “RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas.” Cancers 11, no. 1 (January 11, 2019). https://doi.org/10.3390/cancers11010081.
Valentin, T., T. Lesluyes, S. Le Guellec, and F. Chibon. “Chemotherapy in Localized Soft Tissue Sarcoma: Will We Soon Have to Treat Grade 1 Tumors? Update on CINSARC Performances.” Annals of Oncology: Official Journal of the European Society for Medical Oncology 30, no. 1 (January 1, 2019): 153–55. https://doi.org/10.1093/annonc/mdy465.
Timbergen, Milea J. M., Matthijs L. Janssen, Cornelis Verhoef, Dirk J. Grünhagen, Frederic Chibon, Marcel Smid, Stefan Sleijfer, and Erik A. C. Wiemer. “Wnt Targets Genes Are Not Differentially Expressed in Desmoid Tumors Bearing Different Activating β-Catenin Mutations.” European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 45, no. 4 (2019): 691–98. https://doi.org/10.1016/j.ejso.2018.09.019.
Croce, Sabrina, Tom Lesluyes, Lucile Delespaul, Benjamin Bonhomme, Gaëlle Pérot, Valérie Velasco, Laetitia Mayeur, et al. “GREB1-CTNNB1 Fusion Transcript Detected by RNA-Sequencing in a Uterine Tumor Resembling Ovarian Sex Cord Tumor (UTROSCT): A Novel CTNNB1 Rearrangement.” Genes, Chromosomes & Cancer 58, no. 3 (2019): 155–63. https://doi.org/10.1002/gcc.22694.
Chibon, Frederic, Tom Lesluyes, Thibaud Valentin, and Sophie Le Guellec. “CINSARC Signature as a Prognostic Marker for Clinical Outcome in Sarcomas and Beyond.” Genes, Chromosomes & Cancer 58, no. 2 (2019): 124–29. https://doi.org/10.1002/gcc.22703.
LES MEMBRES DE L’ÉQUIPE
LES PARTENAIRES & FINANCIERS
Centre de Recherches en Cancérologie de Toulouse (Oncopole)
Toulouse – FR
CRCT-Oncopole Suivre 1,434 1,195
Compte officiel du Centre de Recherches en Cancérologie de Toulouse
Prize for the best communication at the French Association for Pancreatic Cancer Research (AFRCP) day for @BousquetVaysse team at @crctoncopole
➡️
Nous contacter
05 82 74 15 75
Envie de rejoindre
L’équipe du CRCT ?
